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Chapter 1
Introducti on
Esophageal atresia (EA) and trachea-esophageal fistula (TEF) [MIM 189960] are severe 
developmental defects that aff ect one in 3,500 newborns. Slightly more boys are aff ected than 
girls1. In The Netherlands, approximately 70 children are born annually with this congenital 
malformati on. It is characterized by a lack of conti nuity of the upper gastro-intesti nal tract 
that is oft en accompanied with a persistent connecti on, or fi stula, between the trachea 
and the esophagus (tracheo-esophageal fi stula). Five subtypes are described by the Gross 
classifi cati on (Figure 1A)2. Subtype C, with a blind-ending proximal pouch (atresia) and a distal 
TEF, occurs most frequently (86%), followed by the pure proximal atresia (subtype A; 7%). As is 
the case with other congenital malformati ons, EA/TEF occurs more in twins than in singletons, 
although usually only one twin is aff ected3. Once a couple has one child with EA/TEF, the risk 
of having a second child with this anomaly goes up to 1%4. Over 50% of infants with EA have 
additi onal anomalies, e.g. vertebral, gastro-intesti nal, urogenital, cardiovascular, renal or limb 
abnormaliti es5-7. 
 EA/TEF is the result of faulty septati on of the foregut. Other congenital anomalies of 
foregut-derived structures, such as tracheal agenesis, are also of interest. In tracheal agenesis 
the trachea is fully or parti ally absent. It occurs in one in every 50,000 births8. Like EA/TEF, 
tracheal agenesis may be part of a complex of malformati ons, and associati ons with notably 
cardiovascular anomalies have been reported9,10.
Presentati on and management
Clinical symptoms and ultrasound signs during pregnancy could suggest the presence of EA. 
The presence of a polyhydramnios may suggest gastro-intesti nal obstructi on, but is also related 
to a wide variati on of other anomalies11,12. Polyhydramnios combined with a small or invisible 
stomach raises the positi ve predicti ve value for EA/TEF to 39-56%12-16. This combinati on 
lacks specifi city, however, because amnioti c fl uid may fl ow into the stomach when a TEF is 
present. Eff orts to improve the detecti on rate of EA/TEF have focused on ultrasound or MRI 
demonstrati on of an esophageal pouch; i.e. a dilatati on of the blind-ending upper esophageal 
segment12,17-22. Prenatal detecti on of EA is diffi  cult; therefore most oft en EA is diagnosed 
postnatally.
 Postnatally, EA is suspected in the presence of excessive oropharyngeal secreti ons, 
with or without respiratory diffi  culti es, and the inability to pass a nasogastric tube, confi rmed 
on chest radiograph. The two ends of the esophagus are usually surgically anastomosed 
within 24-48 hours from the diagnosis6. From 2002 onwards pediatric surgeons have used 
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a thoracoscopic approach23. Recent studies evaluated the safety, effi  cacy and outcome of 
this approach24-27. From the fi ndings it is clear that it will become the procedure of choice, 
provided the surgeon is well experienced. 
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Figure 1 
A: Classifi cati on system for EA/TEF according to Gross (1953)
B: Schemati c representati on of normal development of the foregut
F: foregut, L: lung, LB: lung bud, E: esophagus, T: trachea, S: stomach, GA: gestati onal age. Color fi gures can be found in 
the appendix. See page 180
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 Possible post-operati ve complicati ons are anastomoti c strictures and leaks, recurrent 
tracheo-esophageal fi stula, gastro-esophageal refl ux and sequelae of thoracotomy, such as 
scoliosis and thorax asymmetry. Although mortality and complicati on rates have decreased 
over the past decades, EA/TEF may sti ll cause signifi cant short- and long-term morbidity6,28-34. 
Embryology
The trachea, esophagus and lungs are foregut-derived structures. The endodermal layer of 
the early embryo converts into the primiti ve gut tube. During the fourth week of embryonic 
life, the proximal foregut divides into a ventral respiratory part and a dorsal gastro-intesti nal 
part. This process is initi ated by a ventral evaginati on from the foregut with the two lung buds 
(Figure 1B). The separati on of esophagus and trachea is complete at day 35 of gestati on.
 The process by which the trachea and esophagus are defi ned and separated is not 
well understood. The mechanisms for normal tracheo-esophageal embryogenesis have 
recently been reviewed, focusing on both normal and abnormal morphogenic mechanisms 
and controversies in the development of EA/TEF35,36. For example, competi ng theories of 
separati on exist, e.g. fusing of lateral longitudinal tracheo-esophageal folds in a caudal to 
cranial directi on (traditi onal theory)37, folds that grow into the tracheo-esophageal space 
(no fusing)38,39, or stages or epithelial proliferati on and apoptosis by which the trachea and 
esophagus separate40,41. A diff erent theory was proposed by Crisera et al., studying the 
adriamycin rat model. They proposed that an atresia of the foregut is the primary event, 
leading to a trifurcati on of the lung bud; the left  and right branches develop into the lungs and 
a third branch forms the tracheo-esophageal fi stula39,42.
Eti ology
A plethora of geneti c and environmental factors have been suggested to play an eti ological role 
in EA/TEF, but the developmental mechanisms are far from clear (for overviews, see Felix et al. 
2004 and 2009)43,44. Studying specifi c abnormaliti es in genes or geneti c pathways associated 
with either syndromic or isolated EA/TEF is expected to be helpful5. In additi on, knowledge 
about environmental factors and their possible interacti ons with geneti c factors may provide 
further clues. Unraveling the eti ology may be a starti ng point for preventi ve strategies and 
parental counseling.
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Geneti c factors 
From 6 to 10% of postnatally diagnosed pati ents with EA are also diagnosed with a chromosomal 
abnormality or syndrome5. An overview of geneti c syndromes and the corresponding 
phenotypes is given in Table 1. Geneti c abnormaliti es associated with EA/TEF were found in 
animal studies as well.
Human syndromes and associati ons
EA/TEF is present in a number of syndromes and associati ons. Of these, the VACTERL (Vertebral, 
Anal, Cardiac, Tracheo-Esophageal, Renal, Limb) associati on is the best known, seen in any 
of its various presentati ons in 10-30% of infants with EA/TEF1,45,46. Currently, the eti ology of 
VACTERL associati on is unclear. Litt le is known about a possible geneti c predispositi on. A few 
studies, however, found causati ve mutati ons in the genes FANCB, HOXD13, PTEN, and ZIC3 
in some pati ents with VACTERL-associated anomalies combined with other major anomalies, 
such as hydrocephalus or heterotaxy47-50. However, no specifi c geneti c locus has been found 
yet. Recently Stankiewicz et al. described deleti ons on the 16q24.1 locus in syndromic pati ents 
with overlapping anomalies of the VACTERL associati on. This locus includes the forkhead 
genes FOXF1, FOXC2 and FOXL. Of these transcripti on factors, FOXF1 is of parti cular interest, 
because heterozygote knockout mice for this protein show EA/TEF51. 
 Also, EA/TEF occasionally occurs in combinati ons with hemifacial microsomia, cardiac, 
vertebral and/or central nervous system anomalies (Goldenhar syndrome). This syndrome has 
a familial occurrence, but no geneti c basis has been described52-56. 
 Around 30-40% of pati ents diagnosed with Feingold syndrome have EA/TEF. 
Mutati ons and deleti ons of the MYCN gene on chromosome 2p24.1 were shown to cause 
this syndrome57,58. There is every reason, therefore, to test pati ents with EA/TEF and other 
characteristi cs of Feingold syndrome for variants of this gene, and to counsel them on the risk 
of transmitti  ng the syndrome to off spring. 
 EA/TEF can be part of the spectrum of anomalies seen in Fanconi anemia: mutati ons in 
the FANCA, FANCB, FANCC, FANCD1 (BRCA2), FANCD2, and FANCG genes have been described 
in pati ents with EA/TEF with various combinati ons of defects, including microcephaly, short 
stature, pigment changes, and several VACTERL-associated anomalies, including heart, renal, 
and limb defects47,59-64.
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General Introducti on
 Deleti ons and mutati ons in the SOX2, CHD7 and MID1 genes were shown to be a cause 
of AEG (Anophthalmia-Esophageal-Genital) syndrome, CHARGE syndrome and X-linked Opitz 
syndrome, respecti vely65-67. Que et al. showed that hypomorphic Sox2 mutant mice have EA 
with a distal TEF, thereby providing a link between the animal and human defects68. 
 Other genes implicated in both humans and animals are GLI3 and FOXF1. Mutati ons in 
the GLI3 gene can cause Pallister-Hall syndrome, in which laryngotracheo-esophageal cleft s 
are occasionally described69-72. Combined Gli2/Gli3 knockout mice display severe foregut 
anomalies, as described in more detail below73. 
Chromosomal anomalies
EA/TEF occurs in children with trisomy 21 (0.5-1.0%) and trisomy 18 (up to 25%)3,74-76, but 
also in pati ents with trisomy 13 (Patau syndrome) and (mosaic) trisomy X1,3,75,77. The causati ve 
mechanism for the anomalies in these trisomies is unknown. 
 A number of pati ents with EA/TEF have structural chromosomal anomalies (for review, 
see Felix et al., 200778; Lurie 200779). As many of those display other birth defects and/or 
multi ple chromosomal anomalies as well, it is diffi  cult to link a specifi c chromosomal defect to 
EA/TEF. 
 Deleti ons on several chromosomal loci – including 22q11 (DiGeorge syndrome), distal 
13q, 17q21.3-q24.2, and 16q24.1 – are found occasionally51,78,80-85. Interesti ngly, some of 
these deleted loci include several candidate genes for EA/TEF e.g., the 17q21.3-q24.2 region 
including NOG and TBX4, known from animal studies to be involved in foregut development83-85. 
TBX1 is the most important candidate gene in 22q11 deleti on syndrome, but no mutati ons in 
this gene have been described in pati ents with EA/TEF69,80,86,87.
 Studying specifi c geneti c anomalies involved in EA/TEF may provide valuable 
informati on about the abnormal developmental processes leading to EA/TEF. Additi onally, it 
may give insight into more general processes involved in faulty foregut development.
Knockout and other mutati on models
Aside from human studies, EA/TEF can be studied in experimental animal models, usually the 
mouse, in which specifi c genes have either been mutated or deleted. If the treated mouse 
shows a phenotype that includes EA/TEF, the likely conclusion is that the deleted or mutated 
gene is probably involved in the normal development of the mouse foregut. A number of 
genes and pathways have been studied in mice. Although these results cannot necessarily be 
extrapolated to humans, they can produce valuable insights into developmental mechanisms 
and may provide starti ng points for further studies in humans. 
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 In recent years, Sonic hedgehog (Shh) and its downstream mediators have been a major 
focus of animal research. Shh is a small signalling molecule involved in multi ple developmental 
processes. In mice, Shh null mutants have severe foregut anomalies, including EA/TEF88. 
Deleti on of the chromosomal locus that contains the SHH gene has been reported in only one 
human pati ent with EA/TEF. This child also had other congenital anomalies89. Other pati ents 
reported to have deleti ons of this region did not have EA/TEF or other gastro-intesti nal 
anomalies75,90,91. To the best of our knowledge, there are no studies describing the systemati c 
screening of EA/TEF pati ents for mutati ons or deleti ons of SHH. Interesti ngly, MYCN, the gene 
involved in Feingold syndrome, is a direct signalling target of the Shh pathway92,93. 
 Knockout models of downstream mediators of the Shh signalling pathway, for example 
several genes of the Gli family, which are regulatory transcripti on factors, have phenotypes 
with EA/TEF or lung abnormaliti es. Reducing the Gli3 dosage, by 50% in a Gli2-/- background 
gives a phenotype of EA/TEF; combined knockouts for Gli2 and Gli3 do not form esophagus, 
trachea or lungs at all94. Gli3 thus provides a link between the well-described Shh pathway in 
mouse foregut development and a human defect of foregut development. Also, Shh inhibits 
the expression of the growth factor Fgf10 in the lung, while regulati ng the expression of Gli3. 
Gli3 in its turn controls the expression of Foxf1, a transcripti on factor, which induces Fgf10 
expression (for a review, see Cardoso and Lu, 2006)95. Lack of Foxf1 has also been shown 
to cause EA/TEF in haploinsuffi  cient mice96, and recently a deleti on of the 16q24.1 locus, 
including the FOXF1 gene, was described in a pati ent with EA/TEF51. 
 In additi on, Sonic hedgehog has been shown to induce Bmp4, a bone morphogeneti c 
protein (Bmp) with regulatory functi ons97. Bmp signaling is present in the anterior foregut, 
where the tracheal primordium originates; targeted knockouts for Bmp4 at this site have no 
trachea development98. It also has been suggested that Hox proteins are downstream proteins 
in the BMP-pathway99, and Shh induces a number of Hox genes during development of chick 
hindgut100. 
 Another mouse knockout model for EA/TEF is that of the BMP-antagonist Nog. It results 
in EA/TEF in around 60% of cases101,102. Que et al. demonstrated that Nog transcripti onal 
processes could explain the degree of development of the trachea, and therefore could 
discriminate between the subtypes of tracheal agenesis101. In additi on, Nog knockout mice 
display lung branching defects, abnormal notochord morphogenesis, exencephaly, limb, 
vertebral and carti lage abnormaliti es and lethality at birth. This phenotype does not resemble 
any of the human syndromes in which EA/TEF is described. NOG mutati ons in humans have 
been described, but no associati ons with EA/TEF have been reported101. 
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 The abnormal notochord morphogenesis, similar to those seen in the Adriamycin 
rat model described below, involves a prolonged connecti on of the notochord to the 
foregut101,102. The notochord normally expresses Nog, whose product is the Noggin protein. 
In Nog null mutants the Bmp4 gene is not inhibited, leading to unrestrained BMP4 signalling 
and increased intercellular adhesion. This process might play a role in the development of EA/
TEF101. 
 Li et al. off ered yet another hypothesis for the foregut anomalies observed in Nog null 
mutant mice. They postulate that the imprecise and delayed detachment of the notochord 
from the dorsal foregut causes cells from the dorsal foregut to associate with the notochord as 
it separates from the foregut. This would signifi cantly reduce the number of cells of the dorsal 
foregut, leading to the formati on of an atresia102. 
 Mutati ons in the MID1 gene are a cause of X-linked Opitz syndrome in humans, in 
which TEF has been described67. In the establishment of the right-left  axis in chickens, Mid1, 
encoding a protein involved in cell proliferati on and development, has been shown to positi vely 
infl uence Bmp4 expression and to negati vely infl uence Shh expression. The role of human 
MID1 expression in the patt erning of the left -right axis is sti ll unclear103. 
 Vitamin A has long been known as crucial for normal development. To illustrate this 
we refer to the fi nding that pregnant rats kept on a vitamin A defi cient diet gave birth to pups 
with abnormal lung morphogenesis104. Vitamin A is metabolized into reti noic acid that during 
foregut development binds to one of its receptors and thereby infl uences the expression of 
Hox genes. An example is Hoxa5, which encodes a homeoti c protein that binds to DNA in the 
lungs105. Knockout mice for diff erent combinati ons of subtypes of the reti noic acid receptors 
tend to display abnormal morphology of trachea and esophagus, similar to that observed 
in vitamin A defi cient pups106,107. Some knockout mice for the Hoxa5 gene display tracheal 
occlusion as well as abnormal lung and respiratory tract development108. A proporti on of 
knockout mice for another Hox gene, Hoxc4, have a phenotype that includes EA/TEF and 
vertebral anomalies. However, as these mice also showed aff ected expression of other Hox 
genes, the phenotype cannot yet be conclusively ascribed to Hoxc4109. 
 Various other genes, such as Thyroid Transcripti on Factor-1 (Ttf -1), are involved in 
foregut development and, when knocked out in experimental animals, oft en cause EA/TEF 
combined with severe anomalies of the respiratory system110.
 Another gene, Sox2, has recently elicited interest in both humans and animal research. 
The majority of hypomorphic Sox2 mutant mice display EA/TEF68. In humans, mutati ons 
and deleti ons of SOX2 can cause AEG-syndrome, which includes EA/TEF65,68. Hypomorphic 
Sox2 mice also display severe eye anomalies, similar to those present in AEG-syndrome111. 
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Interesti ngly, in the absence of Sox2 expression, the foregut tube displayed a 'tracheal 
phenotype', with upregulated expression of Ttf -1. In contrast, in Ttf -1-/- mice, the foregut 
showed increased Sox2 expression, suggesti ve of reciprocal regulati on between Sox2 and Ttf -1 
during early foregut development68. 
 A single point mutati on in the Pcsk5 gene caused a phenotype with characteristi cs of 
the VACTERL associati on, caudal regression syndrome and Currarino syndrome, in a mouse 
model using the mutagen ENU (Ethylnitrosourea)112. Pcsk5 is a proprotein convertase that 
mediates postt ranslati onal processing for several integrin alpha subunits. Mutati ons prevent 
its export from the endoplasmati c reti culum and destroy its proprotein convertase acti vity. 
All Pcsk5 mutant mice had abnormal tracheo-esophageal separati on. Additi onally, there were 
pulmonary, anorectal, cardiac, skeletal, limb and renal malformati ons, and pre-sacral mass. 
The Pcsk5 mutati on resulted in abnormal expression of several Hox genes, including genes 
necessary for caudal development. Mutati ons in PCSK5 were also found in human pati ents with 
VACTERL associati on, whose defects included tracheo-esophageal anomalies112. However, the 
mutati ons were inherited from a phenotypically normal parent, so their exact eti ological role 
remains unclear.
 Except for Sox2, Pcsk5, Foxf1, Noggin and Shh, mutati ons or deleti ons of other genes 
that cause EA/TEF in knockout mice have been described in humans. However, the fact that 
none of these pati ents had an esophageal anomaly, again shows that translati ng animal data 
to human malformati ons is problemati c113-115 (for overview: Figure 2).
Environmental factors
Teratogenic models
The Adriamycin rat model, which has also been adapted to the mouse, is a teratogenic model 
of EA/TEF116,117. Adriamycin is a glycosidic anthracyclin anti bioti c used in chemotherapy. 
When given to pregnant rats during a specifi c ti me window in pregnancy, it produces EA/TEF 
in the off spring116. 
 In Adriamycin-treated rats that developed EA/TEF the notochord had an abnormal 
positi on and remained att ached to the foregut longer than usual, similarly to the situati on 
described in the Nog knockout mouse by Li et al. and Que et al.101,102. In additi on, the 
notochord showed abnormal ventral branching118-120. Qi et al. speculated that the abnormal 
positi on of the notochord may cause tracti on on the foregut, thus leading to occlusion or 
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even complete interrupti on of its lumen. Separati on of the notochord from the foregut may 
therefore be a prerequisite for normal foregut development118. 
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Figure 2: Schemati c representati on of abnormal development of the foregut and genes involved in 
abnormal phenotypes
Genes involved in abnormal development of the foregut, resulti ng in EA + TEF, F: foregut, L: lung, LB: lung bud, E: esophagus, 
T: trachea, S: stomach, TEF: tracheo-esophageal fi stula, EA: esophageal atresia, LP: abnormal lung phenotype, * = lung 
phenotype present, ** = deleti on in a single case. Color fi gures can be found in the appendix. See page 180.
 The studies in the Adriamycin rat model have relevance to the teratology and geneti cs 
of EA/TEF and the VACTERL spectrum. Knockout mice for the Shh gene and for its downstream 
mediators, Gli2 and Gli3, display a range of abnormaliti es consistent with the VACTERL 
spectrum121,122. The same patt ern of anomalies is observed in rats exposed to Adriamycin123,124. 
This observati on led to studies into the expression of Shh and its downstream mediators in the 
Adriamycin model125. 
 One of the roles of the notochord in the development of the foregut is to provide a 
source of signaling acti vity126. Like the Nog knockout model described above, the abnormally 
close positi on of the notochord to the foregut in the Adriamycin-exposed rats may lead to 
abnormal signaling of Shh, which acts in a dose-dependent way, from the notochord to the 
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foregut125,126. Shh signalling is normally down-regulated when the notochord separates from 
the foregut and this is an essenti al prerequisite for normal tracheo-esophageal separati on. In 
Adriamycin-exposed rats it remains high due to the close proximity of the two structures, and 
thus thwarts normal development of trachea and/or esophagus125,126. 
 However, as EA/TEF is also found in Adriamycin-treated rats with a normal notochord 
and as not all Adriamycin-rats with a malformed notochord develop EA/TEF, the exact nature 
of the associati on between these two anomalies is not enti rely clear127,128. 
 Although no associati on between Adriamycin or related substances and EA/TEF has 
been reported in humans129,130, this animal model is sti ll of great value for studies into the 
embryology, morphology, histology and geneti cs of EA/TEF. For it produces EA/TEF in a manner 
corresponding to that seen in the commonest type in humans, that is, a proximal atresia with 
a distal fi stula. The model’s disadvantage is that Adriamycin works by interfering with DNA 
replicati on and by inhibiti ng DNA and RNA synthesis131. As such, it will not only aff ect the 
esophagus. The off spring of rats treated with Adriamycin indeed display other anomalies 
besides EA/TEF. Most of these are anomalies of the VACTERL-spectrum, but bladder anomalies 
have also been described124. The eff ects of Adriamycin exposure on the levels of expression of 
genes and proteins are not known.
 As was menti oned above, Ethylnitrosourea, an alkylati ng and mutagenic agent, induces 
a recessive mouse mutati on with a phenotype that includes abnormal tracheo-esophageal 
septati on and VACTERL-associated anomalies112. 
Other environmental factors
Various environmental factors have been suggested to be a risk for the development of 
tracheo-esophageal anomalies, including exposure to methimazole, stati ns, alcohol, smoking 
or exogenous sex hormones, maternal phenylketonuria, infecti ous disease, or work in 
agriculture or horti culture132-144. Observati ons in insulin-dependent diabeti c mothers suggest 
that fi rst trimester exposure to maternal diabetes is associated with the development of 
congenital anomalies, including EA/TEF and VACTERL-associated anomalies145. Studies from 
the EUROCAT birth registry network found that older mothers are at signifi cantly greater risk 
of having a child with EA146. 
 Previous studies implicated that maternal in utero exposure to diethylsti lbestrol 
(DES) might play a role in the eti ology of EA/TEF in the off spring143. Several hypotheses for 
the mechanisms of such a transgenerati onal eff ect have been proposed. These include (epi)
geneti c changes in the oocytes of the mother during her own fetal development, which would 
then become apparent in the next generati on; disrupti on of the cell cycle of the oocytes, 
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making them more vulnerable to detrimental exposures; and (epi)geneti c changes in the 
somati c cells of the exposed mothers, resulti ng in an altered environment that could aff ect 
their embryos147.
 So far, no specifi c environmental risk factor has consistently been identi fi ed, although 
EA/TEF is usually considered part of methimazole embryopathy.
Molecular cytogeneti cs of congenital anomalies
Introducti on
Diagnosti c-geneti c approaches have been applied in pati ents with congenital anomalies since 
the discovery of chromosomes. For more than 50 years, karyotyping has been a successful tool 
to identi fy chromosome aberrati ons in mental retardati on, fetal development abnormaliti es, 
reproducti ve failure, and congenital malformati ons. It could reliably identi fy numerical 
chromosome changes and structural chromosomal rearrangements such as deleti ons, 
duplicati ons, translocati ons or inversions. However, karyotyping using G-banding is limited to 
5-10 Mb of resoluti on; the size of a band roughly depends on the availability of metaphases and 
the quality of the chromosome preparati ons. Sophisti cated molecular cytogeneti c techniques 
implemented in the last decade nevertheless allowed indenti fying chromosomal aberrati ons 
smaller than 5 Mb. As an additi onal advantage, these new techniques use DNA as starti ng 
material. Thus there is no need for cell cultures and stored N2 frozen biopsies can be used for 
analysis.
Karyotyping
One of the prerequisites of conventi onal chromosome analysis is the availability of metaphases. 
Usually blood or ti ssue specimens are cultured to obtain dividing cells and metaphases. 
Peripheral blood samples are cultured for 3-4 days but fetal samples or skin biopsies, for 
example, must be cultured for 1-2 weeks to obtain an adequate number of dividing cells for 
metaphase analysis. Synchronizati on techniques using thymidine or colchicine to stop the cell 
cycle in a parti cular phase to yield a larger number of metaphases. The cultured cells are 
fi xed in methanol/aceti c acid and spott ed on a microscopic slide under controlled humidity 
conditi ons. In the 1950s and 1960s, the pre-banding era, numerical chromosome anomalies – 
e.g. trisomy 21 in Down syndrome, and aneuploidy of sex chromosomes in Turner syndrome 
or Klinefelter syndrome – were described as well as the fi rst structural anomaly in cancer: the 
Ph (Philadelphia) chromosome, a shorter chromosome 22q, detected specifi c in blood and 
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bone marrow of pati ents with chronic myeloid leukaemia148. In the 1970s the applicati on of 
chromosome banding techniques yielded many structural chromosome aberrati ons, such as 
translocati ons, inversions, deleti ons, and duplicati ons. All these aberrati ons can be accurately 
described using the ISCN standards149. 
 The G-banding technique (trypsin-Giemsa staining) became most accepted worldwide 
(see Figure 3). This method routi nely achieves a resoluti on of 500-800 bands and enables 
to disti nguish deleti ons or duplicati ons larger than 5-10 Mb. In specifi c cases, more subtle 
aberrati ons could be recognized with high-resoluti on banding (>1,000 bands) using 
chromosomes in pro-metaphase150. For example, small deleti ons on specifi c chromosomes 
in pati ents suff ering from Prader Willi/Angelman syndrome or velocardiofacial syndrome. 
Despite ongoing developments in the fi eld of molecular cytogeneti cs, standard karyotyping is 
sti ll the best suitable method to detect balanced anomalies such as reciprocal translocati ons 
and inversions151.
 A B
Figure 3: Karyotype of GTG-banded chromosomes
A Karyogram of Giemsa-trypsine G-banded chromosomes. 
B The original non-banded metaphase spread is visible.
Fluorescent in situ hybridisati on (FISH)
FISH is a molecular cytogeneti c technique in which fl uorescently labeled DNA probes are 
hybridized to metaphase spreads or interphase nuclei152. A variety of probe types is available 
to detect aneuploidy and chromosome rearrangements. Parti cularly, locus-specifi c probes can 
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detect gene copy-number changes that are generally missed by classical karyotyping. This is 
helpful in individuals clinically diagnosed with a specifi c microdeleti on syndrome153,154. FISH is 
also useful to detect acquired chromosomal abnormaliti es in tumor samples and can be used 
as a prognosti c marker and predict response to treatment155,156. 
 In a cytogeneti c diagnosti cs setti  ng, FISH is routi nely used to confi rm the clinical 
diagnosis of a wide variety of congenital conditi ons in individuals with developmental delay 
and mental retardati on. The recurrent deleti ons or duplicati ons found are 1-5 Mb large and 
are oft en fl anked by highly repeti ti ve sequence blocks facilitati ng the rearrangement of the 
chromosomal region. More than 200 of these microdeleti on or microduplicati on syndromes 
have been identi fi ed. For most recurrent deleti ons or duplicati ons a combinati on of 2-4 FISH 
probes157 is suffi  cient to detect the anomaly with high effi  ciency. In a diagnosti c setti  ng 
commercially available FISH probes are used to detect these anomalies (Figure 4A). The wider 
applicati on of genome wide screening techniques has led to the recogniti on of more recurrent 
aberrati ons158-160. 
 To detect chromosomal imbalances at the telomeres, a specifi c set of sub-telomere 
region-specifi c FISH probes has been developed to simultaneously explore the enti re sub-
telomeric chromosomal regions in humans. These telomere aberrati ons are oft en the result 
of a balanced translocati on in one of the parents and over 5% of the pati ents with idiopathic 
mental retardati on harbor such an anomaly161,162. Alternati vely, chromosome paints covering 
a whole chromosome can be used to confi rm the unbalanced chromosomal translocati on and 
to visualize a balanced translocati on in the parent (Figure 4B).
 FISH has several limitati ons. The commonly used probes (100-150 kb) are relati vely 
large and fail to detect small deleti ons. Besides, no more than three to fi ve DNA probes can 
be used in one experiment, thus limiti ng the number of targets assayed. However, specifi c 
labeling strategies allow the simultaneous visualizati on of all 24 human chromosomes in a 
single hybridizati on. Each chromosome is visualized in a diff erent color, oft en generated by the 
computer program. These genome wide assays – such as Multi plex FISH (M-FISH)163 or spectral 
karyotyping (SKY)164 – are predominantly used to identi fy complex structural chromosomal 
rearrangements and marker chromosomes in prenatal and postnatal pati ents. Using micro-
dissecti on of a few chromosomal bands, FISH probes combined with the above menti oned 
labeling strategies generate a multi -color chromosome paint. This allows easy detecti on and 
identi fi cati on of complex inter-chromosomal aberrati ons (Figure 4C).
26 
Chapter 1
Figure 4: Fluorescent in situ hybridisati on (FISH) with diff erent probe types 
A  Single copy probes were used for 22qter (red signal) and 22q11(green signal). Note the deleti on of the 22q11 
 locus on chromosome 22*. 
B  Chromosome paints specifi c for chromosome 2 (green signal) and chromosome 6 (red signal) were used. Derivati ve 
 chromosomes of the balanced t(2;6) translocati on, der(2) and der(6) are indicated. 
C  M-FISH probes for chromosome X. Color fi gures can be found in the appendix. See page 181
Quanti tati ve methods: MLPA and qPCR
Multi plex ligati on-dependent probe amplifi cati on (MLPA), and (real-ti me) quanti tati ve PCR 
(qPCR) have been developed to detect gene dosage alterati ons in a variety of prenatal and 
postnatal disorders. MLPA is a PCR variati on that permits the amplifi cati on of multi ple targets 
with only a single primer pair165. Each probe consists of a pair of primers that upon hybridizati on 
to a target sequence are subsequently ligated into a complete target sequence. The advantage 
of splitti  ng the target probe is that only the ligated target sequence and not the original sample 
DNA is amplifi ed. One of the MLPA primer pair is tagged with a DNA sequence of predefi ned 
length, known as the stuff er sequence. During electrophoresis, the stuff er sequence ensures 
that a given amplicon occurs at a known positi on along the gel. Diff erent stuff er-sequence-
lengths are therefore used to separate the various target amplicons. This avoids the resoluti on 
limitati ons of multi plex PCR. The probes are also tagged with a fl uorescent label so that the 
intensity of the measured signal is related to the quanti ty of the target amplicon. Specifi c 
soft ware programs display the quanti tati ve results. This method is parti cularly suitable to 
detect aneuploidy and unbalanced translocati on and is widely used in prenatal diagnosti cs166. 
The effi  cacy of this approach was demonstrated by Ahn et al.167, who validated this method in 
a large series of over 450 pati ents and demonstrated its high effi  ciency in medium-throughput 
screening for subtelomere imbalances.
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Comparati ve genomic hybridizati on 
Comparati ve genomic hybridizati on (CGH) is a technique in which diff erenti ally fl uorescently 
labeled pati ent and reference genomic DNA are hybridized on metaphase chromosome slides. 
For each chromosome, a rati o value of the fl uorescence intensity is generated from fi ve to 
twenty metaphases. Thus, diff erenti al hybridizati on signals allow the detecti on of unbalanced 
gains and losses of chromosomal material across the whole genome168,169. CGH has been 
useful for the analysis of chromosomal imbalances in solid tumors and congenital anomalies. 
This technique allows the detecti on of unbalanced translocati ons, which are not detectable 
with standard karyotyping170-172. However, CGH is limited by a resoluti on of 3-10 Mb and 
aberrati ons with a smaller size will not be detected.
High density microarrays 
Introduced in 2001, microarray-based CGH techniques have changed the fi eld of clinical 
cytogeneti cs173. Array CGH was initi ally developed to detect copy number changes in tumor 
samples; today it is widely used to study neuro-developmental disorders and congenital 
malformati ons with respect to genomic gains and losses174-176. The rapid development 
of diff erent platf orms with high resoluti ons has increased our knowledge on deleti ons and 
duplicati ons, microdeleti on and microduplicati on syndromes, and common variati on in the 
human genome177-180.
 The array CGH technique is based on diff erenti ally labeled test (pati ent) and reference 
(control) genomic DNA simultaneously hybridized to a glass slide with targeted clones. 
Aft er co-hybridizati on the intensiti es of the fl uorescent dyes are scanned and measured. If 
the intensiti es on one spot are equal, the amounts of reference and test DNA are balanced. 
Diff ering intensiti es point at loss or gain of DNA, i.e. a deleti on or duplicati on of a chromosomal 
region, respecti vely (Figure 5). The target sequences on the microarrays can be a variety of 
DNA substrates, e.g. bacterial arti fi cial chromosomes (BACs), oligonucleoti des or cDNAs. The 
resoluti on of the array is determined by the size of the cloned DNA targets and the distance 
between the targets on the genomic maps181,182. Initi ally, simple BAC-arrays with 3,500 FISH 
validated BACs and resoluti ons of 1 Mb were used183. As the technique developed, ti ling 
path arrays with > 35,000 BAC clones and a resoluti on up to 100 kb were achieved184. Higher 
resoluti ons could be reached with 30-60bp oligo-nucleoti de arrays and bett er coverage of the 
genome was established as well. No less than 1-3 x 106 oligomers can now be spott ed on an 
array for a whole genome screening. 
 Single nucleoti de polymorphism (SNP) arrays were developed to detect genome wide 
associati ons (GWA) of a specifi c polymorphism in diff erent disease cohorts. However, when 
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the intensity of the SNPs is incorporated in the analysis, these arrays can also be used to detect 
loss or gain of genomic DNA in a single individual.
Figure 5: Schemati c representati on of the microarray technology 
Genomic DNA of pati ent and control are both labeled with a diff erent fl uorescent dye. These are co-hybridized on a glass 
slide with targeted clones. The signal of hybridizati on is detected with a scanner. The rati o between control and pati ent 
DNA for each clone is plott ed to visualize copy number variati ons, as indicated by a deviati on from the normal log2 rati o 
of zero. In the panel on the right, a normal and an aberrant chromosome 5 with a 5q11 deleti on detected with an Agilent® 
105K Oligo-array, visualized by the Agilent® CGH Analyti cs Soft ware. Color fi gures can be found in the appendix. See page 
181
 With up to 6 million SNPs spott ed on an array, a theoreti cal resoluti on of 6kb can 
be established182. Besides copy number variati ons SNP platf orms can also detect loss of 
heterozygosity and uniparental disomy, which are of interest in pati ents with congenital 
anomalies184. The four largest commercial microarray platf orms are the oligo-array platf orms 
from Agilent® and NimbleGen Systems® and the SNP-platf orms of Aff ymetrix® and Illumina®. 
 Diff erent logarithms and analysing tools are used to process the mountains of data. 
Examples of these tools are the Agilent® DNA Analyti cs Soft ware and the Aff ymetrix® 
Genotyping Console™. Figure 5 illustrates the Agilent® soft ware visualizati on of a normal and 
deleted chromosome 5q11.2.
 For diagnosti c screening some of these platf orms have developed targeted arrays. 
Apart from genome wide coverage, these also include a higher density for the common micro-
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deleti on syndromes. The validity of this technique, an important aspect in a diagnosti c setti  ng, 
is sti ll being debated. 
 The resoluti on of the technique will determine the number of aberrati ons that can be 
detected. In general 5-10 copy number variati ons (CNVs) are detected in a single individual. 
Most of these are non-pathogenic CNVs, seen in other persons as well. Common variati ons are 
collected in central databases, such as the 'Database of Genomic Variants' (htt p://projects.
tcag.ca/variati on)185 and the ‘Copy Number Variati on project’ at the Children’s Hospital of 
Philadelphia (CHOP)186. Some CNVs are recurrent in a given populati on and can serve as a 
signature for a specifi c ethnic origin. In additi on, it is important to check possible pathogenic 
CNVs in an in-house run control set of healthy individuals (local reference set), to disti nguish 
them from non-pathogenic CNVs. This will eliminate the common variati ons178.
 The quality of the DNA also determines the resoluti on of the technique. Hybridizati on 
with minute amounts of DNA or low quality DNA, e.g. from formalin-fi xed-paraffi  n-embedded 
(FFPE) ti ssues results in an increase of the background and therefore requires adjustments in 
the analysis setti  ngs. New labeling methods and protocols to process DNA of FFPE samples 
enlarge the groups of pati ents that can be investi gated with these techniques187. 
 The diff erent array platf orms have a comparable coverage at comparable costs. Sti ll, 
the possibility to design your own array content (targeted arrays) can be an advantage for 
specifi c diagnosti c or research demands. 
 Experiments take about fi ve days, mainly due to the hybridizati on ti me. As the costs are 
going down and process automati on is expected to advance, the microarray technology will 
develop into a robust diagnosti c tool in the fi eld of molecular cytogeneti cs. 
Future prospects
With the development of multi plex-qPCR and microarray techniques, clinicians and researchers 
have powerful tools to identi fy geneti c changes underlying congenital disorders. Although 
karyotyping and FISH are useful for the detecti on of balanced anomalies, array-CGH has proven 
to be instrumental in the identi fi cati on of disease-related chromosomal anomalies188,189 (see 
Figure 6).
 Both clinical and genomic data are collected in large internati onal databases such as 
DECIPHER (htt ps://decipher.sanger.ac.uk) and ECARUCA (www.ecaruca.net). The detecti on 
of rare aberrati ons with concomitant clinical features has lead to the recogniti on of new 
geneti c syndromes. Although this process will conti nue, new techniques, such as exome and 
high-throughput sequencing190,191 or 4C analysis192, are gaining interest. Although sti ll very 
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expensive, these strategies are promising because they provide a soluti on to detect balanced 
translocati ons and inversions.
Figure 6: Resoluti on of the diff erent molecular (cyto)geneti c techniques 
Schemati c presentati on of the possibiliti es and suitability of a specifi c technique to detect the chromosomal aberrati on 
(adapted from Speicher et al.188). At the top, the most common anomalies are depicted. Two chromosome pairs are 
shown in red and blue. To disti nguish between the two parental copies, one of the chromosomes is darker shaded. Filled 
circles indicate that the technique is suitable to detect the aberrati on and open circles indicate that the technique is not 
suitable. Open circle with a ‘+’ show that some of the anomalies can be detected with the technique, depending on probe 
content or percentage mosaicism. UPD: Uniparental disomy; 4C: chromosome conformati on capture-on-chip; HTP seq: 
high-throughput sequencing. Color fi gures can be found in the appendix. See page 181
Aim and outline of the thesis
In the fi eld of eti ological factors in EA/TEF there are many ‘gaps to bridge’. The contributi ons of 
diff erent eti ological factors may vary by pati ent. This thesis in parti cular explores the genotype-
phenotype relati onship of EA/TEF and associated anomalies. The studies therefore focus on 
the phenotypic descripti on of EA/TEF pati ents with an associated anomaly (notably VACTERL), 
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and on the use of geneti c-diagnosti c approaches in unraveling new geneti c eti ological factors 
involved. 
 We used a combined geneti c approach in the search for copy number variati ons 
(deleti ons/duplicati ons). This included karyotyping, screening with Multi plex ligati on-
dependent probe amplifi cati on (MLPA), and a genome-wide approach with microarrays. 
 The study cohort consisted of 321 EA/TEF pati ents treated at the Erasmus MC – Sophia 
Children’s Hospital since 1988. Recently also pati ents from the Pediatric Surgical Center 
Amsterdam (VUmc/AMC) are included in the study. Clinical data, such as prenatal variables, 
pati ent characteristi cs, associated malformati ons and family pedigrees were collected and 
stored in the Sophia MCA database. We carefully phenotyped the pati ents, with a special 
interest in pati ents with VACTERL associated anomalies (Chapter 3). In additi on, ten pati ents 
with tracheal agenesis were recorded in our database. Stored DNA, cell lines and ti ssue of the 
pati ents and parental DNA was analyzed. 
 Table 2 gives an overview of general characteristi cs and geneti c data of the Erasmus 
MC-cohort. In eight of the 321 pati ents, EA/TEF had been diagnosed at autopsy aft er a 
terminati on of pregnancy, at the Pathology Department. Over 55% of pati ents had one other 
major congenital anomaly. Eighty-one of them could be typed as VACTERL associated, with 
at least two other anomalies of the VACTERL spectrum besides EA/TEF. In 37 pati ents a 
chromosomal abnormality or a single gene disorder was causati ve to the EA/TEF phenotype. 
On average, in one in every 10 pati ents a defi ned syndrome was present, which is in line with 
the literature. Many of the known geneti c syndromes were seen in this cohort, including all 
full trisomies (Down Syndrome, Edwards syndrome, Patau syndrome), single gene disorders 
(such as CHARGE syndrome, Feingold syndrome, Opitz syndrome, and Fanconi anemia), and 
some less frequent syndromes (such as Holt-Oram syndrome and Townes Brocks syndrome). 
The distributi on of syndromes is according to the literature5,193.
 From 1998 onwards, the postnatal follow-up of pati ents with congenital anomalies was 
standardized34. This program includes regular examinati ons by specialists and further geneti c 
evaluati on by a clinical geneti cist. All pati ents from 1998 onwards were karyotyped.
 Part I introduces the subject and gives an overview of the current state of knowledge 
on the eti ology of EA/TEF. In additi on, it discusses the molecular-geneti c approaches for 
congenital anomalies used in daily practi ce (Chapter 1). 
 Part II presents the results of clinical studies in this cohort, focusing on the phenotypes 
of pati ents who also showed VACTERL associati on and additi onal congenital malformati ons 
(Chapter 3). Furthermore we studied the relati on between ti me of diagnosis (pre- or postnatal) 
and outcome, specifi cally in pati ents who also showed VACTERL associati on (Chapter 2).
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Table 2: Characteristi cs and syndromes found in the Erasmus MC – Sophia cohort of EA/TEF pati ents
Characteristi cs No of 
cases
Syndromes in cohort No of 
cases
Database of EA/TEF pati ents since 1988 321 Aberrant karyotypes
EA with TEF 274 Down Syndrome (47,XX/XY,+21) 6
EA type A ſ  27 Edwards syndrome (47,XX/XY,+18) 7
Solely TEF  20 Patau syndrome (47,XY,+13) 1
47,XXX 3
Terminati on of pregnancy   8 46,XY,t(3:15)(q28;q22)[4]/46,XY[6] 1
Neonatal death *  33 46,XY,t(5;10)(q13;q23)pat 1
Isolated cases 186 Syndromes
Associated cases 135 22q11 deleti on syndrome 1
VACTERL associated  81 CHARGE syndrome 7
Tracheal agenesis  10 Goldenhar Syndrome 1
Opitz G syndrome 3
Karyotypes 46,XX / 46,XY 250 Townes Brockes syndrome 1
Aberrant karyotypes  19 Holt-Oram syndrome 1
DNA available 190 Feingold syndrome 1
Fanconia Anaemia 1
Klippel-Feil syndrome 1
X-linked heterotaxy 1
* Neonatal death: death of a liveborn infant within the fi rst 28 days of life
ſ, according to the Gross Classifi cati on
 Part III describes the fi ndings of geneti c studies in pati ents with EA/TEF in the search 
for CNVs and specifi c geneti c syndromes (Chapters 4-8). Chapter 4 describes a familial case 
of combined esophageal and anal atresia and the occurrence of the 22q11 microduplicati on 
syndrome. The rare fi nding of several aberrati ons on chromosome X in our cohort is presented 
in Chapter 5. A deleti on on chromosomal locus 5q11.2 in a pati ent with tracheal agenesis is 
described in Chapter 6. Chapter 7 describes the applicati on of high-resoluti on single-nucleoti de 
polymorphism microarrays to identi fy novel and inherited genomic aberrati ons. In additi on, a 
mutati on in the ZIC3 gene is described in a pati ent with EA/TEF and heterotaxy and VACTERL 
associated malformati ons (Chapter 8). 
 In Part IV the results of this thesis are discussed and an overall summary is provided 
(Chapter 9).
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PART II
Clinical Studies in Pati ents with Esophageal Atresia

CHAPTER 2
Pre- and Postnatal Diagnosis and Outcome of 
Fetuses and Neonates with Esophageal Atresia 
and Tracheo-esophageal Fistula
Adapted from:
de Jong EM, de Haan MAM, Gischler SJ, Hop W, Cohen-Overbeek TE, Bax NMA, de Klein A, Tibboel D, 
Grijseels EWM. Pre- and postnatal diagnosis and outcome of fetuses and neonates with esophageal atresia 
and tracheo-esophageal fi stula. Prenat Diagn. 2010; 30: 274-279.
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Abstract
Background: Clinical symptoms and ultrasound signs during pregnancy could suggest the 
presence of esophageal atresia (EA). However, most oft en EA is diagnosed postnatally. The aim 
of our study is to evaluate the course and outcome for prenatally and postnatally diagnosed 
EA. In additi on, we studied the outcome of isolated versus non-isolated EA.
Methods: In a retrospecti ve data analysis, ultrasound characteristi cs, maternal and neonatal 
variables as well as clinical outcome were compared for fetuses/neonates with prenatal 
(n = 30) or postnatal (n = 49) diagnosis of EA. Clinical outcome in terms of morbidity and 
mortality of isolated EA was compared with that of EA complicated by chromosomal or 
structural anomalies. 
Results: Prenatally diagnosed children were born two weeks earlier than postnatally diagnosed 
children (36.4 weeks versus 38.2 weeks; P = 0.02). The former had higher mortality rates (30% 
versus 12%; P = 0.05) and more associated anomalies (80% versus 59%; P = 0.04). In both 
subsets, there was a high morbidity rate in the survivors (not signifi cant). Non-isolated EA was 
associated with greater occurrence of polyhydramnios (53% versus 27%; P = 0.04) and higher 
mortality rate (28% versus 0%; P = 0.002).
Conclusions: Mortality was signifi cantly higher in prenatally diagnosed infants and in infants 
with additi onal congenital anomalies. Isolated EA is associated with good outcome.
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Introduction
Improvements in ultrasound imaging techniques have enabled detecti on of a range of 
developmental disorders and congenital malformati ons early in pregnancy1. One such 
malformati on is esophageal atresia (EA), a conditi on in which the esophagus is interrupted 
and may or may not communicate with the trachea, through a fi stulous tract called the 
tracheo-esophageal fistula (TEF). The incidence of EA is approximately one in 3,500 live births 
and EA with distal TEF is the commonest type (86%)2-4. The eti ology of tracheo-esophageal 
anomalies is largely unknown, but is considered to be multi factorial, comprising geneti c 
and environmental suscepti bility factors, as reviewed recently5,6. Indeed, from 6 to 10% of 
postnatally diagnosed infants with EA are also diagnosed with a chromosomal abnormality 
or syndrome7. Over 50% of infants with EA have additi onal anomalies, e.g. vertebral, gastro-
intesti nal, cardiovascular, renal or limb abnormaliti es4. In approximately 10% of cases, these 
associated anomalies fi t the VACTERL associati on, which is defi ned as EA associated with at 
least two anomalies belonging to the following subsets: vertebrae, anal region, cardiovascular 
system, renal system or limbs7,8. 
 Prenatal detecti on of EA is diffi  cult. The presence of a polyhydramnios may suggest 
gastro-intesti nal obstructi on, but is also related to a wide variati on of other anomalies9,10. 
Polyhydramnios combined with a small or invisible stomach raises the positi ve predicti ve value 
to 39-56%10-14. This combinati on lacks specifi city, however, because amnioti c fl uid may fl ow 
into the stomach when a TEF is present. Eff orts to improve the detecti on rate have focused 
on ultrasound or MRI demonstrati on of an esophageal pouch, i.e. a dilatati on of the blind-
ending upper esophageal segment10,15-19. A new ultrasonographic technique makes it possible 
to visualize the fetal thoracic esophagus between the trachea and the aorta20.
 Postnatally, EA is suspected in the presence of excessive oropharyngeal secreti ons, 
with or without respiratory diffi  culti es, and the inability to pass a nasogastric tube, confi rmed 
on chest radiograph. The two ends of the esophagus are usually surgically anastomosed within 
24-48 hours from the diagnosis. Post-operati ve complicati ons usually include anastomoti c 
strictures and leaks, recurrent tracheo-esophageal fi stula, gastro-esophageal refl ux and 
sequelae of thoracotomy, such as scoliosis and thorax asymmetry4,21,22.
 Bett er diagnosti c techniques and pre- and post-operati ve care have improved the 
prognosis for these infants4. Mortality rates are related to additi onal congenital malformati ons 
and prematurity4,23,24. Morbidity is largely the result of postoperati ve complicati ons, structural 
abnormaliti es of the airways and the presence of additi onal congenital anomalies4,7,22,25. 
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 Litt le has been published about the value of a prenatal diagnosis of EA with regard 
to outcome. We report a study with a twofold aim: (1) to investi gate the disease course and 
outcome of fetuses and neonates with either a prenatal or postnatal diagnosis of EA; and (2) 
to analyze the infl uence of additi onal anomalies on outcome.
Methods
The Erasmus University Medical Center (Erasmus MC) serves as the single referral center for 
both fetal anomaly scanning and pediatric surgery in the south-west of The Netherlands, a 
referral area with 44,000 newborns annually. EA fetuses and infants were identi fi ed from 
the ultrasound (US) databases of the division of Prenatal Medicine and the departments of 
Pediatric Surgery and Pathology in Erasmus MC as well as from those of referring hospitals. 
A retrospecti ve data analysis was carried out concerning all fetuses/ infants born between 
January 2000 and December 2006.
 EA in cases of terminati on of pregnancy (< 24 weeks), fetal or neonatal death, had been 
diagnosed, only if parents granted permission for post-mortem examinati on. Post-mortem 
examinati ons had not been done in pregnancies complicated by a chromosomal anomaly (e.g. 
trisomy 18). Infants with isolated fi stula were excluded. All infants had received standardized 
care, which included further examinati on for congenital anomalies, surgery, and geneti c 
consultati on with karyotyping.
 Polyhydramnios was defi ned as an amnioti c fl uid index >24 cm, measured in four 
quadrants of the uterus26. Absent or small stomach was diagnosed with repeated US 
examinati ons. Prematurity was defi ned as delivery before 37 weeks’ gestati on. Small for 
gestati onal age was defi ned as < -2SD aft er correcti on for gestati onal age and gender27. 
Isolated EA was defi ned as EA without additi onal congenital anomalies and the pati ent having 
a normal karyotype. VACTERL associati on was defi ned as two or more anomalies of the 
spectrum, besides the tracheo-esophageal malformati on8. 
 Two subsets were created: prenatal and postnatal diagnosis. The prenatal subset 
consisted of all women with documented polyhydramnios, and/or absent or small stomach 
bubble on ultrasound, detected in Erasmus MC, or in the referring hospitals with confi rmed 
EA. No 3D-ultrasound or MRI investi gati on was performed. The postnatal subset consisted of 
all infants admitt ed to the department of Pediatric Surgery with an EA, without prenatal US 
examinati on or without any documentati on of the defi ned complaints during pregnancy. These 
subsets were compared with respect to outcome and associated anomalies. The outcome 
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measures were neonatal morbidity (anastomoti c esophageal strictures and leaks, recurrent 
TEF, gastro-esophageal refl ux, number of re-operati ons, length of hospital stay) and mortality. 
Follow up analysis covered the fi rst 12 months aft er birth.
 In additi on, we created subsets of cases with isolated EA and cases with EA and 
associated anomalies (non-isolated EA). These were likewise compared with respect to 
morbidity and mortality.
 Stati sti cal analysis was performed with SPSS version 15.0.0. using the Mann-Whitney 
test or Fisher’s exact test for conti nuous or categorical data, respecti vely. P < 0.05 (two-sided) 
was considered the limit of stati sti cal signifi cance.
Results
Post mortem cases
Three pregnancies had been terminated (< 24 weeks) aft er prenatal US had revealed multi ple 
severe structural anomalies. One was terminated at 21 3/7 weeks and concerned a male 
fetus with an EA with distal fi stula, associated with duodenal atresia and an eventrati on of 
the diaphragm. Karyotype was normal and no dysmorphic features were seen. The second 
pregnancy, terminated at 22 3/7 weeks, was complicated with oligohydramnios. The male 
fetus had an EA with distal fi stula, associated with anal atresia, agenesis of the left  kidney, 
a dysplasti c right kidney, pre-axial polydactyly, bilateral pes equinovarus and dysmorphic 
features, e.g. low implant of ears with malformed ear helixes and a single umbilical artery. The 
third pregnancy had been terminated at 19 1/7 weeks. Multi ple structural abnormaliti es and 
intrauterine growth retardati on were seen on US. The female fetus had EA with distal fi stula, 
associated with a hypoplasti c left  heart, mono-ventricle with common outlet, uterus bicornis 
and dysmorphic features; agenesis of the left  ear and dysplasti c right ear, prognathy, small 
mandible and an asymmetric face. Ultrasound characteristi cs of EA and/or polyhydramnios 
were seen in none of these three cases, most likely due to the gestati onal age at terminati on.
Characteristi cs of the prenatal subset
 In total, the prenatal subset consisted of 17 fetuses diagnosed at Erasmus MC and 13 fetuses 
from referring hospitals. Ultrasound variables of fetuses diagnosed at Erasmus MC were 
measured in a standardized manner, and data were stored in a prenatal database (Table 1). 
Three of these 17 infants had an isolated EA (18%). The other 14 showed one or more additi onal 
anomalies, mainly vertebral, cardiac, renal, or anorectal anomalies. The US diagnosis of EA had 
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been made signifi cantly earlier in the cases of isolated EA (26.4 versus 32 weeks; P = 0.04). 
AFI was > 30 in 8 of these 17 infants (47%). There was no signifi cant diff erence in this regards 
between infants with isolated EA and non-isolated EA. One chromosomal anomaly was found 
(trisomy 21). The prognosis was good for pati ents with isolated EA; none of these infants died 
in the postnatal period, versus 6 of the 14 in the non-isolated group (43%). The presence 
of associated anomalies had no eff ect on postnatal morbidity with regard to durati on of 
hospitalizati on, number of complicati ons and number of re-surgeries.
 From the informati on provided by obstetricians from the referring hospitals about 
the remaining 13 infants, it appeared that all women showed symptoms of polyhydramnios. 
In three pati ents the stomach bubble was absent. However, more detailed ultrasound 
descripti ons or data were lacking.
Table 1: Characteristi cs of the prenatal subset of pati ents with EA from Erasmus MC
Isolated EA
N=3
Non-isolated EA
N=14
P value
GA ultrasound weeks, mean (range) 26.4 (20.0-32.3) 32.0 (25.4-36.1) 0.04*
GA ultrasound < 30 weeks (%) 2 (67) 5 (36) 0.57
AFI, mean† 28.4 31.5 0.39
AFI > 30 (%) 1 (33) 7 (50) 1.00
Spontaneous delivery (%) 2 (67) 8 (56) 1.0
GA delivery weeks, mean (range) 38.0 (32.3-41.1) 35.3 (29.1-42.0) 0.31
Birth weight g, mean (range) 2335 (1640-2825) 2328 (1060-3440) 1.0
Neonatal death (%) 0 6 (43) 0.52
Male gender (%) 2 (67) 9 (64) 1.0
Anomalies (%)
 – Vertebral
 – Anorectal
 – Cardiac
 – Renal
 – Limb
-
2 (14)
4 (28)
6 (42)
5 (36)
1 (7)
Chromosomal anomaly - 1
Length of hospital stay, mean (range)$ 54.7 (19-86) 114.3 (28-325) 0.22
No. of complicati ons 0.7 0.9 0.33
No. of surgeries 4.3 3.7 0.62
GA, gestati onal age; †, excluded anhydramnios due to soluti o placenta or PROM; *, stati sti cally signifi cant; $, excluded 
neonatal death
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Comparison of prenatal and postnatal subsets of EA pati ents
The postnatal subset encompassed 49 pati ents, without prenatal US examinati on or without 
any documentati on of complaints during pregnancy. Delivery and outcome variables for both 
subsets are shown in Table 2. The mean gestati onal age at delivery in the prenatal subset was 
signifi cantly shorter (36.4 weeks) than that in the postnatal subset (38.2 weeks; P = 0.02). 
This was not due to inducti on of labour; the mode of delivery did not diff er between the 
two subsets. Consequently, infants from the prenatal subset had a signifi cantly (P = 0.03) 
lower mean birth weight (2459 g) than the infants from the postnatal subset (2873 g). The 
proporti on of infants with an Apgar Score ≤ 6 at 5 minutes in the prenatal subset (5/30) was 
signifi cantly higher than that in the postnatal subset (0/49) (P = 0.006). The proporti on of 
infants with an isolated EA was highest in the postnatal subset (6/30 versus 20/49; P = 0.04). A 
high percentage of associated anomalies was seen in both subsets; VACTERL associati on was 
seen in 30% of the prenatal subset and in 27% of the postnatal subset. The prenatal subset had 
a higher proporti on of infants with a geneti c syndrome (5/30 versus 1/49; P = 0.03).
 The mortality in the prenatal subset was highest (9/30 versus 6/49; P = 0.05). Three 
of the nine deceased pati ents in the prenatal subset had CHARGE syndrome (Coloboma of 
the eye, Heart defects, Atresia of the choanae, Retardati on of growth and/or development, 
Genital and/or urinary abnormaliti es, and Ear abnormaliti es and deafness), one pati ent 
had Down syndrome and the other fi ve died from severe associated congenital anomalies, 
including cardiovascular, lung and renal defects.
 Post-operati ve complicati ons in the survivors were frequent in both subsets, e.g. 14/21 
of infants from the prenatal subset (67%) and 25/43 from the postnatal subset (58%) had 
gastro-esophageal refl ux. Nine out of 21 infants from the prenatal subset (43%) and 19 out of 
43 from the postnatal subset (44%) had esophageal strictures. The two subsets did not diff er 
in number of surgeries, post-operati ve complicati ons and durati on of hospitalizati on. 
Comparison of pati ents with isolated and non-isolated EA (Table 3)
Twenty-six of the 79 infants (33%) presented with isolated EA; 53 (67%) presented with EA 
and additi onal anomalies. A signifi cantly larger proporti on of pati ents in the non-isolated 
subset showed polyhydramnios (7/26 versus 28/53; P = 0.04), independent of the presence of 
a tracheo-esophageal fi stula. The gestati onal age at delivery was signifi cantly lower in the non-
isolated subset (38.2 weeks versus 37.2 weeks; P = 0.01). There were no signifi cant diff erences 
in the prevalence of prematurity (6/26 versus 17/53) or induced labour (7/26 versus 19/53). 
Neither did birth weight and Apgar scores diff er signifi cantly. The prevalence of VACTERL 
associati on is high (22/53; 42%).
52 
Chapter 2
Table 2: Outcome data of the prenatal and postnatal subset with esophageal atresia
Prenatal subset
N = 30
Postnatal subset
N = 49
P- value
GA at delivery weeks, mean (range)† 36.4 (29.1-42.2) 38.2 (28.4-42.1) 0.02*
Non-spontaneous delivery (%)‡ 12 (40) 14 (29) 0.29
Birth weight, g, mean, (range)† 2459 (1060-3800) 2873 (1130-4000) 0.03*
SGA (%) 12 (40) 11 (22) 0.10
Male gender (%) 18 (60) 30 (61) 0.91
Apgar 5 ≤ 6 (%) 5 (16) 0 0.006*
EA with tracheo-esophageal fi stula (%) 25 (83) 45 (92) 0.29
Isolated esophageal atresia (%) 6 (20) 20 (41) 0.04*
Associated anomalies (%)
 – Vertebral
 – Anorectal
 – Cardiac
 – Renal 
 – Limb
 – VACTERL¶
 – Non-VACTERL
 – Geneti c syndrome§
5 (16)
4 (13)
9 (30)
1 (3)
10 (33)
9 (30)
12 (40)
5 (17)
15 (31)
7 (14)
11 (23)
8 (16)
8 (16)
13 (27)
15 (31)
1 (2)
1.00
1.00
0.60
0.47
0.20
0.74
0.59
0.03*
Neonatal death (%) 9 (30) 6 (12) 0.05*
Primary end-to-end anastomosis (%) 24/26 (92) 42/45 (93) 1.00
No. of surgeries 3.3 3.4 0.90
Length of hospital stay, mean (range)$ 71 (14-325) 70 (11-365) 0.65
Complicati ons (%)$
 – Anastomoti c leaks
 – Strictures
 – Recurrent fi stula
 – Gastro-esophageal refl ux
 – Other complicati ons
13/21 (62)
1 (5)
9 (43)
0
14 (67)
4 (19)
32/43 (74)
3 (7)
19 (44)
3 (7)
25 (58)
13 (30)
0.39
1.00
1.00
0.55
1.00
0.39
GA, gestati onal age; SGA, small for gestati onal age; †, Excluding cases of intrauterine fetal death or terminati on of 
pregnancy; ‡, Induced delivery and caesarean secti on; ¶, Besides EA, two or more anomalies of VACTERL spectrum; §, 
Down syndrome, CHARGE syndrome and 22q11 deleti on syndrome; $, excluded neonatal death; *, stati sti cally signifi cant
 Fift een pati ents in the non-isolated subset had died in the neonatal period, versus none 
in the isolated subset (P = 0.002). Seven of the deceased pati ents had severe other congenital 
anomalies, three had been diagnosed with CHARGE syndrome, two died during surgical repair 
of severe heart defects, two died of sepsis and one died during birth.
 Post-operati ve complicati ons in the survivors were frequent in both subsets, e.g. 16/26 
of infants from the isolated subset (62%) and 21/38 infants from the non-isolated subset (55%) 
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suff ered from gastro-esophageal refl ux. Esophageal strictures were present in 42% (11/26) 
and in 45% (17/38) of infants from the isolated and non-isolated subset, respecti vely. The two 
subsets did not diff er in number of surgeries, post-operati ve complicati ons and durati on of 
hospitalizati on. 
Table 3: A comparison of pati ents with isolated and non-isolated EA
Isolated EA
N=26
Non-isolated EA
N=53
P-value
Polyhydramnios (%) 7 (27) 28 (53) 0.04*
GA at delivery, weeks, mean (range) 38.2 (29.4-40.1) 37.2 (28.4-42.2) 0.01*
Premature delivery < 37 wk (%)‡ 6 (23) 17 (32) 0.44
Non-spontaneous delivery (%) 7 (27) 19 (36) 0.50
Birth weight, G, mean (range) 2846 (1280-4000) 2652 (1060-4000) 0.24
Small-for-gestati onal-age (%) 7 (27) 19 (36) 0.80
Male gender (%) 18 (69) 30 (57) 0.33
Apgar 1 (≤ 6) % 4 (15) 10 (19) 0.76
Apgar 5 (≤ 6) % 1 (4) 4 (8) 0.66
Neonatal death (%) 0 15 (28) 0.002*
EA with tracheo-esophageal fi stula (%) 24 (92) 46 (87) 0.71
VACTERL (%)¶ - 22 (42)
Primary end-to-end anastomosis (%) 24 (92) 42 (79) 1.00
No. of surgeries 2.7 3.7 0.55
Length of hospital stay, mean (range)$ 51 (11-206) 84 (13-365) 0.07
Complicati ons (%)$ 18/26 (69) 27/38 (71) 1.00
 – Anastomoti c leaks
 – Strictures 
 – Recurrent fi stula 
 – Gastro-esophageal refl ux
 – Other complicati ons 
2 (8)
11 (42)
2 (8)
16 (62)
9 (35)
2 (5)
17 (45)
1 (3)
21 (55)
8 (21)
1.00
1.00
0.56
0.80
0.26
‡, Induced delivery and caesarean secti on, ¶ Besides EA, two or more anomalies of VACTERL spectrum; $, excluded neonatal 
death; *, stati sti cally signifi cant
Discussion
The present study compared prenatally and postnatally diagnosed infants and their clinical 
course up to one year of age. Non-isolated EA pati ents are more likely to be diagnosed 
prenatally than isolated pati ents. Overall, the prenatally diagnosed infants were born two 
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weeks earlier at a signifi cantly lower birth weight, aft er correcti on for gestati onal age. The 
lower gestati onal age is likely due to the anomaly combined with polyhydramnios as the mode 
of delivery did not diff er between the two subsets. It would seem, therefore, that pregnancies 
in the prenatally diagnosed subset were more complicated. 
 The mortality rate for the prenatally diagnosed infants was signifi cantly higher than 
for postnatally diagnosed infants. The former also seem to be more severely aff ected, as 
this subset included a signifi cantly higher percentage of infants with additi onal anomalies. 
However, an expected higher, EA-related morbidity rate for infants with additi onal anomalies 
could not be established. These fi ndings do support our clinical experience that infants with 
isolated EA have a bett er prognosis, as also suggested in the literature11,23,28. 
 For only one infant in the prenatal subset a chromosomal anomaly had been 
documented, i.e. trisomy 21. However, in all pregnancies terminated before 24 weeks of 
gestati on because of a chromosomal anomaly, no standard autopsy was done. As the prenatal 
symptoms of an EA occur mainly in the third trimester of pregnancy, the prevalence of EA may 
be underesti mated.
 VACTERL associated anomalies were seen in over 40% of pati ents with non-isolated EA, 
and thus in 28% of the total group. The prenatal and postnatal subsets did not diff er in this 
regard (P = 0.74). Consistent with other studies the prenatal subset included a higher number 
of pati ents with syndromic EA12,14,29,30. 
 All infants received standardized care and were followed for at least one year. While 
mortality diff ered signifi cantly (P = 0.002) there were neither diff erences in complicati ons nor 
in EA related morbidity between survivors with isolated EA and those with complicated EA. 
In contrast to the recent study by Brantberg et al., we found a signifi cantly higher mortality 
in infants in whom EA was suspected prenatally9. As a large proporti on of the postnatally 
diagnosed infants did not receive terti ary antenatal care, it may be doubted whether our 
prenatal fi ndings truly refl ect the predicti on rates of our center. In additi on, we saw signifi cant 
diff erences for the presence of polyhydramnios and for gestati onal age of delivery in the non-
isolated subset. We would recommend improving terti ary care for mothers with complicated 
pregnancies, i.e. adequate referral and good postnatal care, as a means to improve survival.
 In conclusion, the prognosis of isolated EA is good. Morbidity in all survivors is high, 
however, independent of ti me of diagnosis and of the presence of associated anomalies. The 
mortality rate for infants diagnosed prenatally is signifi cantly higher than for infants diagnosed 
postnatally. Parental counseling as to the likelihood of EA should be undertaken cauti ously and 
with the input of a multi -disciplinary team, thus allowing for informed choice of center of birth 
and postnatal care. 
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CHAPTER 3
Non-VACTERL-type Anomalies are Frequent 
in Pati ents with Esophageal Atresia/ Tracheo-
esophageal Fistula and Full or Parti al VACTERL 
Associati on
Adapted from:
de Jong EM, Felix JF, Deurloo JA, van Dooren MF, Aronson DC, Torfs CP, Heij HA ,Tibboel D. 2008. Non-
VACTERL-type anomalies are frequent in pati ents with esophageal atresia/tracheo-esophageal fi stula 
and full or parti al VACTERL associati on. Birth Defects Res A Clin Mol Teratol 82:92-97.
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Abstract 
Background: The VACTERL associati on is the non-random co-occurrence of Vertebral 
anomalies, Anal atresia, Cardiovascular malformati ons, Tracheo-esophageal fistula (TEF) and/
or Esophageal atresia (EA), Renal anomalies and/or Limb-anomalies. The full phenotype of 
pati ents with EA/TEF and other anomalies of the VACTERL spectrum of defects associati on is 
not well described in the literature.
Methods: Data on pati ents with EA/TEF seen in two pediatric surgical centers in the 
Netherlands between January 1988 and August 2006 were evaluated for defects of the 
VACTERL spectrum as well as non-VACTERL-type defects. The presence of two or more defects 
of the VACTERL spectrum in additi on to EA/TEF was the criterion for inclusion in this study. A 
detailed descripti on was made of all defects.
Results: Of 463 pati ents with EA and/or TEF, 107 (23.1%) fulfi lled the inclusion criterion, of which 
seventeen cases had a recognized eti ology and were excluded, leaving 90 cases (19.4%) for 
analysis. Other than the esophagus and the trachea, the vertebrae/ribs and the cardiovascular 
system were most commonly aff ected (68.9 and 65.6%, respecti vely). Interesti ngly, 70% of 
cases had additi onal non-VACTERL-type defects, with high occurrences for single umbilical 
artery (20%), genital defects (23.3%) and respiratory tract anomalies (13.3%).
Conclusions: Many pati ents with EA/TEF and at least two other defects of the VACTERL 
spectrum also display non-VACTERL-type congenital anomalies. 
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Introducti on
Quan and Smith in 1973 introduced the acronym VATER for a sporadic constellati on of birth 
defects that occur together in the same infant more oft en than by chance alone1. VATER stands 
for Vertebral defects, Anal atresia, Tracheo-Esophageal fistula (TEF) and/or esophageal atresia 
(EA), Renal anomalies and Radial dysplasia. Later, cardiac (C) and limb (L) defects were added 
and the acronym was extended to VACTERL2. The inclusion of cardiac defects is sti ll debated, 
however, as is the number of defects needed for the diagnosis of a VACTERL associati on3-9. 
Reported prevalences of a full or parti al VACTERL associati on range from 0.3 to 2.1 per 10,000 
live births, depending on the clinical defi niti on used and the populati on studied3,10,11. 
 Other defects, such as cleft  lip and/or palate and urogenital anomalies occur more 
frequently than expected in conjuncti on with the VACTERL associati on, but are usually not 
considered to be part of it4,9,10,12.
 The eti ology of the VACTERL associati on is sti ll unclear and is considered to be 
multi factorial. A few specifi c chromosomal anomalies, such as distal 13q deleti ons and 17q 
deleti ons, have been described in pati ents displaying characteristi cs of the VACTERL spectrum, 
but no single chromosomal defect has been shown to play an eti ologic role13-16.
 Sonic hedgehog (shh) knockout mice show defects comparable to the VACTERL 
phenotype. However, anomalies of SHH have not specifi cally been associated with the 
VACTERL associati on in humans17.
 Environmental exposures during pregnancy, such as exogenous sex hormones during 
the fi rst trimester of pregnancy, have been suggested as risk factors2; however no single 
environmental risk factor has consistently been identi fi ed8,18-20. When Adriamycin, an 
anti bioti c used in chemotherapy, is given to pregnant rats, it produces many anomalies of the 
VACTERL-type in the off spring21. So far, however, the associati on of Adriamycin or structurally 
related substances with VACTERL-type anomalies has not been observed in humans22-24. 
 The reported proporti ons of pati ents with the full or parti al VACTERL spectrum of 
defects that includes EA/TEF range from 24 to 67%4,9,10,12. However, only fi ve papers describe 
this specifi c group of pati ents9,25-28. Previous studies either describe a small sample of 
cases25,26, or do not describe non-VACTERL-type defects28, or use a wide defi niti on of VACTERL 
associati on27.
 In this study, we evaluated a large sample of pati ents with EA/TEF for the occurrence of 
defects of the VACTERL spectrum and of additi onal non-VACTERL-type structural malformati ons 
in parti cular. Our rati onale was to give a detailed descripti on of all anomalies present in these 
pati ents, who may share a common, but so far unknown, eti ology29.
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Methods
We evaluated data stored in the databases of the Erasmus MC – Sophia Children’s Hospital in 
Rott erdam and the Pediatric Surgical Center of Amsterdam (Emma Children’s Hospital AMC 
and VU University Medical Center), both located in The Netherlands. The pediatric surgical 
departments of these university hospitals are among the six terti ary referral centers for 
pediatric surgery in The Netherlands. All children born with EA/TEF in The Netherlands are 
treated in one of these centers. The Sophia Children’s Hospital is the pediatric referral center 
for the Southwestern part of The Netherlands and has the only specialized pediatric surgical 
intensive care unit in The Netherlands. The Pediatric Surgical Center of Amsterdam is the 
referral center for pediatric surgical pati ents in the Northwestern provinces. Together, these 
hospitals cover almost half of the populati on of The Netherlands and around 70,000 births 
annually. All infants with EA/TEF born in the referral areas are admitt ed to either of the two 
hospitals. Both centers keep comprehensive databases on cases with EA/TEF, including data on 
associated anomalies, pregnancy history, and postnatal clinical course. 
 As a criterion for the diagnosis of the VACTERL associati on, we used the presence of EA/
TEF and at least two additi onal defects of the VACTERL-spectrum, namely, vertebral anomalies 
(including rib anomalies), anal atresia, cardiovascular malformati ons, renal anomalies or radial 
type limb anomalies.
 Karyotyping by G-banding with a resoluti on of at least 550 bands was performed in 
pati ents on clinical grounds. Treati ng physicians decided if this was done. If a pati ent died, an 
autopsy was performed if the parents consented. 
 Aft er approval from the medical ethics review boards of both hospitals, the databases 
were searched for pati ents born from January 1988 up to and including August 2006, who 
fulfi lled these criteria. Cases with known syndromes and chromosomal anomalies were 
excluded from the analysis. 
 Medical records from all pati ents whose defects fulfi lled the criteria were checked 
for the presence of associated non-VACTERL-type anomalies. Undescended testi s was not 
classifi ed as a congenital anomaly in infants who were born preterm. Data were analyzed using 
SPSS 12.0.1.
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Results
A total of 463 pati ents with EA and/or TEF were admitt ed to either of the two centers from 
January 1988 to August 2006. Of these, 107 (23.1%) pati ents had two or more additi onal 
VACTERL-type defects. Seventeen pati ents with a recognized eti ology, such as a syndrome 
or a chromosomal disorder, were excluded (Table 1). Of the 17 excluded pati ents, 13 had 
chromosomal aberrati ons, one had a gene mutati on and three had a syndrome without 
(known) chromosomal or geneti c aberrati ons. This left  90 (19.4%) cases for analysis, which 
included 58 (64.4%) males and 32 (35.6%) females. Using the Gross classifi cati on, we identi fi ed 
four (4.4%) cases with type A (isolated EA), one case (1.1%) with type B (EA with proximal TEF), 
81 (90.0%) with type C (EA with distal TEF), two cases (2.2%) with type D (EA with proximal and 
distal TEF) and one (1.1%) case with TEF without EA (type E)30. One pati ent with type C had 
two distal fi stulas. The type was not recorded in one pati ent.
Table 1: Chromosomal anomalies & syndromes found in 107 cases with EA/TEF and at least 2 
additi onal defects of the VACTERL spectrum of anomalies
Chromosomal anomaly / syndrome No. of cases 
Down syndrome (trisomy 21) 5
Edwards syndrome (trisomy 18) 3
Patau syndrome (trisomy 13) 2
Goldenhar syndrome 1
22q11 deleti on 1
Inversion chromosome 9 1
Smith Lemli Opitz syndrome 1
Townes Brocks syndrome 1
46,XY,t(5;10)(q13;q23)pat 1
Tbx5 mutati on 1
Total 17
 Gestati onal ages ranged from 26 4/7 to 42 3/7 weeks (median 37 4/7 weeks). Thirty-
fi ve cases (38.9%) were born preterm (< 37 weeks) and six cases (6.7%) were post term (42 
weeks or more). Birth weights ranged from 775 to 3825 g (mean 2420 g). Twenty-fi ve cases 
(27.8%) were small for gestati onal age (more than two standard deviati ons below the mean). 
Gestati onal age and birth weight data were missing for one pati ent.
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A total of 25 pati ents (27.8%) died, of whom 13 (52.0%) at a neonatal age (median age of death 
4 days, range 0-21 days) and 11 (44.0%) at an infant age (median age of death 142 days, range 
40-1971 days). For one child, there was no informati on on age at death.
 Exact causes of death are not recorded in the databases. One of the 25 cases had all 
six anomalies of the VACTERL spectrum (full VACTERL associati on), three had fi ve anomalies, 
fi ve had four anomalies and 16 had three. Twenty-two cases had a cardiac defect, of whom six 
had more than one cardiac defect. Four pati ents had severe anomalies of the respiratory tract, 
including one case with tracheal agenesis, and three had central nervous system anomalies, 
one of them a myelomeningocele. Of course, these anomalies are not mutually exclusive and 
the combinati on of defects has likely contributed to the death of those children, taking into 
account withdrawal of treatment in selected cases. Autopsy was performed on 10 (40%) of the 
pati ents who died. This did not reveal new congenital anomalies.
 Karyotyping was performed for 67 (74.4%) cases. As children with chromosomal 
anomalies were excluded from the analysis (see Table 1), all 67 children that were examined 
had a normal karyotype. One of our pati ents had an older brother with isolated EA/TEF.
 Table 2 gives an overview of the VACTERL-type defects other than EA/TEF, found in 
the 90 studied cases. The vertebrae/ribs and the cardiovascular system were most commonly 
aff ected (68.9 and 65.6%, respecti vely). Of the 90 cases, 59 (65.6%) had three defects, 22 
(24.4%) had four defects, seven (7.8%) had fi ve defects and two (2.2%) pati ents (both girls) 
were diagnosed with all six VACTERL components. 
 Interesti ngly, while only 27 cases (30.0%) had only VACTERL-type defects, as many as 
63 cases (70.0%) had VACTERL-type defects in associati on with other structural defects (Table 
3). A high occurrence of a single umbilical artery (20.0%) and of genital defects (23.3%) was 
observed. There was only one preterm infant with undescended testi s and without other 
genital anomalies, so this child was not included in the 'genital' group. Other associated 
defects included respiratory tract anomalies (13.3%), duodenal atresia (8.9%) and cleft  lip/
jaw/palate (4.4%).
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Table 2: Defects of the VACTERL spectrum of anomalies found in 90 cases with EA/TEF
Defect No. of cases (%)
Vertebral 62 (68.9)
 – Vertebral anomalies 50 (55.6)
 – Rib anomalies 37 (41.1)
Anal 38 (42.2)
 – Anal atresia/stenosis/web 31 (34.4)
 – Abnormal placement of anus  7 (7.8)
Cardiovascular 59 (65.6)
 – Atrial septum defect 32 (35.6)
 – Ventricular septum defect 23 (25.6)
 – Atrio-ventricular septal defect  4 (4.4)
 – Fallot tetralogy  9 (10.0)
 – Double outlet right ventricle  1 (1.1)
 – Hypoplasti c left  ventricle  2 (2.2)
 – Hypoplasti c right ventricle  1 (1.1)
 – Univentricular heart  1 (1.1)
 – Anomalies of the cardiac valves  3 (3.3)
 – Transpositi on of great arteries  1 (1.1)
 – Coarctati on/interrupted aorta  3 (3.3)
 – Double aorti c arch  1 (1.1)
 – Other aorti c arch defects  2 (2.2)
 – Dextrocardia  3 (3.3)
 – Arteria lusoria  2 (2.2)
Renal 32 (35.6)
 – Hydronephrosis  7 (7.8)
 – Horseshoe kidneys  7 (7.8)
 – Renal agenesis  8 (8.9)
 – Renal cysts  6 (6.7)
 – Small kidneys  3 (3.3)
 – Renal dysplasia  3 (3.3)
 – Division of renal pelvis  1 (1.1)
 – Ectopic kidneys  3 (3.3)
 – Ureteral anomalies  2 (2.2)
 – Pyelo-ureteral juncti on stenosis  3 (3.3)
Upper Limb 29 (32.2)
 – Radial anomalies 16 (17.8)
 – Thumb anomalies 18 (20.0)
 – Preaxial polydactyly  6 (6.7)
Defects described are not mutually exclusive
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Table 3: Associated non-VACTERL-type structural anomalies found in 90 cases with EA/TEF
Anomaly Number of cases (%)
Single umbilical artery 18 (20.0)
Duodenal atresia/web  8 (8.9)
Cleft  lip/jaw/palate  4 (4.4)
Genital anomalies 21 (23.3)
 – Testi cular anomalies, including undescended testi s  7(7.8)
 – Penile anomalies, including hypospadias  9 (10.0)
 – Bifi d scrotum  3 (3.3)
 – Uterine anomalies  2 (2.2)
 – Anomalies of clitoris  3 (3.3)
 – Absent ovaries  1 (1.1)
 – Double vagina  1 (1.1)
 – Hydrocolpos  2 (2.2)
 – Abnormal labia  1 (1.1)
 – Ambiguous genitalia  2 (2.2)
 – Cloacal malformati on  2 (2.2)
Urinary tract anomalies 14 (15.6)
 – Vesico-urinary refl ux 11 (12.2)
 – Patent urachus  1 (1.1)
 – Bladder anomalies  3 (3.3)
 – Urethral anomalies, including valves  3 (3.3)
Respiratory system anomalies 12 (13.3)
 – Laryngeal/tracheal/bronchial anomalies  7 (7.8)
 – Lung hypoplasia/agenesis  2 (2.2)
 – Cricoid stenosis  1 (1.1)
 – Choanal atresia  1 (1.1)
 – Uvular anomalies  2 (2.2)
Intesti nal anomalies  8 (8.9)
 – Intesti nal malrotati on  3 (3.3)
 – Small bowel atresia/hypoplasia  1 (1.1)
 – Meckel’s diverti culum  4 (4.4)
Lower limb anomalies 15 (16.7)
 – Hypotrophy lower limbs  1 (1.1)
 – Dysplasti c hip(s)  2 (2.2)
 – Club foot  4 (4.4)
 – Rocker-bott om feet  1 (1.1)
 – Anomalies of toes 10 (11.1)
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Anomaly Number of cases (%)
Skeletal (other) 10 (11.1)
 – Upper limbs, non-VACTERL defects  9 (10.0)
 – Abnormally shaped thorax  1 (1.1)
 – Skull anomalies  1 (1.1)
Vascular anomalies (other) 10 (11.1)
 – Abnormal arterial supply right lung  1 (1.1)
 – Anomalies of vena cava  5 (5.6)
 – Right descending aorta  3 (3.3)
 – Anomalous venous return  2 (2.2)
Nervous system anomalies 10 (11.1)
 – Anomalies of spinal cord, including spina bifi da  6 (6.7)
 – Structural brain anomalies  5 (5.6)
Other anomalies  6 (6.7)
 – Polysplenia  2 (2.2)
 – Pancreati c anomalies  2 (2.2)
 – Abnormal positi on gallbladder  1 (1.1)
 – Left  isomerism  1 (1.1)
 – Peters anomaly  1 (1.1)
Anomalies are not mutually exclusive
Discussion
This study, based on data from Pediatric Surgical Centers, describes a group of 90 pati ents with 
both EA/TEF and at least two other defects included in the VACTERL spectrum. The defects are 
well documented, thanks to the routi ne screening of children with EA/TEF for VACTERL-type 
defects by more detailed, mainly non-invasive, diagnosti c techniques (e.g., renal and cardiac 
ultrasound) since the late 1980s. All pati ents in our study were screened for other VACTERL-
type defects by X-rays of the vertebrae and ribs, and by cardiac and renal ultrasound. Further 
imaging techniques were only done on clinical grounds and were not part of the standard 
screening.
 The most remarkable fi nding in our populati on was that as many as 70% of all pati ents 
showed defects other than those included in the VACTERL associati on. The corresponding 
fi gures reported by other authors are oft en much lower, with a maximum of 57%, reported by 
Czeizel et al.9,25. 
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 In a study of the VACTERL associati on that included all cases with any three or more 
of the six defects, but not necessarily EA/TEF, non-VACTERL-type anomalies were described 
in 20%10. The high numbers reported in our populati on may refl ect the high percentage of 
pati ents with EA/TEF that have associated anomalies in general (around 50%)25,31. In additi on, 
our populati on of cases is very well documented, as many cases were also assessed by a clinical 
geneti cist/dysmorphologist, thus increasing the likelihood of reporti ng minor anomalies. 
However, most observed non-VACTERL-type defects were not minor anomalies that would be 
missed on routi ne clinical examinati on.
 Comparing our results to those of others is not an easy task. Several of the defects 
associated with EA/TEF are also associated in the absence of EA/TEF3,7,32. However, we 
focused on defects associated with EA/TEF and only describe those pati ents with EA/TEF and 
at least two other VACTERL-type defects, according to our defi niti on of full or parti al VACTERL 
associati on. There are only a few papers in the literature reporti ng data from populati ons 
similar to ours9,25,26,28,33. 
 In a study that focuses on 1846 infants with anorectal defects, Cuschieri et al. found 
181 cases who also had one or more of the VACTERL associated type of defects. Fift y seven 
of these also had EA/TEF, showing the associati on of these two types of defects from the 
perspecti ve of anorectal defects34. Our study parallels theirs, but starts with a populati on of 
infants with EA/TEF instead of anorectal defects.
 In our populati on, 20% of cases had a single umbilical artery (SUA). The corresponding 
fi gure by Chitt mitt rapap et al. reported 8%, but Temtamy and Miller, in a smaller group, 
described an incidence of 70%35. In a study based on data for 292 cases of EA/TEF in the United 
States, Torfs et al. reported a strong associati on between SUA and EA/TEF in general, with SUA 
found in 18.2% of cases28. This populati on, however, included 36 cases with aneuploidies and 
syndromes. Nevertheless, none of the 28 trisomy cases had a SUA28 and exclusion of these 
cases would therefore bring up this proporti on to 20%, which is similar to our fi nding.
 We found duodenal atresia in 8.9% of our populati on, and cleft  lip, jaw and/or palate in 
4.4%. One of the two other studies with data comparable to ours reports duodenal atresia in a 
similar proporti on of cases (8.0%), but does not report cases of cleft s25. The other comparable 
study, that by Czeizel et al., found cleft  lip and/or palate in 13.2% and intesti nal atresia (n.o.s.) 
in 2.6%9. In studies of associated anomalies in children with EA/TEF, cleft  lip and palate were 
reported in 2.6% and 2.7% of pati ents36,37. Keckler et al. recently described cleft  palate in 4.5% 
and cleft  lip in 0.9% of cases. These latt er numbers are very similar to ours, yet the populati on 
is somewhat diff erent33.
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 In our study, anomalies of the respiratory system were present in 13% of cases. This 
fi nding is not enti rely surprising, as both the esophagus and the respiratory system develop 
from the foregut. The presence of EA/TEF may be a sign of defecti ve foregut development in 
general, which could also lead to respiratory tract anomalies. A number of mouse knockout 
models that show EA/TEF also display anomalies of the respiratory system, e.g. knockout mice 
for either sonic hedgehog, gli2/gli3 or Ttf -138-40. In a group of 25 cases with EA/TEF and at 
least two other defects of the VACTERL-spectrum, Chitt mitt rapap et al. described the absence 
of the right upper lobe of the lung in one pati ent (4%)25. Temtamy reported the occurrence of 
unilateral lung agenesis in an unspecifi ed number of cases among a similar, but smaller, group 
of 10 cases of EA/TEF combined with at least two other VACTERL-type defects26. Czeizel et 
al. found lung hypoplasia/agenesis in 7.9% of their populati on of pati ents with EA/TEF and at 
least two other anomalies of the VACTERL-spectrum9.
 We observed that 19.4% of 463 infants with EA/TEF had at least two additi onal 
defects of the VACTERL-spectrum, a proporti on that falls in the range of prevalences (10-32%) 
reported by others25,28,35,41. We found 64.4% of all these cases to be boys, which compares 
with proporti ons reported earlier9,25. 
 Only a small proporti on of pati ents had the whole spectrum of six anomalies, thereby 
representi ng the 'full' VACTERL associati on. Although several studies on the VACTERL associati on 
include pati ents with only two of the anomalies of the VACTERL spectrum3,12,19, most studies 
include only pati ents with three or more of the defects4,8,9,25,32,35. We have adopted the latt er, 
more stringent defi niti on with the restricti on that EA/TEF always isincluded.
 Therefore, most pati ents in our study have a 'parti al' VACTERL associati on. Our data 
do not permit to draw conclusions about the number of defects, nor which defects of the 
spectrum must necessarily be included for the term 'VACTERL' to apply. Also, some studies 
exclude pati ents who fulfi ll the criteria for VACTERL associati on, but who have been diagnosed 
with a specifi c chromosomal anomaly or syndrome10,12. The same decision was made in the 
present study. However, others have included such cases, which makes comparison between 
studies more diffi  cult27. 
 In many  centers, karyotyping is now standard practi ce for children with multi ple 
congenital anomalies or even for all children with one or more major congenital anomalies. In 
additi on, more sophisti cated cytogeneti c techniques have made it possible to detect smaller 
chromosomal anomalies that may have gone undetected in earlier days. Therefore, studies 
that excluded children with major chromosomal anomalies may unknowingly have included 
children with chromosomal anomalies that less sensiti ve techniques could not detect. In the 
future, it might be indicated to re-examine those children who were diagnosed earlier as 
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having a normal karyotype, both clinically by a clinical geneti cist, as well as by using more 
detailed techniques, such as array-based Comparati ve Genomic Hybridizati on42,43. 
 In summary, this study describes phenotypes of pati ents with EA/TEF and full or parti al 
VACTERL associati on treated in two large pediatric surgical centers. Their clinical data are well-
documented in comprehensive databases. Importantly, this study shows that almost 71% of 
pati ents display non-VACTERL-type congenital anomalies in additi on to defects of the VACTERL 
spectrum. We believe this study gives a good overview of the spectrum of anomalies seen in 
these pati ents and that it adds to the knowledge of the clinical characteristi cs displayed by 
these pati ents.
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PART III
Molecular-Geneti c  Studies in Pati ents 
with Esophageal Atresia 

CHAPTER 5
Congenital Malformati ons of the 
Gastro-Intesti nal Tract and Triple X Syndrome
de Jong EM, Barakat TS, Eussen BH, D'haene B, De Baere E, Poddighe PJ, Galjaard RJ, Gribnau 
J, Brooks AS, Tibboel D ,De Klein A. Congenital malformati ons of the gastro-intesti nal tract in 
Triple X syndrome. Submitt ed.
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Abstract
Introducti on: Esophageal atresia (EA) with or without tracheo-esophageal fistula (TEF) is a 
relati vely common birth defect with an incidence of 1:3,500 births. Over half of the pati ents 
show other major anomalies, predominantly VACTERL associated anomalies (Vertebral, Anal, 
Cardiovascular, Tracheo-Esophageal, Renal and Limb). Both geneti c and environmental factors 
are thought to play causati ve roles. We sought to identi fy genes or loci involved in EA/TEF.
Methods: Retrospecti vely, 269 karyotypes of EA/TEF pati ents were evaluated and telomere-
MLPA was used to identi fy subtelomeric aberrati ons in our EA/TEF cohort. Genome-wide copy 
number profi ling on SNP arrays was done in selected pati ents. In additi on we investi gated X- 
chromosome inacti vati on (XCI) patt erns and mode of inheritance of the aberrati ons.
Results: Three pati ents had a 47,XXX karyotype; two other pati ents showed inherited 
duplicati ons of the SHOX gene. The latt er showed two or more anomalies within the VACTERL 
spectrum apart from EA/TEF. The three pati ents with a 47,XXX karyotype were all small for 
gestati onal age at birth (<P5). One of these displayed VACTERL anomalies, while the other two 
pati ents had in additi on to EA/TEF mild dysmorphic features and a ventricular septal defect. 
Patt erns of X-chromosome inacti vati on (XCI) were normal, leaving one X-chromosome acti ve. 
In all three pati ents the extra X was maternally inherited and the inacti vati on patt ern was 
random in relati on to the parental X.
Conclusions: Unti l now, Triple X syndrome is rarely described in pati ents with EA/TEF and no 
inherited duplicati ons of the SHOX gene were reported so far in pati ents with EA/TEF. Since 
normal patt erns of XCI were seen, overexpression of X-linked genes that escape XCI, e.g. the 
SHOX gene, could infl uence developmental pathways.
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Introducti on
Esophageal atresia (EA) with or without tracheo-esophageal fistula (TEF) is a relati vely 
common birth defect occurring in approximately 1:3,500 births1. There may be causal 
involvement of multi ple geneti c and environmental factors. Associated anomalies occur in 
over 50% of pati ents; these are predominantly VACTERL associated anomalies (Vertebral, 
Anal, Cardiovascular, Tracheo-Esophageal, Renal and Limb). Chromosomal anomalies or point 
mutati ons are found in 10% of EA/TEF cases2. EA/TEF is a variable feature in Feingold, CHARGE, 
Opitz G, and Anophthalmia-Esophageal-Genital (AEG) syndrome, and in Fanconi anemia3, but 
may also occur in syndromes caused by X-linked mutati ons, such as Opitz G syndrome (MID1)4 
and VACTERL associati on with hydrocephalus (FANCB)5. In 90% of EA/TEF pati ents, the cause 
is unknown. 
 Many X-linked syndromes have been described in pati ents with congenital malformati ons, 
such as sex chromosome aneuploidies (e.g. Klinefelter and Turner syndrome)6,7 and mutati ons 
in X-linked genes that cause monogenic diseases, e.g. X-linked mental retardati on in Fragile X 
syndrome (FMR1)8. However, sex chromosome aneuploidies or copy number aberrati ons on 
the X-chromosome are rare in pati ents with EA/TEF9-11. 
 The triple X karyotype, fi rst described by Jacobs et al.12, occurs in 1:1,000 girls13. 
In 90% of cases, the additi onal X-chromosome is the result of a maternal meioti c I error14. 
The incidence of non-disjuncti on errors increases with maternal age15. Girls with the Triple 
X syndrome have a lower birth weight, more accel erated growth unti l puberty, long legs, 
more behavioral problems and more psychiatric disorders than other girls16. A direct relati on 
between gastro-intesti nal anomalies was not yet established, however the literature describes 
at least six cases with gastro-intesti nal anomalies and Triple X syndrome17. 
 Overexpression of the Short stature HOmeoboX-containing gene (SHOX) is rare. 
Duplicati ons of SHOX, located within the pseudoautosomal region (PAR1) of X(p) and Y(p) 
are described, but with no disti nct phenotype18,19. SHOX duplicati ons in relati on to gastro-
intesti nal anomalies have not been described so far.
 This study consisted of a retrospecti ve evaluati on of cytogeneti c abnormaliti es in 
our insti tuti on’s EA/TEF cohort (n=321). Three pati ents had a triple X karyotype. Additi onal 
molecular-geneti c studies with telomere-MLPA and SNP arrays found SHOX duplicati ons in two 
other pati ents. We reviewed the literature for pati ents with Triple X syndrome in relati on to 
congenital gastro-intesti nal malformati ons. We hypothesized that genes on X and/or genes 
that escape chromosome X inacti vati on could infl uence developmental pathways, such as in 
foregut development.
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Methods
Pati ents
From 1988 onwards, all pati ents with EA/TEF, admitt ed to the department of Pediatric Surgery, 
Erasmus MC, Rott erdam, The Netherlands were included (n=321). Pregnancy, clinical and 
follow-up data were collected and stored in a comprehensive database. Available DNA and 
cell lines of pati ents (n=180) and parents were collected and stored. Pati ents with defi ned 
syndromes or point mutati ons in certain genes had been excluded from further molecular-
geneti c evaluati on. From 1988 onwards, the database of the department of Clinical Geneti cs, 
Erasmus MC, The Netherlands, was searched for triple X karyotypes and confi rmed SHOX 
duplicati ons at the departments of prenatal and postnatal diagnosti cs. Phenotypes of pati ents 
were extracted from medical charts available at the Department of Clinical Geneti cs.
Cytogeneti c evaluati on
Routi ne cytogeneti c screening was performed for all pati ents with major congenital anomalies; 
karyotyping was performed according to standard protocols on lymphocytes from peripheral 
blood cultures. From 1988 onwards, 269 karyotypes were available.
Stati sti cal analysis
Diff erences in two proporti ons were tested with the Pearson’s chi-square (χ2) test, reported 
with a 95% confi dence interval (CI), performed in SPSS 15.0.
Multi plex ligati on-dependent probe amplifi cati on (MLPA) and quanti tati ve PCR
Subtelomeric aberrati ons were tested with MLPA analysis, using the P036E1 and P070A2 
Salsa telomere kit (MRC Holland, Amsterdam, The Netherlands). Reacti ons were performed 
according to the manufacturer’s protocol; PCR products were separated and quanti fi ed as 
previously described20. Genemarker 1.6 (Soft Geneti cs, LLC, State College, PA, USA) was used 
for data analysis. Copy number profi ling of the SHOX region was done with a newly developed 
qPCR assay, with 11 amplicons within SHOX and the PAR1 region21. 
Fluorescent in situ hybridizati on (FISH)
To confi rm the results, BAC clones for Xp22 and Xq25 were selected from the University of 
Santa Cruz (UCSC) genome browser and ordered from BACPAC Resources. Aft er isolati on of 
the BAC DNA, the probes were labeled and used for FISH on chromosome preparati ons from 
pati ents and parents, according to standard protocols22.
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RNA-FISH analysis and immunocytochemistry of human cell lines 
RNA-FISH and immunocytochemistry were performed on fi broblast cell lines (confl uency 
reached >90%) and EBV-transformed lymphocytes, as previously described by Jonkers et al.23. 
HUMARA analysis
To determine the parental origin and the methylati on status of the additi onal X-chromosome, 
we used the HUMARA assay (Human Methylati on of the Androgen Receptor Assay)24 in the 
triple X pati ents and their parents; 40ng of genomic DNA was double digested with DdeI 
and HpaII (New England Biolabs) at 37°C in an overnight reacti on. 1μl of reacti on product 
serves as a template for PCR with Phusion polymerase (Finnzymes), using the primers 
GCTGTGAAGGTTGCTGTTCCTCAT and TCCAGAATCTGTTCCAGAGCGTGC. PCR products were 
analyzed by gel electrophoresis on an 8% PAGE gel, runned overnight at 66V at 4°C, stained 
with ethidium bromide and scanned using a Typhoon scanner (GE Healthcare). Images were 
further analyzed using Image Quant soft ware (GE Healthcare). 
Microarrays
To further characterize possible additi onal chromosomal aberrati ons in the pati ents with Triple 
X syndrome, copy number was analyzed using Aff ymetrix® single nucleoti de polymorphism 
(SNP) genotyping microarrays. DNA extracted from blood was genotyped on Aff ymetrix® 
250k Nsp (Aff ymetrix®, Santa Clara, CA). The copy number analysis package within CNAT 4.0 
(Chromosome Copy Number Analysis Tool, htt p://www.aff ymetrix.com/) was used to analyze 
the signal intensity values of SNPs. Samples were normalized by quanti le normalizati on on 
perfect match probes, following allele summarizati on uti lizing the BRLMM soft ware component 
within GTYPE (available from htt p://www.aff ymetrix.com/), per the default CNAT 4.0 protocol. 
 The HumanCytoSNP-12 chip (Illumina®, San Diego, CA, USA) was used in the cases with 
SHOX duplicati ons and their parents, for bett er coverage of the PAR1 region. All procedures 
were done according to the manufacturer’s protocol. All products were scanned with the 
Illumina Beadstati on scanner and raw data were uploaded in Beadstudio v2.0 genotyping 
soft ware (Illumina®, San Diego, CA, USA) for further analysis.
 Visualizati on of all microarrays was done with the Nexus Copy Number soft ware 
package (V4; BioDiscovery® Inc., El Segundo, CA, USA). 
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Results
Triple X syndrome
Karyotyping had been performed for 269 of the 321 pati ents of our cohort, as systemati c 
cytogeneti c follow-up of pati ents with congenital anomalies was not carried out from 1988-
1998. A triple X karyotype was identi fi ed in three pati ents (Figure 1A). The odds rati o for 
Triple X syndrome in our EA/TEF cohort is 11.3, (95% CI= 3.6 to 35.2). All three were small 
for gestati onal age at birth (<5th centi le). One pati ent displayed all VACTERL anomalies and 
additi onal genito-urinary anomalies, while the other two pati ents had mild dysmorphic features 
and a ventricular septal defect in additi on to EA/TEF, respecti vely (pati ents 1-3, Table 1). At 
ti me of delivery the mothers were aged under 35. In additi on, the database of the Department 
of Clinical Geneti cs, Erasmus MC, yielded 59 non-mosaic 47,XXX karyotypes since 1988; 29 had 
been detected prenatally and 30 postnatally (apart from the above three pati ents). Indicati ons 
(not mutually exclusive) for prenatal karyotyping were: maternal age above >35 years (n=25), 
congenital malformati ons on ultrasound (n=4), increased risk for Down syndrome on fi rst 
trimester screening ultrasound (n=2), increase in fetal bowel echogenicity on ultrasound 
(n=1), and congenital anomalies in an earlier pregnancy (n=3). One screening for the reason of 
increased maternal age concerned a twin pregnancy of which one sib had a 47,XXX karyotype. 
Postnatally, pati ents were karyotyped based on the following indicati ons: suspicion of Fragile 
X syndrome (n=5), mental retardati on (n=5), multi ple congenital anomalies (n=4), combined 
mental retardati on and multi ple congenital anomalies (n=3), repeati ng spontaneous aborti ons 
in the index (n=4), failure to thrive (n=4), a chromosomal abnormality in the family (n=3), 
suspicion of trisomy 21 (n=1), and a possible chromosomal aberrati on in juvenile systemic 
lupus erythematosus (n=1).
 Postnatal follow-up of thirteen pregnancies was not documented. Seven pregnancies 
were terminated, in one case because the fetus showed anencephaly. Congenital malformati ons 
had been documented for three of the nine live-borns; a neural tube defect, hygroma colli 
with generalized edema, and osteogenesis imperfecta, respecti vely. A review of the medical 
charts of the postnatally diagnosed pati ents identi fi ed at least four pati ents with congenital 
heart defects. Most pati ents had psychomotor retardati on and psychiatric problems. 
 RNA-FISH and immunocytochemistry were performed to assess the X inacti vati on status 
of cell lines derived from the 47,XXX pati ents in our cohort. This RNA-FISH revealed two XIST 
clouds in almost every fi broblast and lymphocyte cells (>95% of the nuclei), co-localizing with 
an area of low level COT-1 expression (Figure 2A). Immunocytochemistry of 47,XXX fi broblasts 
detected enrichment of the facultati ve heterochromati n markers H3K27me3 and MacroH2A1 
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Figure 1: Triple X syndrome and SHOX aberrati ons in pati ents with EA/TEF
1A 47,XXX karyotype confi rmed with FISH. BAC probe on Xp22 (RP11-800K15; red)
1B Validati on of SHOX duplicati ons with SHOX specifi c qPCR in both pati ents. The green lines indicate the length of the 
 duplicati ons, with a larger duplicati on in pati ent 4 (amplicon 1-13) and a specifc SHOX duplicati on in pati ent 5 
 (amplicons 2-8). 
1C SHOX duplicati on confi rmed with FISH in pati ent 5. Probe RP11-800K15 on Xp22 (red), covering the SHOX gene, 
 shows a duplicated signal (*) and a control probe RP11-49N19 on Xq25 (green). 
1D The HumanCytoSNP-12 chip (Illumina®, San Diego, CA, USA) showing an intersti ti al duplicati on of the PAR1 region 
 (base pair positi on chrX:248,968-1,229,976), including the SHOX gene, in the father of pati ent 4. In the left  panel, 
 the elevated log2 rati o indicates the duplicated segment (green bar, **) and the B-allele frequencies change in rati o 
 indicated in the enlarged right panel (purple bar). Color fi gures can be found in the appendix. See page 185
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Figure 2: Chromosome X inacti vati on studies in triple X pati ents
2A  RNA-FISH analysis detecti ng XIST and COT-1 RNA. XIST RNA was detected using a digeoxin-labelled cDNA probe 
 (FITC), and a bioti n-labelled COT-1 DNA probe detected expression of repeti ti ve sequences (Rhodamine). In 47, XXX 
 pati ent cells two XIST clouds and COT-1 holes were detected in the majority of the cells (> 95% of the nuclei, n >100). 
 Nuclei were counterstained with DAPI.
2B Immunocytochemistry detecti ng H3K27me3 (Rhodamine) and MacroH2A1 (FITC). Enrichment of H3K27me3 and 
 MacroH2A1 was found on two X-chromosomes in 47, XXX fi broblast cell lines, co-localizing with DAPI-dense Barr 
 bodies, indicati ve of two inacti ve X-chromosomes. Nuclei are counterstained with DAPI. Color fi gures can be found
 in the appendix. See page 188
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on two X-chromosomes, co-localizing with the DAPI-dense Barr-bodies (Figure 2B). HUMARA 
analysis confi rmed a maternal origin of the additi onal X-chromosome in all three pati ents. In 
both the pati ents and their mothers random XCI was observed, with no skewed preference 
of inacti vati on of a parti cular X-chromosome (data not shown). Additi onal SNP array analysis 
(Aff ymetrix® 250k Nsp) performed to exclude copy number variati ons elsewhere in the 
genome, did not reveal additi onal possible pathogenic copy number variati ons in any of the 
three pati ents. 
SHOX duplicati ons 
DNA of 180 pati ents was screened with telomere-MLPA. The results indicated SHOX duplicati ons 
in two boys (pati ents 4 and 5). The twin sib of pati ent 4 was spontaneously aborted in the third 
month of gestati on. His mother was diagnosed with Goldenhar syndrome and two relati ves on 
the mother’s side have thumb anomalies. The boy was small for gestati onal age at birth (<2SD) 
and had associated cardiovascular, renal, limb and genital anomalies (Table 1). Pati ent 5 was 
also small for gestati onal age at birth. He displayed associated cardiac and limb anomalies. 
The database of the Department of Clinical Geneti cs, Erasmus MC, yielded no additi onal SHOX 
duplicati ons with a congenital phenotype.
 Both SHOX duplicati ons were validated with a SHOX-specifi c qPCR (Figure 1B). 
Validati on confi rmed the duplicati ons of the SHOX gene and the amplicons in the PAR1 region 
in pati ent 4, as being inherited from his father. Cultured lymphocytes for FISH validati on 
were not available. Validati on also confi rmed the SHOX gene duplicati on in pati ent 5, as 
being inherited from his mother. FISH also confi rmed the duplicati on of the SHOX gene 
on Xp22 in this pati ent (Figure 1C). The father and mother in questi on had no EA/TEF.
To exclude additi onal copy number variati ons of other regions in the genome, both pati ents 
and their parents were screened with genome-wide microarrays (HumanCytoSNP-12 chip V2, 
Illumina®). These arrays revealed multi ple copy number polymorphisms in both the pati ents 
and their parents. However, closer examinati on of these regions did not indicate potenti al 
pathogenic copy number variati ons. 
 To delineate the duplicated segment in pati ent 5 and his father, we focused on the 
CNVs in the X/Yp PAR1 region. Although the exact boundaries of the duplicati on could not 
be determined in the pati ents’ sample, due to diminished quality of the array, the duplicated 
segment could be delineated in the father to a intersti ti al duplicati on of PAR1 of 981Kb (base 
pair positi on chrX:248,968-1,229,976) (Figure 1D).
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Table 1: Congenital anomalies of pati ents with EA/TEF and an anomaly on the X-chromosome
Pt no Karyotype MLPA results Clinical features
1 47,XXX X/Yp SHOX enh Absent sacrum 
Anal atresia
Pulmonary stenosis
EA + TEF
Vesico-urethral refl ux; urethral atresia
Absent thumbs
Cloacal malformati on; abnormal labia; hydrometrocolpos
2 47,XXX X/Yp SHOX enh TEF
Dysmorphic features 
3 47,XXX X/Yp SHOX enh EA + TEF
Ventricular septum defect
Thin fi ngers
4 46,XY X/Yp SHOX enh
paternal inheritance
Aberrant subclavia
EA + TEF 
Horseshoe kidneys
Adducted thumbs; left  thumb smaller than right
Hypospadias
Frontal bossing
Dysmorphic features
5 46,XY X/Yp SHOX enh
maternal inheritance
Atrial septum defect (type II)
EA + TEF
Proximal placement of thumbs
EA, esophageal atresia; TEF, tracheo-esophageal fi stula; enh, enhanced signal with P036E1 and P070A2
Discussion
Congenital malformati ons and mental retardati on syndromes have been linked to the 
X-chromosome. Our search for genes or loci involved in EA/TEF or other foregut-related 
anomalies identi fi ed fi ve pati ents in our cohort with chromosome X/Yp aberrati ons; three with 
Triple X syndrome and two with inherited SHOX duplicati ons. 
 The Triple X syndrome is usually a random fi nding in cytogeneti c follow-up of pregnancies 
and in geneti c screening of pati ents with mental retardati on, psychiatric disorders and/or 
congenital malformati ons. A large proporti on of triple X females have a subclinical phenotype. 
With an esti mated occurrence of 1 in 1,000 females, many females are undiagnosed. In 
our cohort the incidence of Triple X syndrome is 11 ti mes higher than that in the general 
populati on. Congenital anomalies associated with the Triple X syndrome described in case 
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reports, include anomalies of the urinary tract, genital anomalies and craniofacial anomalies, 
specifi cally a reduced head circumference and/or decreased brain volume16,25-27. Gastro-
intesti nal anomalies, including atresias of the esophagus, duodenum and jejunum, as well 
as omphalocele and anorectal malformati ons, have been reported sporadically11,17,28-34. All 
thirteen reported pati ents with gastro-intesti nal and/or foregut-related anomalies are reviewed 
in Table 2. The pati ent described by Hoang et al. shows a similar phenotype compared to 
our pati ents; higher mesodermal defects (esophageal atresia) and lower mesodermal defects 
(anal atresia, genito-urinary defects)11. Genito-urinary malformati ons are well-described in 
triple X pati ents. Since many of the gastro-intesti nal anomalies also aff ect the lower gastro-
intesti nal tract, perhaps a cloacal septati on problem gives rise to the higher incidence of these 
types of malformati ons. 
 Guichet et al. reviewed prenatally and postnatally diagnosed 47,XXX karyotypes from 
18 laboratories35. Mental retardati on or congenital malformati ons were described in over one 
third of the 190 pati ents reported. In all cases weight-for-gestati onal-age at birth was under 
the 25th percenti le. The authors did not report any gastro-intesti nal anomalies. Our results are 
in agreement with these fi ndings, with the exepti on of the three cases found in our EA/TEF 
cohort. 
 The HUMARA assay demonstrated the maternal origin of the supernumerary 
X-chromosome in our triple X pati ents. RNA-FISH analysis and immunocytochemistry 
demonstrated inacti vati on of two out of three X-chromosomes with no skewed preference of 
a parti cular X-chromosome. Approximately 15% of the genes on the X-chromosome, located 
in the PAR regions, escape XCI36. The extent of this escape is ti ssue specifi c. Here, dosage 
compensati on of gene expression on chromosome X is of interest37-39. Expression of genes on 
the inacti ve X can therefore result in low transcripti on levels40. Why and how certain genes 
escape XCI, especially in humans, is sti ll unknown41. Female ‘escapees’ may have a dosage-
sensiti ve functi on, which would explain the phenotype in pati ents with sex chromosome 
anomalies, such as Turner and Klinefelter syndrome. The observati on that 47,XXX females 
also have decreased brain volume in the presence of normal pubertal maturati on, suggests 
a possible direct dosage eff ect of X-chromosomal genes27. Similarly, other genes that escape 
XCI could perhaps cause the gastro-intesti nal anomalies found in our cohort. One clear 
candidate in the PAR1 region is the SHOX gene. In two pati ents SHOX duplicati ons were found. 
The SHOX gene encodes a cell-specifi c homeodomain protein that plays an important role 
during human embryonic bone and limb development42,43. A possible role for SHOX in limb/
vertebrae anomalies as observed in the VACTERL associati on is not well established, however 
it is remarkable that EA/TEF pati ents with SHOX aberrati ons also have limb anomalies. All 
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pseudoautosomal genes, including SHOX, escape X-inacti vati on and are candidates for 
gene dosage eff ects when this region is deleted or duplicated. As a result of deleti ons and 
point mutati ons, SHOX haploinsuffi  ciency is associated with idiopathic short stature (OMIM 
300582)44, and mesomelic short statured skeletal dysplasia (Leri-Will syndrome OMIM 
127300)45. Homozygous loss of the SHOX gene has been correlated with Langertype mesomelic 
dysplasia (OMIM 249700)45. 
 While haploinsuffi  ciency of the SHOX gene has been related to diff erent phenotypes, 
the associati on with SHOX duplicati ons is less well-defi ned19,46. Thomas et al. could not defi ne 
a disti nct phenotype in four families with inherited SHOX duplicati ons. There was female 
predominance (six out of eight cases) in these families, however our cases were two males18. 
It is diffi  cult to defi ne the clinical relevance of an inherited SHOX duplicati on and the possible 
role in the eti ology of congenital anomalies when the parent is phenotypically normal18,19. 
Incomplete penetrance and variable expressivity have been described in microdeleti on/
duplicati on syndromes. Recently a two-hit model was proposed, in which the combinati ons of 
inherited and de novo copy number variati ons predisposed to neuropsychiatric phenotypes47.
 All fi ve pati ents had duplicated loci of genes that escape XCI. The expression of these genes 
could possibly add up to the phenotype. As a consequence of the additi onal X-chromosome, 
triple X females express more genes that escape XCI. Furthermore, the expression levels of 
inacti ve X-chromosomes may vary between individuals and diff erent ti ssues48. As previously 
described the phenotypic variability of Triple X syndrome ranges widely, from subclinical 
phenotypes to mental retardati on and congenital malformati ons. Nevertheless, a increased 
gene dosage of X-linked genes may indeed have an impact on development, as suggested 
in a large study that characterized pati ents with mental retardati on using an X-chromosome 
specifi c ti ling array49. Also, mutati ons on chromosome X or elsewhere on the genome could 
contribute to this variability. 
 In conclusion, we describe fi ve pati ents with sex chromosomal aberrati ons and EA/TEF. 
The incidence of this combinati on in our cohort is 11 ti mes higher than expected compared to 
the general populati on. Screening of chromosome X with high-throughput sequencing, may 
reveal new X-linked syndromes related to gene dosage diff erences in congenital phenotypes 
such as EA/TEF. Improved copy number variati ons detecti on could reveal new duplicati on 
syndromes related to EA and other congenital anomalies. 
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5q11.2 Deleti on in a Pati ent with 
Tracheal Agenesis
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Tibboel, A de Klein. 5q11.2 deleti on in a pati ent with Tracheal Agenesis. Eur J Hum Gen (provisionally 
accepted)
102 
Chapter 6
Abstract
Introducti on: Tracheal agenesis is a rare congenital anomaly of the respiratory tract. Many 
pati ents have associated anomalies, suggesti ng a syndromal phenotype. 
Methods: In a cohort of twelve pati ents we aimed to detect copy number variati ons. In 
additi on to routi ne cytogeneti c analysis, we applied oligonucleoti de Array CGH. 
Results: Our pati ent cohort showed a variety of copy number variati ons of which many were 
parentally inherited variants. One pati ent had, in additi on to an inherited 16p12.1 deleti on, 
a 3.6 Mb deleti on on chromosomal locus 5q11.2. This pati ent had a syndromic phenotype, 
including VACTERL associated anomalies, and other foregut-related anomalies, such as 
carti lage rings in the esophagus and an aberrant right bronchus. 
Conclusions: No common deleti ons or duplicati ons are found in our cohort, suggesti ng that 
tracheal agenesis is a geneti cally heterogeneous disorder. 
 103 
6
del(5)(q11q11) in a pati ent with Tracheal Agenesis
Introducti on
Tracheal agenesis (TA) is a rare congenital anomaly in which the trachea is fully or parti ally 
absent. Venti latory support may be successful occasionally, but TA typically has fatal 
consequences. Eff orts have been directed at clarifying the anatomy of TA and at improving 
treatment1,2. Tracheal agenesis may be part of a complex of malformati ons and it is oft en 
associated with cardiovascular anomalies3,4. The complex phenotypes show an overlap 
with the VACTERL associati on (Vertebral, Anal, Cardiovascular, Tracheo-Esophageal, Renal 
and Limb anomalies)5,6 or with an associati on including tracheal agenesis (TACRD; TA, 
Cardiac anomalies, Radial ray defects and Duodenal atresia)6,7. Tracheal agenesis can also 
be part of Fraser syndrome, an autosomal recessive malformati on disorder characterized by 
cryptophthalmos, syndactyly, and abnormaliti es of the respiratory and urogenital tract, that is 
caused by mutati ons in the FRAS1 and FREM2 genes8,9. 
 Litt le is known about the aeti ology of TA, apart from the fact that environmental factors 
might play a role3. Animal models of diff erent geneti c defects, such as (conditi onal) inacti vati on 
of Gli2, Gli3, Shh, Foxf1 and β-Catenin, show agenesis of the trachea or incorrect septati on of 
the foregut10-14. To date, however, no mutati ons or chromosomal anomalies of any of the 
genes or pathways implicated in these animal models have been described in human pati ents 
with TA. In additi on, there are no published reports on systemati c screening of TA pati ents for 
copy number variati ons. To determine whether microdeleti ons/duplicati ons could explain the 
TA phenotype, we conducted genome wide assays in twelve TA pati ents. 
Methods
Cases
Ten cases were retrieved from the medical records of the Erasmus MC ͵ Sophia Children’s 
Hospital, Rott erdam, from 1988 onwards. Two cases had been seen and included at the 
department of Pathology, University Medical Centre Utrecht. The medical records and 
pathology records were reviewed. Fibroblast cell lines and paraffi  n blocks had been stored. 
Cytogeneti c analysis
Karyotyping was performed according to standard analysis methods. DNA for genomic analysis 
was extracted from fi broblast cells by the Puregene DNA purifi cati on kit (Gentra Systems, USA). 
Regarding six pati ents, only Formalin Fixed Paraffi  n Embedded (FFPE) samples from thymus 
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ti ssue were available. DNA was extracted according to protocols provided by the supplier of 
the microarrays.
Array comparati ve genomic hybridizati on (Array CGH)
Array CGH was performed using the 105K Oligonucleoti de-based array CGH (Agilent 
Technologies, Santa Clara, CA, USA) according to the manufacturer’s protocol. For analysis and 
visualizati on the Feature Extracti on soft ware (version 9.1) and CGH analyti cs soft ware (version 
3.3.28) was used. Aberrati ons were detected with the ADM2 algorithm and fi ltering opti ons of 
a minimum of 3 probes and abs(log2Rati o) >0.3. Aberrati on segments were manually reviewed.
FISH analysis
To confi rm the results, BAC clones were selected from the University of Santa Cruz (UCSC) 
genome browser and ordered from BACPAC Resources. Aft er isolati on of the Bac DNA the 
probes were labeled and used for Fluorescence In Situ Hybridizati on (FISH) on chromosome 
preparati ons from the pati ents and parents, according to standard protocols15.
Real-ti me quanti tati ve PCR
Quanti fi cati on was done by real-ti me quanti tati ve PCR. Primer pairs were designed with Primer 
Express V2.0 (Applied Biosystems, Branchburg) and tested for validity. DNA was processed 
using the IQ SYBR green master mix (Biorad) and analysed on the AB7300 (Applied Biosystems, 
Branchburg).
Prioriti zati on
We used the Endeavour prioriti zati on program16 to prioriti ze the genes in the 5q11.2 
chromosomal region. Reference genes were selected based on recently reviewed genes on 
foregut-related anomalies in human and murine models: SHH, GLI2, GLI3, FOXF1, TTF1, NOG, 
FGF2, HOXA5, RARα, RARβ, BMP4, FOXF1, SOX2, FRAS1 and FREM2. In relati on to cell cycle 
control and cell death processes, we performed an additi onal prioriti zati on with selected 
reference genes: cell-division cycle 2-like genes, protein phosphatases, cyclin-dependent 
kinases, interleukins, apolipoprotein B, P53, TNF-genes, PDCD-genes, and CIDE genes. The 
program is based on the hypothesis that the novel candidate genes play roles similar to those 
of the genes known to be associated with the anomaly, or share biological processes with 
these genes.
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Results
Clinical data are summarized in Table 1. Conventi onal G-banding karyotyping was apparently 
normal in all pati ents. The quality of the array was poor in three from whom only FFPE 
material was available. The array CGH analysis revealed copy number variati ons in all pati ents. 
Most of these were known polymorphisms, described in the Toronto Database of Genomic 
variants (DGV), the Copy Number Variati on project at the Children’s Hospital of Philadelphia 
(CHOP), or seen in our in-house control cohort17,18. In two pati ents (Nos. 3 and 10) these 
were deleti ons of loci not known as polymorphic variants: a 57.9 kb deleti on on chromosome 
15q25.1, containing exons 12-21 of the BLM gene, and a 488 kb deleti on on chromosome 
16p12.1, respecti vely. The deleti ons were confi rmed with FISH and real-ti me quanti tati ve PCR. 
However, they were also found in their unaff ected mothers, so we concluded that they were 
likely not causal.
 We found an additi onal 3.6 Mb deleti on on chromosomal locus 5q11.2 in pati ent 10 
(Figure 1A), who presented with TA, anal atresia, persisti ng hemiazygos, cryptorchid testes, fork 
rib and mild dysmorphic features, including low set posterior rotated ears, mild hypertelorism 
and a unilateral simian crease. The pregnancy was achieved aft er in vitro ferti lizati on with an 
unknown sperm donor, and had been complicated by polyhydramnios. In additi on, absence of 
the stomach bubble was seen on ultrasound examinati on. Prenatal cytogeneti c analysis was 
normal. As labour started prematurely, antenatal corti costeroids were given twice to induce 
lung development. The male baby was spontaneously delivered at 29 3/7 weeks. Body weight 
was 1090 g (30th centi le), length 38 cm (50th centi le), and occipitofrontal circumference 28 
cm (40th centi le). Cyanosis, severe respiratory distress and the absence of an audible cry were 
noted immediately aft er birth. Intubati on failed aft er multi ple att empts. Apgar scores were 
3, 0 and 0 aft er 1, 5 and 10 minutes, respecti vely. Autopsy confi rmed multi ple congenital 
anomalies, including TA, which was classifi ed as Floyd III19. In additi on, carti lage rings in the 
esophagus and aberrant right bronchus were reported.
 The deleti on, ranging from 51.32–55.00 Mb (NCBI Build 36.1), was confi rmed by 
FISH analysis (Figure 1B). Karyotyping and FISH analysis on lymphocytes of the mother were 
normal. Paternal material was not available because pregnancy has been achieved aft er in 
vitro ferti lizati on; the sperm donor was unknown. Neither the DGV, and the CHOP nor our 
control cohort describes this large deleti on. This chromosomal region contains twelve protein-
encoding genes. 
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Figure 1: Visualizati on and confi rmati on of deleti on 5q11.2 by FISH
A 5q11.2 deleti on visualized with Agilent CGH analyti cs soft ware (version 3.3.28); deviati on from zero on a log2 scale, 
 experiment performed in duplicate. The maximum deleted region ranged from 51,079,864-55,001,348 Mb (NCBI 
 Build 36.1). The minimum deleted region ranged from 51,321,507-54,958,112 Mb.
B FISH to a metaphase spread, showing the absence of a green fl uorescent signal (BAC RP11-160F8) at 5q11.2 on one 
 chromosome 5. The red signal (BAC RP11-11K19; control probe) is present on both chromosomes on the 5q 
 subtelomeric regions. Color fi gures can be found in the appendix. See page 189
Discussion
As far as we know, one other pati ent with a deleti on in the 5q11.2 region is described in 
the literature20. This pati ent showed Tetralogy of Fallot, a bifi d uvula and signifi cant 
developmental delay. The 5 Mb deleti on found in this pati ent includes the 3.6 Mb region found 
in our pati ent. Another case of overlapping deleti on was retrieved from a search in two public 
online databases (htt p://www.ecaruca.net/21; htt ps://decipher.sanger.ac.uk/22). The Decipher 
database reports a pati ent with a large deleti on del(5)(q11.2;q13.2), with a 2 Mb overlap with 
our pati ent. This pati ent had signifi cant developmental delay and hypochondroplasia. To the 
best of our knowledge this deleti on has not yet been described as a common variant. Due to 
lack of paternal material, we could not verify the inheritance of the deleti on, but we expect 
this deleti on to be de novo.
 We used the Endeavour prioriti zati on program16 to prioriti ze the genes in the 5q11.2 
chromosomal region whose haploinsuffi  ciency may have infl uenced the congenital TA 
phenotype in our pati ent. Integrin alpha-1 (ITGA1) was ranked the highest priority, followed 
by Follistati n (FST), Endothelial cell-specifi c molecule-1 (ESM1) and Integrin alpha-2 (ITGA2). 
Integrin alpha-1 integrin is crucial in regulati ng mesenchymal stem cell proliferati on and 
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carti lage producti on23. FST is an acti vin-binding protein. FST-defi cient mice are growth 
retarded, have decreased intercostal muscles mass, skeletal defects, and abnormal tooth 
development24. The protein also modulates the acti ons of several members of the TGF-beta 
family, e.g. it inhibits BMP-4. Li et al. confi rm that Bmp signaling is present in the anterior 
foregut, the site of origin of the tracheal primordium, and that targeted knockouts for Bmp4 
at this site have no trachea development25. Que et al. demonstrated that certain proteins that 
antagonize these BMPs, such as Noggin transcripti onal processes, could explain the degree of 
tracheal development, and therefore could discriminate between the subtypes of TA26. 
 The variable phenotypes in the pati ents described with 5q11.2 deleti ons can be 
potenti ally explained by diff erent causes: environmental factors, incomplete penetrance, other 
geneti c mutati ons elsewhere in the genome, compensati on of other genes, and/or epigeneti c 
factors. This pati ent in additi on to the 5q11.2 deleti on, also had an inherited 16p12.1 deleti on, 
that could possibly contribute to the phenotype. This deleti on was recently described by 
Girirajan et al.27. In additi on to large de novo deleti ons, they identi fi ed a recurrent 520 kb 
microdeleti on of 16p12.1 associated with development delay. They proposed a two-hit model: 
the inherited 16p12.1 deleti on in additi on to a large copy number variati on indicates the 
variable expressivity of the developmental delay phenotype27. We were unable to ascertain 
the developmental status of the pati ent as he died. However as the mother is of normal 
intelligence and carries the 16p12.1 deleti on, the pati ent could fi t the two-hit model; the 
additi onal large copy number variati on could indicate the variable expressivity in our pati ent.
 The presence of inherited and polymorphic variati ons in our TA cohort suggests that 
TA is geneti cally heterogeneous. The rare 5q11 deleti on found in one of our pati ents includes 
several candidate genes. The clinical signifi cance of this large chromosomal aberrati on is 
hard to pinpoint, however, seeing the variability in the clinical presentati on. We recommend 
standard detailed molecular cytogeneti c analysis in pati ents with TA as a means to further 
unravel the geneti c background of TA. 
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Abstract
Background: Esophageal atresia (EA) and/or trachea-esophageal fistula (TEF) are common life-
threatening congenital anomalies. The cause is unknown in over 90% of cases. We investi gated 
possible roles of copy number variati ons (CNVs) in de the development of EA/TEF and VACTERL-
associated anomalies.
Methods and Results: A positi onal candidate approach based on chromosomal data generated 
with genome wide microarrays, yielded 56 inherited and six de novo CNVs, in a two center 
cohort of more than 200 pati ents. These variati ons were absent in published cohorts of 
normal individuals and in our in-house control cohort. In additi on, we evaluated ti ssue of the 
esophageal pouch of 13 pati ents for somati c CNVs, but no change in CNV patt erns nor loss of 
heterozygosity was found in a paired analysis with blood DNA of the corresponding pati ent.
Conclusions: Several loci, such as 4q35, 6q23.2, 7p22, 7p13, and 8q13.1 harbor new de 
novo copy number variati ons and some involve interesti ng disease related genes. Although 
identi fi cati on of rare de novo CNVs would be considered strong evidence for causality, some 
of the inherited variants on chromosomal loci 5q11.2, 8p13.1, 10q25.3, 12p12.3, 19p13.3, and 
Xp22, were found in recurrently. This could suggest that the role of inherited variati ons may be 
underesti mated and the majority of cases may result from a combinati on of inherited changes 
aff ecti ng important developmental pathways combined with environmental stressors.
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Introducti on
Esophageal atresia (EA) with or without trachea-esophageal fistula (TEF) is a common 
congenital malformati on of the foregut, occurring in approximately 1 in 3,500 live births1. All 
foregut-related anomalies are thought to be complex diseases, with involvement of multi ple 
geneti c and environmental factors2-4. In 90% of cases the cause for EA/TEF is unknown, 
but a number of defi ned monogenic syndromes for which the underlying genes have been 
elucidated5. EA is a variable feature in e.g. Feingold syndrome (MYCN), CHARGE syndrome 
(CHD7), Opitz G syndrome (MID1), Anophthalmia-Esophageal-Genital (AEG) syndrome (SOX2), 
and in Fanconi anemia (multi ple genes involved)2. Moreover, EA/TEF may be associated with 
cytogeneti c abnormaliti es, including trisomies of chromosome 13, 18, 21, and X6,7, deleti ons 
of chromosomal loci 22q11 (DiGeorge syndrome), 13q, 17q21.3-q24.2, and/or 16q24.1 in 
some cases8-10.
 EA/TEF is oft en associated with other structural birth defects; the VACTERL associati on 
(Vertebral, Anal, Cardiac, Tracheo-Esophageal fi stula, Renal, Limb; three or more anomalies 
present) is seen in approximately 10% of cases11. The high occurrence of associated anomalies 
seems to point at very many causes; an underlying geneti c defect or possible environmental 
defects that involve more than one structure. Mutati ons in certain genes (HOXD13, PCSK5) or 
copy number variati ons (CNVs) (del 16q24.1) have been suggested to be the causati ve defect 
in a small number of VACTERL associated pati ents10,12,13.
 Geneti c studies usually look for germline mutati ons as a cause of structural birth defects, 
although somati c mosaicism for copy number variati ons might also play a role. Non-aff ected 
individuals were assumed to have geneti cally identi cal normal cell types, but rearrangements 
of cells of the immune system display somati c mosaicism14. Recently it was found, however, 
that somati c mosaicism for stochasti c CNVs occurs in a substanti al percentage of cells15. It is 
now assumed that somati c CNVs must occur in somati c cells. Diff erences in CNVs between 
cell types of malformed ti ssue have not been investi gated yet. In pati ents with congenital 
anomalies, such as EA/TEF, somati c mosaicism might explain the low levels of heritability.
 Microarray studies have proved eff ecti veness in mapping and identi fying genes that 
predispose to congenital anomalies in an unbiased fashion, such as non-isolated congenital 
diaphragmati c hernia16, isolated tetralogy of Fallot17 or neuro-developmental diseases18,19. 
Therefore, we applied a positi onal candidate approach to localize and identi fy genes that 
cause or predispose to the development of EA/TEF. We hypothesize that each of these CNVs 
harbors one of more EA/TEF-related genes.
116 
Chapter 7
Methods
Cases
Pati ents with EA/TEF and VACTERL associated anomalies were identi fi ed from the medical 
records of the Erasmus MC – Sophia Children’s Hospital, Rott erdam, The Netherlands. In 
additi on, pati ents referred to clinical geneti cists at Baylor College of Medicine, Houston, 
USA, were included. This study was approved by the Medical Ethical Review Boards at both 
insti tuti ons. The medical records were reviewed for pati ent characteristi cs and geneti c follow 
up. The VACTERL associati on was judged present if the records reported two or more anomalies 
of the VACTERL spectrum in additi on to the EA/TEF.
Cytogeneti c analysis and Multi plex ligati on-dependent probe amplifi cati on (MLPA)
Karyotyping was performed according to standard analysis methods. DNA for genomic analysis 
was extracted from blood and fi broblast cells by the Puregene DNA purifi cati on kit (Gentra 
Systems, USA). DNA was extracted from Formalin Fixed Paraffi  n Embedded (FFPE) samples 
(thymus ti ssue) as instructed by the supplier of the microarrays (Agilent®). All DNA was tested 
for subtelomeric aberrati ons with MLPA-analysis, using the P036E1 and P070A2 Salsa telomere 
kits (MRC Holland, Amsterdam, The Netherlands) as published previously20.
Microarrays
To identi fy CNVs, high-resoluti on analyses were performed using single-nucleoti de 
polymorphism (SNP) microarrays (Illumina®, Aff ymetrix®) and oligonucleoti de-based (105K, 
244K, 1M) Array CGH (Agilent®). The 250K Nsp1 array (Aff ymetrix®) was used according to 
the manufacturer’s instructi ons (htt p://www.aff ymetrix.com/). Imaging was done with the 
Aff ymetrix® GCS3000-G7 scanner. Genotype calls and probe intensiti es were extracted with 
the Aff ymetrix® GeneChip Command Console (AGCC) soft ware version 1.1. Genotype- and 
CNV-analysis were performed using the BRLMM and CNAT 4.0.1 algorithms. CNVs in pati ent 
samples were visualized as log2 rati os detected by comparison to a common reference set of 
40 CEU samples from the HapMap project (www.hapmap.org/downloads/raw_data/500K/). A 
second CNV analysis was done by comparison with an in-house run male control sample. The 
segment-reporti ng tool fi lter was set to a minimum of three aberrant markers per segment 
and a minimum segment size of 10Kb. 
 The Human 610-Quad BeadChip and the Human Cyto SNP-12 chip (Illumina®, San 
Diego, CA, USA) were used according to the manufacturer’s protocol (htt p://www.illumina.
com/). Both types of arrays were scanned with the Illumina Beadstati on scanner and raw data 
 117 
7
Microarray Studies Identi fying Novel and Inherited Genomic Aberrati ons
were uploaded in Beadstudio V2.0 genotyping soft ware (Illumina®) for further analysis. CNVs 
were visualized with the log-normalized intensity rati o for each SNP in the pati ent sample and 
compared with a pooled reference set of 120 female CEU samples from the HapMap project. 
Heterozygous deleti ons or duplicati ons were detected with a minimum of 5 consecuti ve SNPs.
 In additi on, paired analysis was performed for proximal pouch DNA and blood DNA 
samples. In the paired-sample analysis, the Log R Rati o for a sample is the log (base 2) rati o of 
the normalized R value for the SNP from the subject sample (blood) divided by the normalized 
R value from the reference sample (pouch).
 For the SNP platf orms, log2 rati os and the B-allele frequency (BAF) were visualized. 
with the Nexus® Copy Number soft ware package version 4.0 (BioDiscovery Inc., El Segundo, 
CA, USA).
 Array CGH was performed using the 244K, the 105K and the 1M oligonucleoti de-
based array CGH platf orms (Agilent® Technologies, Santa Clara, CA, USA), according to the 
manufacturers protocol. Genomic DNA from the pati ent and reference DNA (Promega 
Corporati on, Madison, WI), pooled normal male and female, was labeled with Cy5 and Cy3 
respecti vely. The 244K and 1M arrays were done with sex matched controls of unaff ected, 
unrelated individuals. Correct labelling was checked using the NanoDrop Spectrophotometer 
ND1000 (NanoDrop Technologies). For the FFPE samples, pati ent and reference DNA were 
labeled using the Oligo Array CGH Labelling kit for FFPE samples (Agilent® Technologies). For 
analysis and visualizati on the Feature Extracti on soft ware (version 9.1) and CGH analyti cs 
soft ware (version 3.3.28) was used. Aberrati ons were detected with ADM2 algorithm and 
fi ltering opti ons of a minimum of 3 probes (1M and 105K) or 2 probes (244K), and abs(log2Rati o) 
> 0.3. Aberrati on segments were manually reviewed. 
Validati on of microarray results
All results were checked against our in-house control database of common CNVs found in 
healthy controls, the Toronto Database of Genomic Variants (DGV) and the Copy Number 
Variati on project at the Children’s Hospital of Philadelphia (CHOP)21,22.
 To confi rm the results, quanti fi cati on of the DNA was done by Real Time RT-PCR and/
or Fluorescence In Situ Hybridizati on (FISH) on chromosome preparati ons from the pati ents 
and parents. Primer pairs were designed with Primer Express V2.0 (Applied Biosystems, 
Branchburg), the OLIGO 6.0 Soft ware, or Primer3Plus and tested for validity. DNA was 
processed using the IQ SYBR green master mix (Biorad) and analyzed on the AB7300 (Applied 
Biosystems, Branchburg), according to standard protocols. Each sample, including the no 
template control (NTC) and control DNA, was run in triplicate. Exon 4 of the KIAA1279-gene 
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served as a control locus. Values of < 0.7 and > 1.3 served as boundaries for deleti ons and 
duplicati ons respecti vely. 
 For FISH validati on, BAC clones were selected from the University of Santa Cruz (UCSC) 
genome browser and ordered from BACPAC Resources. Aft er isolati on of the BAC DNA the 
probes were labeled and used for FISH, according to standard protocols23.
Prioriti zati on
We used the Endeavour prioriti zati on program24 to prioriti ze the genes found in all the de novo 
and inherited aberrati ons. Reference genes were selected based on recently reviewed genes 
on foregut-related anomalies in human and murine models: SHH, GLI2, GLI3, FOXF1, TTF1, 
NOG, FGF2, HOXA5, RARα, RARβ, BMP4, FOXF1, SOX2. The program is based on the hypothesis 
that the novel candidate genes play roles similar to those of the genes known to be associated 
with the anomaly, or share biological processes with these genes.
Results
The study cohort consisted of over 200 pati ents. Pati ents with defi ned syndromes, such as 
trisomies or proven mutati ons in disease causing genes in Feingold and AEG syndrome, had 
been excluded. 
 Over 60% of pati ents showed other major congenital anomalies, predominantly 
VACTERL associated anomalies. A classifi cati on was made into: isolated cases, EA/TEF and heart 
anomalies, EA/TEF and anal anomalies, and VACTERL associated pati ents. These subgroups 
were not mutually exclusive, as a large part of the VACTERL pati ents were also included in the 
heart and/or anal subgroup. 
 The results of the diff erent platf orms are summarized in Table 1. Genomic changes 
were considered rare variants if similar changes were not found in databases of unaff ected, 
unrelated individuals (htt p://projects.tcag.ca/variati on/21; htt p://cnv.chop.edu/22) or in an in-
house database of unaff ected control individuals. All rare variants found were confi rmed by 
real-ti me quanti tati ve PCR and/or FISH. An example of the investi gati on of a variant is given in 
Figure 1.
 We compared aff ected ti ssue (proximal pouch) and peripheral blood DNA for somati c 
changes. Of 13 pati ents, DNA from proximal pouch ti ssue could be extracted. In four pati ents 
a paired analysis could be performed with the blood DNA of the corresponding pati ent on the 
Illumina SNP platf orm. This did not reveal change in CNV patt erns nor loss of heterozygosity. 
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The other 9 ti ssue/blood DNA pairs were manually compared for copy number changes. Over 
90% of the changes were seen in both ti ssues samples; they were mainly polymorphic or 
inherited variants and did not include possible candidate genes. 
Table 1: Copy number variati ons in pati ents with EA/TEF and VACTERL associati on
Type Chr. Band Mb Size Genes aff ected Confi rmati on
Del 1 q24.2 chr1:166,707,913-166,964,241 256 kb XCL2, XCL1, DPT Inherited - Mat
Del 1 q25.2 chr1:177,954,393-178,059,341 104 Kb FAM163A Inherited - Pat
Dup 1 q31.1 chr2:176,828,859-176,965,152 136 Kb MTX2 Inherited - Mat
Del 2 p22.1 chr2:39,835,726-39,898,547 63 Kb THUMPD2 Inherited - Mat
Del 2 p15 chr2:62,058,607-62,081,510 23 Kb COMMD1 Inherited - Pat
Del 2 p14 chr2:66,539,109-66,625,441 86 Kb MEIS1 Inherited - Mat
Dup 2 q36.3 Chr2: 228,069,192- 228,082,423 13.2 Kb TM4SF20 Inherited - Pat
Del 3 q13.12 chr3:108,892,833-109,053,887 161 Kb BBC, LOC151658 Inherited - Pat
Del 4 p16.1 chr4:7,761,879-7,810,539 49 Kb SORCS2, AFAP Inherited - Pat
Dup 4 q12 chr4:54,846,096-54,874,109 28 Kb PDGFRA Inherited - Mat
Del 4 q35.2 chr4:189,262,840-189,279,737 16.9 Kb TRIML2 De Novo
Del 5 p13.1 chr5:40,814,789-40,821,601 6.8 Kb PRKAA1 Inherited - Pat
Del 5 q11.2 chr5:54,127,000-54,369,473 242 Kb ESM1, GZMK Inherited - Pat
Del 5 q11.2 chr5:54,133,714-54,401,751 268 Kb ESM1, GZMK Inherited - Pat
Del 6 p22.1 chr6:26,580,422-26,611,236 31 Kb BTN1A1 Inherited - Mat
Dup 6 q14.1 chr6:76,268,597-76,491,113 223 Kb SENP6 Inherited - Pat
Dup 6 q16.3 chr6:100,426,259-100,576,358 150 Kb MCHR2 Inherited - Pat
Del 6 q23.2 chr6:134,772,684-135,062,237 289 Kb No De Novo
Del 6 q24.1 chr6:142,513,441-142,660,062 147 Kb VTA1 Inherited - Mat
Del 7 p22 chr7:6,090,284-6,106,523 16.2 Kb Distal to USP42 De Novo
Del 7 p13 chr7:43,592,420-43,597,873 5.5 Kb STK17A Homozygous Del
De Novo
Del 7 p12.3 chr7:48,556,504-48,562,351 5.8 Kb ABCA13 Inherited - Mat
Del 7 p12.3 chr7:48,556,504-48,562,351 5.8 Kb ABCA13 Inherited - Mat
Dup 7 q11.23 chr7:72,338,350-74,208,716 1.87 Mb Multi ple Inherited - Pat
Del 7 q22.1 chr7:101,907,906-102,123,873 216 Kb POLR2J2, POLR2J3, RASA4, 
SPDYE2, UPLP
Inherited - Pat
Del 7 q34 chr7:142,535,765-142,600,931 65 Kb PIP, TAS2R39 Inherited - Mat
Dup 8 q13.1 chr8:67,118,081-67,126,592 8.5Kb DNAJC5B Inherited – Pat *
Dup 8 q13.1 chr8:67,118,081-67,143,367 25 Kb DNAJC5B Inherited – Pat *
Dup 8 q13.1  chr8:67,118,081-67,143,367 25 Kb DNAJC5B De Novo
Del 8 q13.3  chr8:71,779,310-71,789,822 10.5 Kb XKR9 Inherited - Mat
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Type Chr. Band Mb Size Genes aff ected Confi rmati on
Del 8 q13.3  chr8:71,779,310-71,789,822 10.5 Kb XKR9 Inherited - Pat
Del 8 q21.3 chr8:91,676,176-91,824,081 147 Kb TMEM64 Inherited - Pat
Dup 10 p11.22 chr10:33,133,081-33,321,872 189 Kb ITGB1 Inherited - Pat
Del 10 p11.21 chr10:35,916,849-35,950,279 33 Kb GJD4 Inherited - Pat
Dup 10 q25.3 chr10:116,250,269-116,546,953 296 Kb ABLIM1 Inherited - Mat
Dup 10 q25.3 chr10:116,261,258-116,515,586 254 Kb ABLIM1 Inherited - Mat
Del 11 p15.4 chr11:8,915,512-8,919,362 3.9 Kb ASCL3 Inherited - Mat
Del 11 q14.2-
14.3
chr11:86,775,384-91,610,110 4.8 Mb multi ple Inherited - Pat
Dup 12 p13.31 chr12:7,894,681-8,009,303 115 Kb SLC2A14, NANOGP1, SLC2A3 Inherited - Mat
Del 12 p12.3 chr12:16,035,488-16,170,844 135 Kb DERA Inherited - Mat
Del 12 p12.3  chr12:16,047,790-16,164,597 117 Kb DERA Inherited - Mat
Del 12 q12 chr12:39,429,168-39,438,782 9.6 Kb CNTN1 Inherited - Pat
Dup 12 q13.2 chr12:55,025,975-55,122,663 97 Kb STAT2, APOF, TIMELESS Inherited - Mat
Dup 12 q24.12 chr12:110,668,304-110,802,629 134 Kb ACAD10, ALDH2, PNAS-1, 
MAPKAPK5
Inherited - Mat
Del 13 q12.3 chr13:28,612,594-28,703,794 91 Kb KIAA0774 Inherited - Pat
Del 13 q21.33 chr13:69,261,108-69,678,603 417 Kb KLHL1 (B) Inherited - Pat
Del 15 q13.3 chr15:30,202,944-30,653,250 450 Kb CHRNA7, FAM7A Inherited - Pat
Dup 15 q21.3 chr15:53,194,652-53,737,840 543 Kb CCPG1, DYX1C1, PIGB, PRTG, 
PYGO1, RAB27A, RSL24D1
Inherited - Mat
Del 15 q26.1 chr15:87,149,810-87,164,592 14.8 Kb ACAN Inherited - Mat
Dup 16 q24.3 chr16:8,671,293-9,200,858 530 Kb ABAT, TMEM186, PMM2, 
CARHSP1, USP7 
Inherited - Mat
Del 18 p11.31 chr18:6,092,791-6,102,462 9.7 Kb L3MBTL4 Inherited - Mat
Dup 18 p11.31 chr18:5,460,006-5,550,340 90 Kb EPB41L3 Inherited - Mat
Del 19 p13.3 chr19:2887367-2915807 28 Kb ZNF77 Inherited - Pat
Del 19 p13.3 chr19:595,208-602,228 7 Kb RNF126, FLJ45684 Both Parents Del
Del 19 p13.3 chr19:4,350,702-4,354,182 3.5 Kb SH3Gl1, CHAF1A Inherited - Mat
Del 19 p13.3 chr19:4,350,702-4,354,182 3.5 Kb SH3Gl1, CHAF1A Inherited - Mat
Del 20 13.13 chr20:48,242,315-48,242,775 0.5 Kb CEBPB Inherited - Mat
Dup 22 11.2 chr22:17,147,764-18,648,997 1.5 Mb multi ple incl. TBX1 Inherited - Mat
Del 22 13.31 chr22:46,188,483-46,861,153 672 Kb none Inherited - Mat + 
unaff ected twin 
Dup 22 q13.33 chr22:48958906-48966272 7.4 Kb PANX2 Inherited - Mat
Del X p22.2 chrX:13,878,418-14,021,051 142 Kb GEMIN8 Inherited - Mat
Dup X P22.33 chrX:501,091-693,629 102 Kb SHOX Inherited - Mat
Del X q13.1 chrX:69,378,166-69,383,712 5.5 Kb Distal to DGAT2L3 Inherited - Mat
Dup X 47,XXX chrX:1-154,913,754 155 Mb whole chromosome De Novo
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Type Chr. Band Mb Size Genes aff ected Confi rmati on
Dup X 47,XXX chrX:1-154,913,754 155 Mb whole chromosome De Novo
Dup X 47,XXX chrX:1-154,913,754 155 Mb whole chromosome De Novo
Dup X/Y p22.33 chrX:248,968-1,229,976 981 Kb SHOX, PPP2R3B Inherited - Pat
Dup Y q11.2 chrY:14,225,506-14,603,722 378 Kb TMSB4Y Inherited - Pat
Genomic changes found in a cohort of >200 pati ents with EA/TEF and VACTERL associati on. Confi rmati on of the rare 
variants and their inheritance patt ern was done by real ti me quanti tati ve PCR if similar changes were absent in published 
cohorts of normal individuals and in our in-house control cohort. The recurrent aberrati ons are presented in the darkgrey 
fi elds. Del, deleti on; dup, duplicati on; Pat, paternal; Mat, maternal; *, three pati ents with same deleti on. Base pair 
positi ons according to Build 36.1/hg18.
 Recurrent aberrati ons were found for several genes including SHOX, TBX1, TRIML2, 
ESM1, ABLIM, ITGB1, and MEIS1. With the Endeavour prioriti zati on tool genes were prioriti zed 
according to their functi on processes and relati ons to genes involved in foregut development. 
The top 10 genes according to this analysis are: CEBPB, SHOX, PDGFRA, ITGB1, MEIS1, TBX1, 
SH3GL1, STK17A, CHRNA7, and ALDH2.
Discussion
In many geneti c disorders candidate genes can be determined by a linkage-analysis approach. 
In most EA/TEF cases, however, there is no familial recurrence. In congenital anomalies with 
mostly a de novo occurrence, genomic rearrangements may explain the human phenotypic 
variati on and suscepti bility to disease17-19. We therefore used high-resoluti on oligonucleoti de 
and SNP microarrays to identi fy possible CNVs. This approach yielded both de novo and 
inherited CNVs, widely distributed over the genome. The identi fi ed regions included some 
interesti ng genes such as SHOX, TBX1, TRIML2, ESM1, ABLIM, ITGB1, and MEIS1. However, 
large recurrent variants were not found, so a positi onal candidate approach is less applicable. 
Studies describing somati c mosaicism for CNVs in diff erent cell types are rare15. In our cohort 
we were able to check diff erences in CNVs between the proximal pouch and blood cells, but 
manual comparison and a paired analysis did not detect somati c diff erences. Comparison of 
the recorded CNV data with known EA/TEF loci from animal models or recorded chromosomal 
anomalies yielded no overlapping CNVs. In none of the regions describing a new variant 
imprinted genes were discovered.
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Figure 1: Identi fying genomic alterati ons in pati ents with EA/TEF and VACTERL associati on. 
Examples of array comparati ve genome hybridizati on data from 244K Agilent arrays depict duplicati on events on 
chromosome 6 and chromosome 12. Quanti tati ve real-ti me PCR is used to confi rm the changes and to determine the 
inheritance patt ern within families. In this case the duplicati on on chromosome 6 was inherited from the pati ent’s father 
and the duplicati on on chromosome 12 from the pati ents mother. Color fi gures can be found in the appendix. See page 189
De novo variants
Several loci such as 4q35, 6q23.2, 7p22, 7p13, and 8q13.1 harbor new de novo CNVs and some 
involve interesti ng disease related genes. A possible de novo deleti on of the triparti te moti f 
family-like 2 gene (TRIML2) was found. TRIML2 is expressed in whole brain and in lymphoblast 
B-cells, but no studies in relati on to pathogenicity and disease have been published unti l now. 
A 289 Kb deleti on of 6q23.2 was described in a pati ent who showed dysmorphic features and 
a ventricular septal defect. However, this locus did not involve any genes. A 5.9 Mb deleti on 
of 7pter was found in one pati ent. Deleti ons of 7p are cytogeneti cally heterogeneous and 
result in a wide spectrum of congenital abnormaliti es, minor facial and hand anomalies, and 
oft en including craniosynostosis. Terminal deleti ons of 7pter are rare, but EA/TEF was not yet 
described for this deleti on25,26. None of these variants were described in EA/TEF pati ents so 
far. Additi onally, we reported three females with the Triple X syndrome and two pati ents with 
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inherited duplicati ons of SHOX within the X/Yp PAR1 region. Gastro-intesti nal anomalies have 
not been described in pati ents with SHOX duplicati ons so far, and were reported in only a small 
number of individuals with triple X syndrome27,28.
Inherited variants
Non-pathogenic and/or inherited CNVs were predominant in our cohort, and many have 
already been described in unaff ected individuals21,22. Inheritance from a phenotypically 
normal parent favors the interpretati on of a benign variant29,30. Sti ll, the phenotype of a 
genomic disorder can be variable due to variable gene expressivity, incomplete penetrance, 
skewed X-inacti vati on and/or mutati ons elsewhere in the genome. Some genomic alterati on 
syndromes, such as microdeleti ons of 3q29 and microduplicati ons of 7q11.23 and 22q11, 
seem to have a lower penetrance31-33. Incomplete penetrance was noted in our cohort, too; 
the pati ent with an inherited 22q11 microduplicati on syndrome had a VACTERL phenotype 
and his mother only had mild dysmorphic features33,34. Additi onally, we reported two males 
with inherited duplicati ons of the The Short stature HOmeoboX-containing gene (SHOX) 
[MIM312865]. This gene is located within the pseudoautosomal region (PAR1) of X(pter) 
and Y(p) and was also prioriti zed. SHOX haploinsuffi  ciency, as a result of deleti ons and point 
mutati ons, is associated with multi ple growth-related phenotypes35-37. However, with limited 
SHOX duplicati ons published, no disti nct phenotype can be established38,39. The recurrent 
aberrati ons involving ABLIM1 [MIM:602330] and ESM1 [MIM:601521] are also of interest. 
ABLIM1, an acti n-binding LIM domain protein, functi ons as protein-binding interfaces, 
mediati ng specifi c protein-protein interacti ons40 and plays important roles in regulati ng 
developmental pathways41. ESM1, endothelial cell-specifi c molecule 1, is mainly expressed 
in the endothelial cells in human lung and kidney ti ssues. The expression is regulated by 
cytokines suggesti ng that it may play a role in endothelium-dependent pathological disorders, 
especially colorectal cancer42,43.
 In a recent study, Girirajan et al. described a recurrent 520 kb large 16p21.1 
microdeleti on in a cohort of pati ents with developmental delay. Comparison with other large 
cohorts of unaff ected controls and aff ected pati ents provided evidence of a two-hit model 
in pati ents with inherited 16p12.1 deleti ons. These deleti ons are oft en inherited from an 
unaff ected parent, and occur in associati on with a large copy number variati on that could 
explain the variability in these and other microdeleti on syndromes44. The two-‘hit’ model 
represents the assumpti on that two modifi ers add up to each other’s eff ects or that it is 
part of an epistati c process, which in this case created a severe phenotype of developmental 
delay. In additi on the CNVs themselves could explain reduced penetrance of disease-causing 
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mutati ons; there is evidence that a dominant loss-of-functi on mutati on might be rescued by 
a gain in copy number resulti ng in increased gene expression45. However, our data do not 
support this theory and therefore the other causal theory of incomplete penetrance for CNVs 
in EA/TEF pati ents sti ll stands.
 Aft er prioriti zati on some interesti ng genes were discovered. In one pati ent, the 22q11 
microduplicati on syndrome, inherited from his mother, was found. This included the TBX1 
gene, a dosage sensiti ve gene, responsible for the phenotype in DiGeorge syndrome [MIM 
188400]46. The phenotype driven detecti on approach clearly explains the heterogeneous 
phenotype of pati ents with 22q11 microduplicati ons47. Unti l now, 22q11 microduplicati on was 
not described in pati ents with EA/TEF.
 Data of cohorts of EA/TEF pati ents screened for CNVs with single-nucleoti de 
polymorphism microarrays and oligonucleoti de-based Array CGH will be available soon. These 
can be used in genome wide associati on studies aiming to identi fy suscepti bility loci for EA/
TEF. This approach already proved successful in other congenital anomalies, such as non-
syndromic cleft  lip/palate and replicated in independent samples48,49. GWAS studies require 
large sample sizes to obtain suffi  cient stati sti cal power. Mangold et al. found relati ve risks of 
1.8 (95% CI interval) for two loci in 401 individuals with cleft  lip with or without cleft  palate49. 
These data provide evidence for the success rate found in other congenital anomalies, based 
upon the geneti c heterogeneity of the disorder.
 Microarrays are expected to fully replace karyotyping in diagnosti c screening for 
underlying causes in congenital anomalies. Translocati ons will sti ll be missed, but microarrays 
are already routi nely used in pati ents with mental retardati on50. The data presented in this 
study provide limited evidence for the causal eff ects of CNVs in EA/TEF. We found only few 
de novo changes. Platf orms with higher resoluti ons, such as the Aff ymetrix 6.0 GeneChip SNP 
arrays or the Illumina CytoChips, could allow for more detailed analysis. On the other hand, 
such approaches may lead to data interpretati on problems such as high false positi ve rates 
and the discovery of smaller CNVs of unknown clinical signifi cance51. Studies of healthy control 
populati ons are necessary to understand the implicati ons of specifi c CNVs in congenital 
disorders, such as EA/TEF and foregut-related anomalies. However, with the advances in high-
resoluti on techniques, including whole genome sequencing, the search for underlying geneti c 
defects will intensify. 
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CHAPTER 8
Polyalanine Expansion in the ZIC3 Gene Leading 
to X-linked Heterotaxy with VACTERL Associati on: 
A New Polyalanine Disorder?
Adapted from:
Wessels MW, Kuchinka B, Heydanus R, Smit BJ, Dooijes D, de Krijger RR, Lequin M, de Jong EM,
Husen M, Willems PJ, Casey B. 2010. Polyalanine expansion in the ZIC3 gene leading to X-linked
heterotaxy with VACTERL associati on, a new polyalanine disorder ? J Med Genet In press.
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Abstract
Case report: We describe a newborn male with features of the VACTERL associati on, including 
anal atresia, laryngeal and esophageal atresia with tracheo-esophageal fi stula, dextropositi on 
of the heart with persistent left  superior vena cava, and unilateral multi cysti c kidney. 
Methods and Results: As the clinical picture of the VACTERL associati on overlaps with X-linked 
heterotaxy caused by ZIC3 mutati ons, we sequenced the ZIC3 coding region, and found a 
6-nucleoti de inserti on that is predicted to expand the amino-terminal polyalanine repeat from 
ten to twelve polyalanines. This novel mutati on was not present in the mother, nor in 336 
chromosomes from 192 ethnically-matched controls. 
Conclusion: We hypothesize that this novel and de novo polyalanine expansion in the ZIC3 
gene contributes to the VACTERL associati on in this pati ent. 
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Introducti on
Mutati ons in ZIC3, a zinc fi nger transcripti on factor gene located at Xq26, typically result in 
a spectrum of left -right asymmetry defects, including complex cardiac anomalies, altered 
lung lobati on, splenic and hepatobiliary abnormaliti es, and gut malpositi on. Also renal, anal 
and lumbosacral anomalies are common. The combinati on of ZIC3-associated anomalies is 
referred to as X-linked heterotaxy (HTX1, MIM 306955)1-5. However, also isolated congenital 
heart disease can be due to mutati ons in ZIC34. Though usually unaff ected, some female 
heterozygotes manifest abnormaliti es whose spectrum and severity is indisti nguishable from 
aff ected males. 
 The VACTERL associati on, which comprises vertebral anomalies (V), anal atresia (A), 
cardiovascular malformati ons (C), tracheo-esophageal fi stula and/or esophageal atresia (TE), 
renal malformati ons (R) and limb defects (L) is a non-random associati on of defects with an 
unknown eti ology in the majority of pati ents6,7. In several recent reviews the syndromes 
resembling VACTERL associati on have been discussed: these include Feingold syndrome 
(NMYC gene), Fanconi syndrome (FANC genes), CHARGE syndrome (CHD7 gene), Pallister-Hall 
syndrome (GLI3 gene), Anophthalmia-Esophageal-Genital syndrome (SOX2 gene), Opitz G/BBB 
syndrome (MID1 gene), Townes-Brocks syndrome (SALL1 gene) and Fryns syndrome (disease 
gene not identi fi ed yet)8,9,10. VACTERL associati on phenotypically also overlaps with ZIC3-
associated X-linked heterotaxy: anal atresia and cardiac defects are common in both disorders, 
and typical VACTERL features such as tracheo-esophageal fi stula, renal and vertebral anomalies 
have occasionally also been reported in ZIC3-associated heterotaxy (Table 1)5. 
 In the case presented here, we describe a novel ZIC3 mutati on (elongati on of the amino-
terminal alanine repeat) in a pati ent with overlapping features between VACTERL associati on 
and X-linked heterotaxy. 
Case report
A healthy Caucasian gravida 2 para 1 was referred for ultrasound examinati on at 31 weeks 
of gestati on because of suspected polyhydramnios. Apart from polyhydramnios advanced 
ultrasonography revealed absent stomach fi lling, suggesti ng esophageal atresia, and a right 
multi cysti c kidney. Amniocentesis showed a normal male karyotype, and FISH analysis to 
exclude a 22q11.2 deleti on was normal. In her previous pregnancy the mother delivered a 
healthy son of 4,500 grams at 41 weeks of gestati on. There were no congenital anomalies in 
the family of both nonconsanguineous parents. 
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 She went into premature labor at 33 weeks, and a male infant with birth weight of 
2060 grams (50th centi le) was born by ventouse extracti on because of failure to progress in 
the second stage of labor and fetal distress. The male newborn was hypotonic, bradycardic, 
and showed respiratory distress. Bag valve mask venti lati on was not successful as no air entry 
into the fetal lungs could be established. Also oropharyngeal and nasopharyngeal intubati on 
was not successful because of a blind-ending larynx, distal to the vocal cords. An att empt 
to put a tube in the proximal esophagus to venti late the lungs through a possible fi stula 
failed. A tracheotomy was established but nevertheless prolonged eff orts to resuscitate were 
unsuccessful, and the pati ent died one hour aft er birth.
 External examinati on showed a proporti onate male neonate with anal atresia and a 
sacral dimple. Postmortem MRI revealed a heart positi oned in the right thorax with the apex 
of the heart towards the left  indicati ng dextropositi on of the heart, a persistent left  superior 
vena cava, and myocardial hypertrophy of both ventricles (Figure 1). Both lungs, parti cularly 
the left  lung, were hypoplasti c. A normal trachea with bifurcati on was seen, but there existed 
no connecti on to the larynx. The distal esophagus was identi fi ed, but had no connecti on to 
the proximal porti on. The right kidney was multi cysti c and positi oned centrally in the lower 
abdominal region. The left  kidney and the spleen showed a normal positi on and aspect. The 
rectosigmoid was dilated, as seen in anal atresia. No abnormaliti es of the vertebral bodies or 
conus medullaris were observed. MRI of the brain showed normal infra- and supratentorial 
structures. Autopsy confi rmed the laryngeal and esophageal atresia. A low tracheo-esophageal 
fi stula was present. The persistent left  superior vena cava was connected to the coronary 
sinus. No other structural abnormaliti es of the heart were observed. A centrally located right 
dysplasti c kidney with multi ple cysts, and a blind-ending rectum with a possible recto-urethral 
fi stula were found. Autopsy of the brain showed no abnormaliti es. A fi broblast culture showed 
normal chromosomal breakage aft er diepoxybutane (DEB) exposure, making Fanconi anemia 
unlikely. Dysmorphologic examinati on of the parents was normal.
Results
Bi-directi onal sequencing of all coding exons of the ZIC3 gene did not reveal mutati ons, apart 
from a 6-nucleoti de inserti on within the porti on of exon 1 that codes for a polyalanine repeat. 
The inserti on sequence, GCCGCC, maintains the wild-type reading frame and codes for two 
additi onal alanines. The repeat therefore contained 12 instead of the normal 10 polyalanines. 
The polyalanine sequence of the mother of the pati ent was normal, and the GCCGCC inserti on 
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was not present, which suggests that the repeat amplifi cati on is de novo in the aff ected 
pati ent. Randomly selected controls, 44 males and 146 females, from the ethnically-matched 
populati on (Dutch Caucasian) were screened for variati on in length of this ZIC3 polyalanine 
repeat. All 336 X-chromosomes showed a wild-type length of 10 repeats of the ZIC3 polyalanine 
repeat.
Figure 1: Postmortem coronal body MRI showing dextropositi on of the heart, persistent left  superior 
vena cava and normal positi on of liver stomach and spleen. The stomach is fi lled with air and 
pneumothorax is present aft er reanimati on
Discussion
We describe a male neonate with a combinati on of features resembling the VACTERL 
associati on, including anal atresia, esophageal atresia with tracheo-esophageal fi stula and a 
unilateral multi cysti c kidney. Dextropositi on of the heart (heart positi oned in the right thorax 
with the apex of the heart towards the left ), with persistent left  vena cava, abnormaliti es not 
typically seen in VACTERL, were also present. As this phenotype shared characteristi cs with 
ZIC3-associated heterotaxy, the ZIC3 gene (HTX1, MIM 306955) was analyzed and a de novo 
ZIC3 mutati on was found.
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 VACTERL associati on represents a spectrum of anomalies including vertebral defects, 
anal atresia, esophageal atresia and/or tracheo-esophageal fi stula, renal malformati ons 
and predominantly preaxial limb anomalies11-13. This broad associati on has considerable 
overlap with other syndromes including X-linked heterotaxy due to a ZIC3 mutati on. X-linked 
heterotaxy typically presents with heart defects characteristi c of heterotaxy including common 
atrioventricular (AV) canal, double outlet right ventricle, transpositi on of the great arteries 
and abnormal pulmonary or systemic venous connecti on. Dextrocardia, indicati ng a mirror 
image positi on of the heart, is present in some pati ents1,5. In our pati ent dextropositi on of 
the heart was found, which could be a result of displacement of the heart, as can be seen 
in pati ents with lung hypoplasia. Intesti nal malrotati on, symmetric liver, abnormal lung 
lobulati on, asplenia or polysplenia are frequently seen in pati ents with X-linked heterotaxy. 
Also midline malformati ons are common, and include imperforate anus, rectal stenosis, 
sacral agenesis, meningomyelocele, cerebellar hypoplasia, and arhinencephaly3,5. X-linked 
heterotaxy shares anorectal, renal and vertebral malformati ons with VACTERL associati on 
(Table 1). However, laterality defects are rarely found in pati ents with VACTERL associati on11. 
Nevertheless, all separate malformati ons within the VACTERL associati on have been reported 
in pati ents with laterality defects. In two large studies of pati ents with esophageal atresia 
and tracheo-esophageal fi stula, dextrocardia was reported in 3% of pati ents12,14. Esophageal 
atresia can also be associated with other features of heterotaxy such as gut malrotati on12,15 
and situs inversus16,17. Esophageal atresia and tracheo-esophageal fi stula are common in 
VACTERL associati on, but not in X-linked heterotaxy. Two pati ents that were initi ally diagnosed 
with VACTERL associati on were later shown to have a ZIC3 mutati on5,18. The fi rst pati ent, 
described by Purandare et al.18 showed features of VACTERL, including lumbar and sacral 
agenesis, anal stenosis, fused kidneys and aqueductal stenosis with hydrocephalus without 
thoracic or abdominal situs anomalies. This pati ent did have a heart malformati on consistent 
with heterotaxy including total abnormal pulmonary venous return and bilateral superior 
vena cava18. The other pati ent had VACTERL associati on with typical vertebral, anal and 
renal malformati on in combinati on with tracheo-esophageal fi stula, but also dextrocardia, 
congenital heart malformati ons and asplenia5. The anomalies present in these two VACTERL 
pati ents are very similar to those of the pati ent described here. The combinati on of the 
VACTERL associati on with heterotaxy is therefore suggesti ve of a ZIC3 mutati on, certainly if the 
disorder is X-linked (Table 1). The presence of tracheo-laryngeal and/or esophageal anomalies 
in these 3 pati ents suggests that ZIC3 plays a role in the development of the foregut. 
 The majority of ZIC3 mutati ons reported to date consist of point mutati ons (nonsense, 
missense) or small inserti on-deleti ons resulti ng in a frameshift , although rarely whole-gene 
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deleti ons and X-autosome translocati ons have been described (Table 1)2,3,5,19. In our pati ent 
an inserti on of GCCGCC in exon 1 of the ZIC3 gene was identi fi ed. This mutati on maintains 
the wild-type reading frame and codes for two additi onal alanines in the polyalanine stretch 
of ZIC3. The polyalanine stretch of ZIC3 is an almost perfect repeat where all alanines are 
encoded by GCC with the excepti on of the ninth alanine, which is encoded by GCT. As in some 
dynamic diseases repeat amplifi cati on occurs aft er transiti on of an incomplete to a complete 
repeat, we sequenced the alanine repeat from the mother of the pati ent, but the ninth repeat 
was normal (GCT). The ZIC3 repeat amplifi cati on is a novel mutati on, not reported before 
neither in pati ents nor in controls. It is a de novo mutati on as it was not present in the mother, 
whereas the pati ent is also the only aff ected family member. All randomly selected controls 
(336 X-chromosomes) from an ethnically-matched Dutch-Caucasian populati on had 10 ZIC3 
repeats. All together, the ZIC3 repeat amplifi cati on is most likely a disease-causing mutati on. 
 Polyalanine stretches have been predicted in about 500 human proteins, mainly 
transcripti on factors. Polyalanine domains in vertebrates are conserved between mammals 
and the polymorphic nature of sequences coding for polyalanine domains makes them 
prime candidates for mutati ons in geneti c disorders20. Up to now, 9 human diseases have 
been described that are due to polyalanine stretch elongati on21-23, and X-linked heterotaxy 
might be the tenth polyalanine repeat disease (Table 2). Nine of these disease genes, including 
ZIC3, encode transcripti on factors; the only excepti on is PABPN1, a nuclear protein involved 
in mRNA polyadenylati on. Polyalanine stretch elongati on of another ZIC gene family member 
ZIC2 is associated with holoprosencephaly23-26. The ZIC3 repeat expansion described here 
is the smallest expansion (+ 2 residues) reported, together with the 2-residue polyalanine 
expansions in ARX and PABPN1 (Table 2). This polyalanine stretch of 12 residues is also 
the smallest polyalanine stretch reported to be pathogenic, together with the 12-residue 
polyalanine expansion in PABPN1. 
 Polyalanine tracts expansions in several transcripti ons factors, including HOXD13, 
HOXA13, RUNX2, SOX3, PHOX2B and FOXL2 have been shown to induce cytoplasmati c 
mislocalisati on and aggregati on as well as nuclear aggregati on22,27-30. Several pathogeneti c 
mechanisms have been proposed: (1) Cytoplasmati c aggregati on might be dependent upon 
repeat length as larger oligomers might be unable to pass through the nuclear pores, leading 
to loss-of-functi on of the transcripti on factor as it may not reach the target genes30; (2) 
Intranuclear aggregates might have a toxic gain-of-functi on aff ect, as has been suggested for 
PABPN1 and ARX31,32; (3) Aggregati on might also induce a dominant-negati ve eff ect through 
the sequestrati on of the wild type protein or associated proteins in the aggregates. As ZIC and 
GLI proteins interact, whereby GLI proteins are translocated to the cell nuclei by coexpressed 
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ZIC3 proteins33, it is possible that formati on of ZIC3 aggregates might also infl uence the 
functi on of ZIC3-related proteins such as GLI3.
In conclusion, we suggest here that ZIC3 might be the tenth gene implicated in polyalanine 
expansion diseases, and that ZIC3 mutati ons may be present in pati ents with VACTERL 
associati on in combinati on with heterotaxy.
Table 2: Polyalanine expansions in human disease
Gene Disease Expansion
ZIC3 Heterotaxy (HTX1) with VACTERL-like features 10→12
ZIC2 Holoprosencephaly (HPE5) 15→25
FOXL2 Blepharophimosis-ptosis-epicanthus inversus (BPES) 14→22, 24
PHOX2B Congenital central hypoventi lati on, Haddad syndrome 20→25–33
ARX West syndrome, Parti ngton syndrome 16→18, 23
12→20
SOX3 Mental retardati on with growth hormone defi ciency 15→26
RUNX2 Cleidocranial dysplasia 17→27
HOXA13 Hand–foot–genital syndrome 14→24, 26
12→18
18→24–30
HOXD13 Synpolydactyly 15→22–25, 29
PABPN1 Oculopharyngeal muscular dystrophy 10→12-17 (AD)
10→11 (AR)
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Summary
Background
Esophageal atresia (EA) and tracheo-esophageal fistula (TEF) are congenital malformati ons 
that occur in approximately 1:3,500 live-born infants1. Five subtypes are described, based on 
the locati on of the atresia and the type of connecti on between trachea and esophagus2. Half 
of the pati ents show other anomalies as well, including vertebral, anal, cardiovascular, renal, 
and limb abnormaliti es (occurring together in the VACTERL associati on). As is the case with 
other congenital malformati ons, EA/TEF is more prevalent in twins, but usually only one twin 
is aff ected1. Once a couple has one child with EA/TEF, the risk of having a second child with 
this anomaly is as high as 1%3.
 Clinical symptoms and ultrasound signs during pregnancy may point at the presence 
of EA/TEF. However, EA/TEF is most oft en diagnosed postnatally, because ultrasound signs 
in relati on to EA/TEF are diffi  cult to interpret. We found a signifi cantly higher mortality in 
prenatally diagnosed infants and also in infants with additi onal congenital anomalies (Chapter 
2). The latt er pati ents are more likely to have experienced a complicated pregnancy4.
 Bett er surgical techniques and pre- and post-operati ve care have improved the prognosis 
of EA/TEF over the last few decades, but pati ents sti ll have considerable short- and long-term 
morbidity5. These include post-operati ve complicati ons, esophageal stricture, dysphagia 
associated with esophageal dysmoti lity, gastro-esophageal refl ux, growth impairment, 
persistent pulmonary dysfuncti on, and/or symptoms associated with other major congenital 
anomalies5-8.
 The pathological mechanism leading to EA/TEF is unknown. The organs involved ͵ 
trachea, esophagus and lungs ͵ are foregut-derived structures. During the fourth week of 
embryonic life, the foregut divides into a ventral respiratory part and a dorsal esophageal 
part. EA/TEF is thought to be a multi factorial complex disease, with involvement of geneti c 
and environmental factors. However, in no more than 6-10% of pati ents a defi ned geneti c 
syndrome can be diagnosed9. 
 In this thesis we describe the phenotypic (Chapters 2 and 3) and molecular-geneti c 
(Chapters 4-8) approach to EA/TEF and other foregut-related anomalies in the search for more 
clues to ‘bridge the gap’ in knowledge on the eti ology of EA/TEF. 
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Environmental factors
Various environmental factors have been suggested to be risk factors for the development of 
tracheo-esophageal anomalies, including maternal exposure to methimazole10, exogenous sex 
hormones11, maternal alcohol and smoking12, infecti ous diseases13, and working in agriculture 
or horti culture14. Previous studies implicate a possible role for maternal in utero exposure to 
diethylsti lbestrol (DES)15. Observati ons in insulin-dependent diabeti c mothers suggest that 
fi rst trimester exposure to maternal diabetes is associated with the development of congenital 
anomalies, including EA/TEF and VACTERL-associated anomalies16. Very recently, studies from 
the EUROCAT birth registry network found that older mothers are at signifi cantly greater risk 
of having a child with EA17. 
 Congenital anomalies are more common in twins than singletons but in the majority the 
eti ology remains unknown. EA/TEF is more frequent in twins than in singletons, but the twin 
concordance rate is low18,19. It has been suggested that early loss of a twin conceptus could 
be a signifi cant risk factor for congenital anomalies20. This implicates a possible ‘teratogenic 
environmental’ role of twin pregnancies in the development of congenital anomalies. However, 
how many pati ents this potenti ally aff ects is unknown. 
 Administrati on of the anthracycline anti bioti c Adriamycin to pregnant rats causes EA/
TEF and other major congenital anomalies in the off spring21. However, no such associati on has 
been reported for humans22. A role for vitamin A defi ciency in the development of EA/TEF has 
also been suggested. A vitamin A defi cient diet given to pregnant rats caused severe congenital 
anomalies in the off spring, including agenesis of the lung and TEF23. Ethylnitrosourea (ENU), 
an alkylati ng and mutagenic agent, induced a recessive mouse mutati on with a phenotype 
that includes abnormal tracheo-esophageal septati on and VACTERL-associated anomalies24. 
So far, no specifi c environmental risk factor has consistently been identi fi ed. 
Geneti c factors
Human syndromes and associati ons involving EA/TEF
More than half of EA/TEF pati ents have associated anomalies, notably cardiovascular defects, 
renal agenesis, microcephaly, duodenal atresia, limb reducti on defects, and polycysti c 
kidney25,26. 
 More than 30% of EA/TEF cases in our cohort (syndromal cases excluded) were defi ned 
as VACTERL-associated (Chapter 3). This means that they showed at least three defects 
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occurring in the VACTERL associati on. The use of this acronym as a clinical enti ty is sti ll being 
debated, as is the minimum number of defects that must be present. It is known to be a very 
heterogeneous associati on. 
 VACTERL-associated pati ents are of interest in the search for new geneti c factors 
underlying foregut-related and associated anomalies. However, the combinati ons of EA/
TEF and its associated anomalies resemble and/or overlap phenotypically with defi ned 
syndromes, such as CHARGE syndrome, Feingold syndrome, and 22q11 deleti on syndrome 
(discussed below). It is not easy, therefore, to discriminate between the causal syndromes, the 
more so as the eti ology of the VACTERL associati on is sti ll unclear. Specifi c phenotypes, such 
as VACTERL-associated anomalies combined with hydrocephalus, were found to be due to 
causati ve mutati ons in the genes FANCB and PTEN27,28. In additi on, causati ve mutati ons in the 
genes HOXD13, PCSK5 and ZIC3 (Chapter 8) were found in VACTERL-associated pati ents24,29,30. 
A recent study found deleti ons in the FOX gene cluster on chromosome 16q24, and mutati ons 
in the FOXF1 gene, in pati ents with alveolar capillary dysplasia combined with VACTERL-
associated anomalies, including EA/TEF31. 
 EA/TEF occasionally occurs in combinati ons with hemifacial microsomia, cardiac, 
vertebral and/or central nervous system anomalies (Goldenhar syndrome), but no geneti c basis 
has been described for this syndrome32. Additi onally, an associati on involving multi ple gastro-
intesti nal atresias (esophageal, duodenal, recto-anal, and biliary atresia), hypoplasti c pancreas 
and gallbladder, intesti nal malrotati on, and neonatal diabetes mellitus was reported33-37. 
Recently, mutati ons in the RFX6 gene were found in pati ents with neonatal diabetes and small 
bowel obstructi on. With the discovery of this human RFX6 mutati on, a phenotypic link with 
Rfx6 knockout mice has been made; Rfx6 is required for endoderm and islet development and 
for the producti on of insulin in humans and mice38.
Single gene disorders involving EA/TEF
Feingold syndrome
Feingold syndrome is caused by germline mutati ons in, or deleti ons of, the MYCN gene on 
chromosome 2p24.1. It is the most frequent cause of familial syndromic gastro-intesti nal 
atresias. From 30 to 40% of pati ents diagnosed with Feingold syndrome have EA/TEF39. 
Marcelis et al.40 reviewed the clinical features of Feingold syndrome in relati on to the 
genotype; 23 diff erent mutati ons of the MYCN gene and 5 deleti ons encompassing MYCN have 
been described over the years. The authors suggest that the presence of digital anomalies 
in combinati on with microcephaly is enough to justi fy MYCN analysis40. Such analysis is also 
recommended in pati ents with EA/TEF in combinati on with microcephaly. 
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CHARGE syndrome
The well defi ned CHARGE syndrome – involving Coloboma, Heart anomalies, choanal Atresia, 
growth and/or mental Retardati on, Genital and Ear anomalies – is in some 60% of cases 
caused by mutati ons in the chromodomain helicase DNA-binding (CHD7) gene41. Around 10% 
of pati ents diagnosed with CHARGE syndrome display EA/TEF. The CDH7 gene is thought to 
have a role in early embryonic development aff ecti ng epigeneti c regulati on by chromati n 
organizati on and euchromati c gene expression. Sti ll, its regulatory functi on and involvement 
in CHARGE syndrome and foregut development should be clarifi ed in functi onal studies in 
humans and animal models.
AEG syndrome
Deleti ons and mutati ons of the SOX2 gene are causati ve for the phenotype of clinical 
Anophthalmia/opti c nerve hypoplasia, Esophageal atresia, and/or Genital anomalies in the 
AEG syndrome42. Studies in chickens and Xenopus implicate a role for Sox2 in the developing 
foregut. Que et al. demonstrated EA/TEF in Sox2 mutant mice and thus provided evidence that 
down regulati on of Sox2 plays a role in the eti ology of EA43,44. The proven relati on between 
murine models and the human phenotype was a breakthrough in the knowledge about 
syndromic EA/TEF.
Opitz G syndrome
Opitz G syndrome is characterized by midline abnormaliti es with mental retardati on and 
agenesis of the corpus callosum. Even though EA/TEF is rare in Opitz G syndrome, the 
combinati on of EA/TEF with corpus callosum agenesis warrants testi ng for mutati ons in the 
MID1 gene, which causes the X-linked form of Opitz syndrome. Laryngotracheo-esophageal 
defects in general are present in most MID1 mutated males, but EA/TEF is rare45. In additi on, 
deleti ons on chromosome 22q11.2 cause the autosomal dominant form of Opitz syndrome, 
which has the same size of the deleti on as observed in DiGeorge syndrome46. Also several 
pati ents with DiGeorge syndrome were reported to have EA/TEF (see below).
Fanconi anemia
Fanconi anemia (FA) is a geneti cally and phenotypically heterogeneous syndrome characterized 
by progressive bone marrow failure and early occurrence of acute myeloid leukemia, combined 
with several congenital malformati ons, including gastro-intesti nal malformati ons. Thirteen 
geneti c subtypes have been described (A, B, C, D1, D2, E, F, G, I, J, L, M, and N), of which FANCA, 
FANCC, and FANCG are the three commonest disease-causing genes47. Mutati ons in the FANCA, 
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FANCB, FANCC, FANCD1 (BRCA2), FANCD2, and FANCG genes have been described in pati ents 
with EA/TEF with various combinati ons of defects, including microcephaly, short stature, 
pigment changes and several VACTERL-associated anomalies, including heart, renal, and limb 
defects27,47-51. EA/TEF is not a common feature of FA, but gastro-intesti nal malformati ons, 
including duodenal atresia, anorectal malformati ons, and EA/TEF, are seen in 14% of all FA 
pati ents47. In additi on, mutati ons in the FANCB gene, on chromosome Xp22.31, were causes of 
X-linked VACTERL with hydrocephalus in pati ents who also had EA/TEF, lung lobulati on defects, 
and confi rmed central nervous system anomalies27. The diagnosis of Fanconi anemia calls 
for early therapeuti c interventi ons and chromosome breakage studies. Faivre et al. advised 
breakage studies in pati ents with common VACTERL-associated anomalies, including EA/TEF, 
in combinati on with skin pigmentati on abnormaliti es, growth retardati on, microcephaly, and/
or dysmorphism48.
X-linked Heterotaxy (Chapter 8)
In this thesis, we describe a new single gene disorder related to EA/TEF. In a pati ent with 
features of the VACTERL associati on, including EA/TEF and laterality defects, a 6-nucleoti de 
inserti on in the X-linked heterotaxy gene ZIC3 was found (Chapter 8)30. This expands the 
amino-terminal polyalanine repeat from ten to twelve polyalanines. The clinical picture of 
the VACTERL associati on overlaps with X-linked heterotaxy caused by ZIC3 mutati ons, as anal 
atresia and cardiac defects are common in both disorders. Some pati ents with ZIC3-associated 
heterotaxy show TEF, renal and vertebral anomalies52,53.
Chromosomal abnormaliti es
Many well known chromosomal aberrati ons are observed in EA/TEF pati ents, such as Down 
syndrome (trisomy 21), Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13)1. 
Several structural chromosomal anomalies were reported and reviewed54,55. Deleti ons on 
several chromosomal loci, including 22q11 (DiGeorge syndrome), distal 13q, 17q21.3-q24.2, 
and 16q24.1 are found in some cases31,54,56-58. Some of the above-menti oned deleti ons are 
of interest, because the deleted loci include several candidate genes for EA/TEF, e.g., the 
17q21.3-q24.2 region including NOG and TBX4. Recently Stankiewicz et al. described deleti ons 
on the16q24.1 locus, including the forkhead genes FOXF1, FOXC2 and FOXL1. Of these 
transcripti on factors, FOXF1 is of parti cular interest, because heterozygote knockout mice for 
this protein have EA/TEF31.
 Improved molecular cytogeneti c techniques allow mass screening of large cohorts 
of pati ents with congenital anomalies; the copy number variati ons in microarray studies 
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yield additi onal deleti ons and duplicati ons. Microarray studies used in other congenital 
malformati ons proved eff ecti ve in mapping and identi fying genes that predispose to the 
phenotype in an unbiased fashion59-63. In studies included in this thesis we used the 
above techniques to identi fy possible causati ve geneti c anomalies in EA/TEF pati ents. We 
confi rmed several chromosomal aberrati ons in pati ents with EA/TEF: 22q11 microduplicati on 
syndrome (Chapter 4), Triple-X syndrome (Chapter 5), and a 5q11.2 deleti on (Chapter 6). In 
additi on, microarray screening in large cohorts of pati ents has provided more insight into the 
polymorphic regions of the human genome in relati on to inherited aberrati ons in pati ents with 
congenital anomalies (Chapter 7). 
Murine models 
Several murine models exhibit tracheo-esophageal anomalies (Table 1)24,44,64. Genes of 
developmental pathways are involved, including Vitamin A eff ectors (Rarα, Rarβ), eff ectors 
of the sonic hedgehog (Shh) pathway (Shh, Gli2, Gli3, Foxf1), other homeobox-containing 
transcripti on factors and their regulators (Hoxc4, Ttf -1, Pcsk5), and developmental 
transcripti onal regulators (Tbx4, Sox2). 
 Research into the human homologues of these genes has shed some light on the 
molecular basis underlying some human cases of EA/TEF. For example, Que et al. found 
that 70% of null mutant mice for Noggin display EA/TEF. In several human TEF cases there 
is a deleti on of the 17q21.3-24.2 locus, which includes the human orthologue NOG44,58. 
Mice haploinsuffi  cient for Foxf1 may show EA/TEF and other foregut-derived anomalies, 
including lung hypoplasia and lobulati on defects65. A pati ent with a heterozygote deleti on 
on chromosome 16q24, including the FOXF1 gene, displayed lung anomalies, EA/TEF and 
other VACTERL-associated features31. The Gli2 and Gli3 genes are essenti al for formati on 
of the trachea and the esophagus. Deleti ons of these genes are associated with congenital 
defects that resemble the VACTERL associati on, at least in mice44,66. Szumska et al. describe 
an ENU-induced recessive mouse mutati on in the Pcsk5 gene, a regulator of Hox genes. 
Such mutati ons, in a heterozygote form, were also present in two pati ents with EA/TEF and 
features of VACTERL associati on. However, in these cases the mutati ons were inherited from a 
phenotypically normal parent. The eti ological role of these mutati ons remained unclear24.
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Table 1: Overview of genes essenti al for tracheo-oesophageal development and their human 
homologues 
Gene Mutant phenotype Human 
homologue
Human locus
Shh-/- EA; TEF; lungs form rudimentary sacs SHH 7q36
Rarα-/-;β2-/- or 
Rarα1-/-;β-/-
TEF; lung hypoplasia or agenesis RARα; RARβ RARα: 17q21.1; 
RARβ: 3p24
Gli2-/-; Gli3+/- EA; TEF; severe lung phenotype
GLI2; GLI3
GLI2: 2q14; GLI3: 
7p13Gli2-/-; Gli3-/- No formati on of esophagus, trachea, and lungs
Foxf1-/- Lethal before embryonic day 10; 
extra-embryonic defects
FOXF1 16q24.1
Foxf1+/- EA; TEF; lung immaturity/hypoplasia; 
lobulati on defects
FOXF1 16q24.1
Ttf -1-/- TEF; rudimentary peripheral lung primordial TTF1 14q13
Sox2 -/- EA; TEF; lung branching defects SOX2 3q26.3-q27
Noggin-/- EA; TEF; lung branching defects; 
abnormal notochord morphogenesis
NOG 17q22
Pcsk5 C470R mutant* Abnormal trachea-esophageal septati on; 
hypoplasti c lungs
PCSK5 9q21.3
Hoxc4-/- Parti ally or completely blocked esophageal lumen; 
disrupti on of esophageal musculature
HOXC4 12q13.3
Tbx4 misexpression TEF TBX4 17q21-q22
Adapted from Felix et al.64, supplemented with fi ndings from recent studies by Szumska et al.24 and Que et al.43,44. EA, 
esophageal atresia; TEF, tracheo-esophageal fi stula; *, Ethylnitrosourea(ENU)-induced mouse mutati on
Conclusions
In conclusion, EA/TEF is oft en part of either a spectrum of anomalies in specifi c syndromes 
with a known cause or an associati on. Many geneti c pathways have been implicated in the 
development of EA/TEF. Pati ents with disti nct phenotypes may be diagnosed with geneti c 
syndromes such as Feingold syndrome, AEG syndrome and CHARGE syndrome. There is a 
substanti al gap in our knowledge of how environmental factors combined with geneti c factors 
would disrupt foregut development. 
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General Discussion
‘Mind the Gap’ 
Over the last few decades, eff orts have been made in understanding the molecular 
mechanisms of normal and pathological foregut development. They have led to substanti al 
progress in uncovering mutated genes in specifi c syndromes involving esophageal atresia 
(EA) and tracheo-esophageal fistula (TEF). However, in 90% of pati ents with these congenital 
malformati ons the eti ology remains unknown.
 Overall, it can be assumed that EA/TEF is a clinically, phenotypically, and geneti cally 
heterogeneous disorder that can be caused by various factors. So we truly have to work hard 
at ‘Mind(ing) the gap’. The pediatric surgeon will expertly bridge the physical ‘gap’, but sti ll 
there remain many ‘gaps’ in knowledge on eti ological factors to be bridged by researcher and 
clinicians. Therefore, in this thesis we tried to ‘mind the gap’ by performing clinical studies 
focusing on pati ent phenotyping (Chapters 2 and 3), combining these with targeted molecular 
geneti c studies (Chapters 4-8) in the EA/TEF pati ent cohort at the Sophia Children’s Hospital.
Clinical and phenotypical heterogeneity
To illustrate the clinical heterogeneity of EA/TEF, we evaluated the course and outcome for 
infants either prenatally or postnatally diagnosed with EA/TEF (Chapter 2)4. Because ultrasound 
signs during pregnancy are diffi  cult to interpret, the diagnosis is oft en made postnatally. Only 
very recently, eff orts to improve the prenatal detecti on rate have focused on ultrasound or 
MRI demonstrati on of the esophageal pouch67. From the present level of knowledge we know 
that certain clinical symptoms and ultrasound signs could suggest the presence of EA/TEF. Our 
study confi rmed that interpretati on of these signs is not easy. With regard to postnatal course 
and outcome, we found that mortality is signifi cantly higher in prenatally diagnosed infants 
and in infants with additi onal congenital anomalies. Pati ents with associated anomalies have 
more complicated pregnancies with a worse outcome. Parental counseling as to the likelihood 
of EA/TEF should be undertaken cauti ously.
 The phenotypic heterogeneity is easily ascertained in our pati ents, but not easily 
explained. Generally, associated anomalies are found in over half of EA/TEF pati ents. Most 
relevant is the VACTERL associati on68. In Chapter 326, we have made a detailed descripti on 
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of the pati ents who showed at least three defects included in the VACTERL associati on. The 
vertebrae/ribs and the cardiovascular system appeared to be most commonly aff ected in 
combinati on with EA/TEF. In additi on, 70% of the pati ents with VACTERL defects displayed 
other congenital malformati ons as well. It is not easy, therefore, to discriminate between the 
causal syndromes, the more so as the eti ology of VACTERL associati on is sti ll unclear. The 
phenotype of VACTERL overlaps with several geneti c syndromes, such as CHARGE syndrome, 
Feingold syndrome, 22q11 deleti on syndrome and Pallister-Hall syndrome. In clinical practi ce, 
syndrome-diagnoses are made on the basis of the phenotypic evaluati on of the anomalies 
present, combined with an approach targeted on known mutati ons in genes or known loci 
for microduplicati on/microduplicati on syndromes. This approach oft en remains without 
results due to the rarity of the syndromes, leaving most of the VACTERL pati ents without 
a geneti c diagnosis. In additi on, clinical practi ce shows that phenotyping and screening for 
syndromes is dependent on awareness of the att ending clinician. Structured relati onships with 
clinical geneti cists result in standardized protocols for further geneti c evaluati on. However, 
in the near future more detailed molecular-diagnosti c techniques will be available. With this 
heterogeneous group of pati ents under investi gati on, it is likely that some of them can be 
listed with an identi fi able geneti c syndrome instead of descripti ve term as diagnosis (discussed 
in detail below).
 Standardized clinical and surgical care is necessary to ‘bridge the gap’ in knowledge on 
the clinical and phenotypical heterogeneity. This includes an echocardiogram and vertebral 
and limb X rays, complemented with renal ultrasound evaluati on if features of the VACTERL 
associati on are present. In additi on, EA/TEF pati ents should be evaluated following standardized 
geneti c protocols for counseling and research. This process should be complemented with the 
evaluati on of possible gene-environment interacti ons that could provide more insight into new 
eti ological factors14. Environmental factors in families of pati ents with EA/TEF could be further 
explored by means of structured and validated questi onnaires, adding to the knowledge 
gained from case-control studies. Such studies require large cohorts, as have been used in 
populati on-based registries for surveillance of congenital anomalies, such as ‘Eurocat’ (htt p://
www.eurocat-network.eu/), the ‘Internati onal Clearinghouse for Birth Defects Surveillance 
and Research’ (htt p://www.icbdsr.org/), and the ‘California Birth Defects Monitoring Program’ 
(htt p://www.cbdmp.org/). 
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Geneti c heterogeneity
The term ‘geneti c heterogeneity’ is used when a single disorder, trait, or patt ern is caused by 
geneti c factors in some cases and non-geneti c factors in others. Similar phenotypes may be 
caused by mutati ons in diff erent genes or caused by a chromosomal abnormality. Evidence 
for geneti c heterogeneity in EA/TEF and/or VACTERL associati on comes from animal models 
describing the phenotypes64, and from diff erent defi ned geneti c syndromes9,19,69. 
VACTERL associati on
Marti nez-Frias and colleagues proposed that in the VACTERL associati on, a 'hit' during 
blastogenesis infl uences the enti re embryo, which then responds as a coordinated unit, 
the primary developmental fi eld. This would produce congenital defects in multi ple organ 
systems70,71. Mutant animal models could give more clues on the geneti c origin of this 
combinati on of anomalies. Deleti ons of the mutant Gli2 and Gli3 genes cause defecti ve 
Shh-signalling and are associated with congenital defects that resemble the VACTERL 
associati on66,72. In humans, however, mutati ons involving Shh have been associated rather 
with holoprosencephaly and microphthalmia than with VACTERL defects73,74.
 Szumska et al. describe an ENU-induced recessive mouse mutati on in the Pcsk5 gene, 
a regulator of Hox genes. Such mutati ons, in a heterozygote form, were also present in two 
pati ents with EA/TEF and features of VACTERL associati on24. Recently, Cao et al. proved in a 
rat-model that the Gli3 promotor contains two putati ve Hoxd13 binding sites; it was concluded, 
therefore, that Gli3 expression is regulated by Hoxd1375. Reports on mutati ons in downstream 
signaling-molecules of Shh, such as HOXD13 and FOXF1, suggest that these developmental 
pathways are key to foregut development and associated anomalies29,76. 
 A recent study describes deleti ons of the FOX gene (FOXF1, FOXC2, FOXL1) cluster on 
chromosome 16q24, and mutati ons in the FOXF1 gene, in pati ents with alveolar capillary 
dysplasia (ACD) combined with VACTERL-associated anomalies31. The 16q24 candidate region 
includes the FOXF1 gene. This gene is a major candidate in foregut development, because 
Foxf1 haploinsuffi  cient mice display EA/TEF65. The implicati ons of this recent fi nding and 
the possible role of FOXF1 mutati ons and deleti ons of the FOX gene cluster, were elegantly 
reviewed77. 
 Interesti ngly Foxf1 and Foxl1 are direct targets of the SHH signalling pathway in the 
murine developing gastro-intesti nal tract. Shh-induced Fox expression is depending on Gli2 
and Gli3. Additi onally, several highly conserved Gli binding sites are located upstream of the 
Foxf1 and Foxl1 promoter sequences78. One of the Gli binding sites is located 55kb upstream 
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of the Foxf1 promoter and this might explain why also deleti ons proximal of the FOXF1 gene 
are associated with a VACTERL-like phenotype in some of the ACD pati ents76. The interacti ons 
between several players of the SHH signaling pathway (Patched, Smoothened, Gli2/3 and 
Foxf1) expressed in diff erent cell types of the developing foregut, could give more clues (Figure 
1, adapted from Shaw-Smith, 200977). With diff erent candidate genes in foregut development 
(SHH, GLI, FOXF1) linked to the 16q24 locus, this is an important candidate region for further 
research. 
Shh
Gli2/3
Foxf1
downstream effectors
epithelial cell
Patched / Smoothened
messenchymal cell
Figure 1: Epithelial-mesenchymal interacti ons mediated by the Sonic Hedgehog pathway in the 
developing foregut. Adapted from Shaw-Smith77
 In additi on, studies in pati ents with anorectal malformati ons implicate a lower 
expression of SHH, GLI2 and BMP4 in the malformed ti ssue. Down-regulati on of the SHH/
BMP4 signaling pathway may be instrumental here, but this could also be the case in foregut-
related anomalies79. Therefore, it is of interest not only to check blood DNA of the pati ents 
with VACTERL-associated anomalies, but also DNA from aff ected ti ssue; the proximal pouch or 
the distal fi stula. 
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 The deleti ons in the FOX gene cluster were detected through genome wide screening 
with microarrays. With microarray data available of over 200 EA/TEF and VACTERL-associated 
pati ents, we screened our cohort for possible deleti ons in the 16q24 region (Chapter 7). This 
did not reveal any copy number variati ons of the 16q24 locus. For some of the arrays used, such 
as the Aff ymetrix® 250K Nsp, the coverage of the 16q24 region was low and small deleti ons 
on this locus could have been missed. In additi on, we performed quanti tati ve PCR studies for 
FOXF1, FOXC2 and FOXL1 in this cohort to detect possible intragenic deleti ons. These were 
found in six EA/TEF pati ents and two pati ents with ACD. However, validati on with a second 
technique is indicated. The role of the FOX genes in the SHH–GLI pathway and its downstream 
targets, in relati on to foregut development, ACD and VACTERL-associati on, should be further 
explored.
Syndromes
We identi fi ed a pati ent with features of the VACTERL associati on and a 6-nucleoti de inserti on 
in the X-linked heterotaxy gene ZIC3 (Chapter 8)30. This pati ent’s disti nct phenotype fi ts the 
geneti c diagnosis caused by mutati ons in ZIC3. It is of interest that GLI proteins are translocated 
to the cell nuclei by coexpressed ZIC3 proteins80. ZIC3 aggregates might infl uence the 
functi oning of ZIC3-related proteins such as GLI3, which is a major candidate gene in foregut 
development, specifi cally in EA/TEF66.
 As menti oned earlier, the clinical picture of the VACTERL associati on overlaps with 
X-linked heterotaxy caused by ZIC3 mutati ons. We therefore hypothesized that this novel 
and de novo polyalanine expansion in the ZIC3 gene contributes to the VACTERL associati on. 
To check this hypothesis we screened an additi onal 25 pati ents with VACTERL-associated 
anomalies, without heterotaxy, for ZIC3 mutati ons. As these were not found, we conclude that 
mutati ons in ZIC3 contribute to the heterotaxy and the VACTERL-associated anomalies, but 
not exclusive for the VACTERL anomalies. 
 Another interesti ng feature of the heterogeneity concerns the type of EA (EA+TEF, 
isolated EA, isolated TEF). None of these types proved correlated to any of the described 
syndromes. All we can say is that isolated TEF was more frequent in CHARGE syndrome. 
Perhaps, mutati ons in the CHD7 gene are associated with diff erent modes of inheritance and 
infl uence early developmental pathways related to foregut development41.
Copy number variati ons
Microarray studies for other congenital malformati ons proved eff ecti ve in mapping 
and identi fying genes that predispose to the phenotype in an unbiased fashion59-63. In 
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collaborati on with Baylor College of Medicine, we screened over 200 pati ents with EA/TEF 
and foregut-related anomalies for copy number variati ons (CNVs) (Chapter 7). This approach 
yielded both de novo and inherited CNVs, widely distributed over the genome. Additi onally, 
we found many polymorphic, non-pathogenic variants81,82. A few recurrent inherited CNVs 
were found, specifi cally on chromosomal loci 5q11, 8p13, 10q25, 12p12 and 22q11. These loci 
might provide more insight into the polymorphic regions of the human genome in relati on to 
inherited aberrati ons in pati ents with congenital anomalies. The origin of non-pathogenic and/
or inherited variati ons and their possible role in the eti ology of congenital disease remains 
unknown. 
 The degree to which malformati ons may manifest can be variable in microduplicati on/
microdeleti on syndromes. Diff erent causes have been proposed for the variable expression 
and incomplete penetrance; i.e. other geneti c mutati ons elsewhere in the genome causing the 
phenotype, compensati on of other genes or downregulati on of gene targets of the deleted/
duplicated genes, epigeneti c factors, or a functi onal SNP on the non-rearranged chromosome 
could be aff ected by the genomic rearrangement83-85. Recently, a recurrent 520 kb large 
16p21.1 microdeleti on was described in a cohort of pati ents with developmental delay. These 
deleti ons are oft en inherited from an unaff ected parent, and occur in associati on with a large 
CNVs that could explain the variability in these and other microdeleti on syndromes86. In 
our cohort, this same inherited deleti on was found in a pati ent with tracheal agenesis and 
other VACTERL associated anomalies; the 16p12.1 deleti on was inherited from his mother, 
but associated with an additi onal 5q11.2 deleti on of 3.6 Mb87. Comparisons with other 
large cohorts of unaff ected controls and aff ected pati ents provided evidence of a two-hit 
model in pati ents with these inherited 16p12.1 deleti ons86. Clearly this could have profound 
implicati ons for geneti c counseling, especially in the newly discovered microduplicati on/
deleti on syndromes88. 
 Only a few de novo aberrati ons were found; these included 4q35, 5q11, 6q23, 7p22, 
8q13, and chromosome X. Not all regions include (candidate) genes and therefore it is diffi  cult 
to relate these aberrati ons to our phenotype. With a genome-wide approach, we found 
limited de novo aberrati ons and therefore it is unlikely that CNVs, in general, contribute to the 
phenotype of EA/TEF. 
 In additi on, we checked all human homologues of genes implicated in murine models 
for possible CNVs. This did not reveal any additi onal aberrati ons, but for some genes the 
coverage of the chosen platf orms was limited.
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 A new approach is in the making however. Data generated from the SNP-platf orms will 
allow performing genome wide associati on studies, provided pati ent numbers are such that 
there is suffi  cient stati sti cal power. 
 In a recent pilot study we collected 14 sib-pairs of twins, i.e. 13 discordant and one 
pair concordant for EA/TEF. Eight pairs were monozygoti c and six were dizygoti c. Screening for 
CNVs of both concordant sibs (male/female; dizygoti c) revealed an identi cal 6p22.2 duplicati on 
in both. The duplicati on was confi rmed with qPCR. This region includes many histone-genes. 
Both pati ents showed the VACTERL associati on. However, we were not able to determine 
whether this duplicati on is inherited from one of the parents, since parental DNA was not yet 
available. Familial cases of EA/TEF, especially concordant twins, are extremely rare89-93. Most 
concordant twins display the same type of EA/TEF and this seems to indicate that they may 
have (at least partly) overlapping eti ologies.
 Findings in twin-studies, e.g. epigeneti c diff erences in both monozygoti c and dizygoti c 
twins and our recent fi nding, can help us to unravel possible geneti c and environmental roles in 
the eti ology of congenital malformati ons20,94-96. Therefore, further studies are recommended. 
 
Strategies and future prospects 
Genotypic approach
Counseling by a clinical geneti cist is advised, including standard karyotyping and screening 
for subtelomeric aberrati ons with Multi plex Ligati on-dependent Probe Amplifi cati on. Clinical 
data should be reviewed and stored in comprehensive databases, together with geneti c 
informati on, including pedigrees, DNA, ti ssue, and cell lines. With improvements in microarray 
technologies, genome-wide screening for CNVs will replace standard karyotyping in the near 
future. Diagnosti c workfl ows for pati ents with congenital malformati ons and/or mental 
retardati on are being assessed already97,98. 
 The importance of detecti ng possible pathogenic CNVs with a genome wide microarray 
approach has been proven: haploinsuffi  ciency in dosage-sensiti ve genes was causati ve 
in specifi c phenotypes and with increasing coverage of the genome the CNVs will become 
smaller, displaying the true eff ects on the phenotype. Genome wide microarray studies will 
change the fi eld of geneti c counseling in pati ents with congenital malformati ons, because in 
the future it is expected to be standard applied as a diagnosti c tool99. 
 Advances in genotyping technology and in knowledge of human geneti c variati on have 
enabled genome-wide associati on studies to identi fy suscepti bility loci for common diseases, 
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but also for congenital abnormaliti es, as proven in neural tube defects100 and syndromic cleft  
lip/palate101,102. This approach, however, requires large cohorts to provide stati sti cal and 
clinical signifi cance. 
 Direct sequencing of candidate genes in pati ents and controls will provide an alternati ve 
approach that could reveal low-frequency alleles that infl uence disease suscepti bility (see 
experimental approach)103. In additi on, next generati on sequencing will soon be an excellent 
tool in the search for new pathogenic mutati ons and copy number variati ons104-106. 
Experimental approach
Studies in animal models implicate an essenti al role for sonic hedgehog signaling and its 
downstream eff ectors during normal development of the foregut. Bett er understanding of 
normal and abnormal development of the foregut could be achieved by focusing on the 
overlapping eff ectors of Shh-signaling, described in pati ents and animal models, e.g. Gli2, 
Gli3, FOXF1, MID1, Noggin, Bmp4, and TBX144,77. Research into the human homologues of 
these genes has already shed some light on the molecular basis underlying some human cases 
of EA/TEF, e.g. for the genes Noggin/NOG44,58 and Foxf1/FOXF131,65. With the advances in 
genotyping technology and genome wide direct sequencing, specifi c candidate genes can be 
screened for specifi c mutati ons. As for EA/TEF and the VACTERL associati on, several candidate 
genes of the SHH-pathway are should be screened, including FOXF1, GLI2 and GLI3.
 Additi onally, there is increasing evidence that epigeneti c modifi cati ons play an 
important role in developmental defects107. Epigeneti c deregulati on of germ cells may be 
caused by certain environmental agents such as diethylsti lbestrol108, pesti cides109, or assisted 
reproducti on technologies110,111. Also, mutati ons in certain genes, already causing a syndromic 
phenotype, infl uence epigeneti c regulati on. An example is the recent fi nding that mutati ons 
the BCOR gene, causing the oculofacialcardiodental syndrome, increase the histone H3K4/36 
methylati on in mesenchymal stem cells, thereby reacti vati ng transcripti on of silenced target 
gene112. To the best of our knowledge, there have been no studies specifi cally studying the role 
of epigeneti c factors in EA/TEF, but it is conceivable that processes such as (de)methylati on of 
genes and imprinti ng are involved.
Conclusions
A unifying approach seems to be the answer, therefore analysis of multi ple candidate genes 
should be done in large groups of well-genotyped individuals using next generati on high 
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throughput genomic technology. This will be of great help in detecti ng possible gene-gene 
interacti ons as well as a possible role for CNVs and regulatory mutati ons in pati ents with EA/
TEF. Then we could sooner or later ‘close the gap’ in the search for new eti ological factors in 
EA/TEF.
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Klinisch en Moleculair-Geneti sch Onderzoek bij Oesophagus 
Atresie
Oesophagusatresie (OA) is een aangeboren afwijking van het spijsverteringskanaal die voorkomt 
bij ongeveer 1 op de 3,500 pasgeborenen. Er is geen verbinding tussen de slokdarm en de maag. 
Bij meer dan 85% van de pati ënten is een tracheo-oesophageale fi stel (TOF) aanwezig. OA/TOF is 
vaker aanwezig bij tweelingen, waarbij meestal slechts één van de kinderen de afwijking vertoont. 
Meer dan 50% van de pati ënten heeft  naast de slokdarmafwijking één of meer structurele 
aangeboren afwijkingen, bijvoorbeeld afwijkingen aan de wervels, het anorectale kanaal, het 
hart, de nieren of afwijkingen aan de ledematen. Deze zijn vertegenwoordigd in het spectrum 
van afwijkingen dat ‘VACTERL’ genoemd wordt. 
 In ongeveer 10% van de pati ënten met OA/TOF is er een oorzaak bekend voor de 
afwijking, dit kan gaan om een chromosomale afwijking of een puntmutati e in een bepaald gen. 
De belangrijkste syndromen beschreven bij OA/TOF pati ënten zijn: Down syndroom, Edwards 
syndroom, AEG syndroom, Feingold syndroom en CHARGE syndroom. Waar voor de rest van de 
pati ënten geen exacte oorzaak bekend is, wordt aangenomen dat er een multi factoriële eti ologie 
is, waarbij zowel omgevingsfactoren als geneti sche factoren een rol spelen.
 In dit proefschrift  wordt het onderwerp ingeleid en wordt een overzicht gegeven van 
bekende oorzakelijke geneti sche en omgevingsfactoren bij OA/TOF (Hoofdstuk 1). Daarna worden 
de resultaten van klinisch (Hoofdstukken 2 en 3) en moleculair-geneti sch (Hoofdstukken 4-8) 
onderzoek bij pati ënten met OA/TOF gepresenteerd. In het laatste deel (Hoofdstuk 9) worden de 
resultaten samengevat en bediscussieerd.
 De relati e tussen prenatale signalen ti jdens de zwangerschap (excessieve hoeveelheid 
vruchtwater en geen of kleine maag zichtbaar op de echo) en postnatale bevindingen bij 
pati ënten met OA/TOF (morbiditeit en mortaliteit) wordt beschreven in Hoofdstuk 2. In een 
retrospecti ef onderzoek wordt aangetoond dat deze prenatale symptomen negati ef gerelateerd 
zijn aan problemen na de geboorte van een kind met OA/TOF. Wij concluderen dat pati ënten met 
deze prenatale symptomen postnataal meer geassocieerde afwijkingen hebben, en een hogere 
mortaliteit vertonen. In Hoofdstuk 3 beschrijven wij de pati ënten die, naast OA/TOF, minimaal 
twee VACTERL-geassocieerde afwijkingen hebben. Bij 23% van alle pati ënten in ons cohort bleek 
dit het geval. Afwijkingen van de wervels/ribben (68.9%) en van het hart (65.6%) komen in deze 
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groep pati ënten het meest voor. Een belangrijke bevinding is dat 70% van deze pati ënten ook nog 
afwijkingen hebben die niet tot het VACTERL spectrum behoren.
 In Hoofdstuk 4 wordt een familiaire vorm van OA/TOF beschreven, gecombineerd met 
anorectale afwijkingen. De indexpati ënt en zijn niet-aangedane moeder werden gediagnosti ceerd 
met het 22q11 microduplicati e syndroom. OA/TOF is niet eerder beschreven bij dit microduplicati e 
syndroom. Deze overervende duplicati e (moeder op zoon) bij een familiaire OA/TOF wordt 
bediscussieerd. In Hoofdstuk 5 worden drie pati ënten met het Triple X syndroom en OA/TOF 
beschreven. Daarnaast werden in ons cohort van pati ënten ook twee pati ënten met overgeërfde 
duplicati es van het SHOX-gen gevonden. Overexpressie van genen op het X chromosoom zouden 
wellicht ontwikkelingsprocessen leidend tot aangeboren afwijkingen kunnen beïnvloeden. 
Een andere X-gebonden afwijking, namelijk een mutati e in het ZIC3-gen, wordt later in dit 
proefschrift  beschreven (Hoofdstuk 8). Bij een pati ënt met heterotaxie, gecombineerd met 
VACTERL afwijkingen, werd een inserti e van 6 nucleoti den in het ZIC3-gen geïdenti fi ceerd. Dit 
leidt tot een polyalanine expansie van 10 naar 12 alanines. Deze nieuw beschreven mutati e in 
ZIC3 is naast heterotaxy waarschijnlijk de oorzaak van de VACTERL afwijkingen.
 In Hoofdstuk 6 beschrijven wij een groep van twaalf pati ënten met een aangeboren 
afwijking van de luchtwegen, namelijk luchtpijp-agenesie. Aangezien deze pati ënten naast 
afwijkingen aan de luchtpijp een breed scala aan afwijkingen hebben, zoals VACTERL geassocieerde 
afwijkingen, zijn deze pati ënten moleculair-geneti sch gescreend met de array-CGH techniek. 
Hierbij kwamen meerdere niet-pathogene en overgeërfde afwijkingen aan het licht. Daarnaast 
werd in één pati ënt een 3.6 Mb grote deleti e op chromosoom 5 gevonden. De bevindingen van 
deze studie ondersteunen het heterogene fenotype en genotype dat bij deze pati ënten wordt 
gezien. De cohort studie van alle pati ënten met OA/TOF, in samenwerking met het Baylor College 
of Medicine (Houston, USA), wordt beschreven in Hoofdstuk 7. Meer dan 200 pati ënten met 
OA/TOF zijn gescreend op chromosomale veranderingen (deleti es en/of duplicati es). Bij alle 
pati ënten zijn afwijkingen gevonden, die niet-pathogeen of overgeërfd waren. De betekenis van 
de overige afwijkingen is tot op heden moeilijk te bepalen. 
 In Hoofdstuk 9 wordt een algemene samenvatti  ng gegeven en worden de resultaten 
van de studies in dit proefschrift  besproken. De huidige stand van kennis wordt in een 
toekomstperspecti ef geplaatst, waarbij een interacti e tussen klinisch en moleculair-geneti sch 
onderzoek nodig is om de eti ologie van OA/TOF verder te ontrafelen. 
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de Krijger: vanaf het begin liep ik ‘in’ en ‘uit’ bij de pathologie. Ik ben me er welkom blijven voelen 
en daarom ben ik blij dat je in mijn grote commissie wilt plaatsnemen. Prof.dr. J. Molenaar: het 
is een enorme eer dat u wilt plaatsnemen in de grote commissie. Prof.dr. Frans Hazenbroek: ik 
dank u dat u mijn promoti e wilt voorzitt en als ‘oud-gediende’ van de afdeling waarop ik met veel 
plezier heb gewerkt.
 171 
Dankwoord
 Kinderchirurgen ErasmusMC en Kinderchirurgisch Centrum Amsterdam: DANK voor 
elk stukje distale fi stel of proximale pouch dat kon worden uitgenomen ten behoeve van het 
onderzoek! Daarnaast dank aan alle verpleegkundigen, fellows, kinderartsen en arts-assistenten 
op de afdeling Intensive Care Kinderen waardoor het onderzoek voortgang kon vinden!
 Alle co-auteurs wil ik bedanken voor de inzet bij de stukken die we geschreven hebben. 
Specifi ek wil ik dr. Els Grijseels en dr. Alice Brooks noemen: ik wil jullie danken voor de hulp en 
inzet bij het schijven van de arti kelen. 
 ‘In additi on’ wil ik graag Ko Hagoort danken voor de snelle en doeltreff ende hulp! Crispijn, 
mijn leken-lezer, fi jn dat je in het Engels ook zo snel kunt lezen! Danielle Gerritsen, dank voor je 
adobe-illustrator-kennis!
 Alle collegae van de 9e dank ik voor de gezellige en leerzame ti jd! Specifi ek wil ik noemen: 
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 Dank aan iedereen van de 9e: ik heb me thuis gevoeld op de klinische geneti ca, ook al 
kwam ik uit het ‘Sophia’. Jullie zijn een gezellige groep mensen! Jeanett e, dank voor alles wat 
geregeld moest worden. Stefan, dank voor je uitleg en de X-inacti vati e experimenten! En niet te 
vergeten…43210…wie kent het nummer niet uit zijn hoofd? Dank, dank, dank… Ton, Leo, Pim, 
Sjozef en Mario.
 Dank aan iedereen van het Postnatale en het Prenatale lab op de 24e, waar ik vele uren 
heb mogen doorbrengen: van kweekkamer tot materiaalafgift e! Daarnaast, aan het begin van de 
rit heb ik veel op de pathologie geleerd: dank aan Pieter, Monique, Luc en Frieda voor de uitleg 
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 Het onderzoekersteam van Dick, uit heden en verleden, verdienen stuk voor stuk een 
dankwoord…maar ik zal enkelen bij naam noemen. Janine, dank je voor alles; vanaf het begin 
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 Mijn paranimfen, twee mensen met een gouden randje: Bart de Jong en Danielle 
Veenma. Bartje, het is een grote eer dat je op deze dag naast mij staat. Samen opgroeien, uiteen 
gegroeide interesses, maar alti jd een ijzersterke band, je bent mij zeer dierbaar! Lieve Daan, 
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